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Allogeneic stem cell transplantation (allo-SCT ) is a treatment 
option with curative potential for patients with various malig-
nant and non-malignant hematological diseases($). Conventional 
myeloablative transplantation includes pre-transplantation con-
ditioning with high dose chemo- and radiotherapy to eradicate 
residual disease and recipient (host) immunity in preparation for 
healthy donor-derived hematopoietic stem cells (graft). Allo-SCT 
is performed to replace the lethally damaged hematopoietic 
stem cells from the patient by donor hematopoietic stem cells 
that have the ability to proliferate and di-erentiate into mature 
blood cells and reconstitute the patient’s hematopoietic system 
with donor-derived healthy blood cells. 
Unfortunately, T-cells present in the stem cell graft from 
the donor can lead to severe damage to various tissues, named 
graft versus host disease (GvHD). GvHD is characterized by 
lesions of the skin, gut and the liver and is clinically subdivided 
in four degrees of severity. GvHD is one of the main causes of 
morbidity and mortality after allo-SCT. GvHD after allo-SCT can 
be inhibited by administering immunosuppressive agents that 
a-ect T-cell activation and proliferation. To prevent GvHD, T-cell 
depleted allo-SCT can be applied, resulting in a decreased inci-
dence and severity of GvHD("-)). 
However, T-cell removal resulted in increased incidence 
of relapse of leukemia after allo-SCT and did not result in sig-
ni!cantly improved overall survival(%,5). In line with this !nding 
was the association of the occurrence of GvHD with a decreased 
likelihood of relapse of the leukemia after allo-SCT(6,'). These 
observations indicated that donor derived T-cells present in the 
stem cell graft not only mediate GvHD, but can also mediate a 
Graft versus leukemia (GvL) e-ect. Indirectly, the role of T-cells in 
GvL e-ect was demonstrated by the induction of remissions in 
patients after withdrawal of immunosuppression(&,$#). The obser-
vation that allo-SCT was associated with a lower risk of relapse 
and better disease-free survival than autologous SCT indicated 
that the T-cells mediating the GvL e-ect had to be from donor 
origin($$,$"). In addition, the !nding of higher relapse rates in recipi-
ents of syngeneic compared to allogeneic transplants indicated 
that genetic disparities between patient and donor are neces-
sary for the GvL e-ect($(,$)). The demonstration that infusions of 
lymphocytes from the original marrow donor without additional 
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chemotherapy could eradicate the recurrence of leukemia after 
allo-SCT provided the !rst direct evidence for a GvL e-ect($%,$5). 
The recognition that donor derived T-cells could mediate 
GvL activity laid the foundation for the subsequent development 
of non-myeloablative allo-SCT. The high intensity of myeloabla-
tive treatment aims at e7cient killing of malignant stem cells. 
Regimen-related toxicity of the myeloablative treatment, however, 
limits this procedure to younger patients. The perception that 
donor T-cells were capable of e7ciently eradicating leukemic 
cells resulted in development of reduced intensity conditioning 
regimens (RIC) in order to be able to perform nonmyeloabla-
tive allo-SCT in patients of older age, or with comorbidities($6-"$). 
These regimens do not eradicate all residual disease but result 
in su7cient immunoablation to permit engraftment of donor 
hematopoietic stem cells and induce a state of host-versus-graft 
tolerance that gives donor derived T-cells the opportunity to 
recognize and eliminate residual malignant stem cells. Although 
RIC regimens have been shown to permit engraftment with lower 
toxicity, GvHD is still an important complication, with consider-
able morbidity and mortality(""). 
D O N O R  LYM P H O C Y T E  I N F U S I O N  /  T $ C E L L 
B A S E D  I M M U N OT H E R A PY
The acknowledgement that donor derived T-cells have the capac-
ity to speci!cally recognize and eradicate malignant cells initiated 
the development of T-cell based immunotherapy. After allo-SCT 
relapse of the hematological malignancy can occur that can be 
treated with donor lymphocyte infusion (DLI) from the original 
stem cell donor("(-"%). Treatment with DLI after allo-SCT can induce 
sustained complete remissions("(,")). The best responses to DLI 
occur in patients with chronic myeloid leukemia (CML). Close to 
'#8 of patients with relapsed chronic-phase CML after transplant 
will achieve a complete remission in response to unmanipulated 
DLI($%,"(,"),"5-"'). Patients with other malignancies respond less 
frequently to DLI("(,"6,"&-("). Response rates of "%-%#8 have been 
reported in hematological malignancies like multiple myeloma 
(MM), chronic lymphocytic leukemia (CLL) and myelodysplasia 
(MDS). In acute lymhoblastic (ALL) and acute myeloid leukemia 
(AML), remissions have been documented even less frequently. 
Possibly, the time of donor T-cells to respond is too long in rapidly 
growing acute leukemia. Alternatively, the di-erence in responses 
to DLI may be due to intrinsic di-erences in susceptiblity of the 
diverse tumor types to adoptive immunotherapy. 
Next to the bene!cial GvL e-ect, induction of detrimen-
tal GvHD can be a severe complication of the application of DLI, 
especially in HLA-mismatched allo-SCT(((). It remains challenging 
to separate GvL from GvHD. Individuals are genetically disparate 
due to a broad variety of single nucleotide polymorphisms (SNPs) 
that result in small di-erences in amino acid sequence of many 
proteins. Processing of these polymorphic stretches of amino 
acids that di-er between patient and donor can lead to strong 
immune responses. Polymorphic peptides presented in the 
context of HLA-molecules able to elicit a donor immune response 
are de!ned as minor histocompatibility antigens (MiHAs) and 
&
are thought to be the prime mediators of both GvL and GvHD 
after HLA-identical allo-SCT(()). To selectively induce GvL, more 
de!ned T-cell populations with restricted anti-leukemic speci!c-
ity should be used. 
The possibility to isolate antigen-speci!c T-cells and 
reinfuse them to patients to reconstitute antigen-speci!c immu-
nity has been demonstrated in immunode!cient bone marrow 
transplant recipients at risk for developing Cytomegalovirus 
(CMV) disease((%-(&), Epstein-Barr virus (EBV) reactivation or devel-
opment of EBV positive B cell lymphomas()#-)(). These opportun-
istic infectious diseases form a major clinical problem during the 
post-transplant period of immunode!ciency. It has been demon-
strated that these viral diseases can be both prevented or cured 
by adoptive transfer of CMV-((%-(&) and EBV-speci!c T-cells()#-)() 
isolated from the donor. This adoptive transfer was demonstrat-
ed not only to be e-ective but also to be safe without the induc-
tion of GvHD. Long-term persistence of the virus-speci!c donor 
T-cells could be demonstrated())). 
The isolation of therapeutic T-cells resulting in GvL 
without induction of GvHD has proven more di7cult. Some pa-
tients with leukemia that were treated with MiHA-speci!c T-cells 
selected on bases of  recognition of patient’s normal hemat-
opoietic and malignant cells but no recognition of non-hemato-
poietic cells like !broblasts experienced  exclusive GvL e-ect, 
whereas other patients su-ered from GvHD without apparent 
GvL e-ect()%). Previously, we reported the successful treatment of 
a patient with accelerated phase CML refractory to DLI infusion 
who received in vitro generated leukemia-reactive donor T-cells 
resulting in a molecular complete remission()5). Based on this evi-
dence that GvL can be separated from GvHD by using de!ned 
leukemia-reactive donor T-cells we have recently completed a 
phase I/II feasibility study analyzing the possibility of large scale 
in vitro generation of leukemia-reactive T-cells to treat patients 
with relapsed leukemia after allo-SCT()6). Despite some evidence 
of clinical bene!ts, this technique is complex and very time-con-
suming and not feasible for every patient. In addition, it is now 
recognized that long in vitro culture periods negatively in9uence 
the in vivo functional activity of the T-cells()'-%#).
In conclusion, adoptive transfer of donor derived T-cells 
with de!ned speci!city directed against patient’s malignant cells 
may be a potential strategy to separate the GvL e-ect from the 
GvHD. However, current approaches to obtain leukemia-speci!c 
donor T-cells are complex and time-consuming, and need to be 
customized for every patient. 
T $ C E L L S
TCR rearrangement and selection
T-cells play a criticial role in protective immunity against di-erent 
pathogens. Within the T-cell compartment, T-cells expressing the 
CD) coreceptor and T-cells expressing the CD' coreceptor can 
be distinguished that recognize peptides in the context of HLA 
class II or HLA class I molecules, respectively. T-cell precursors 
originating in the bone marrow migrate through the thymus 
where the de!nitive stages in T-cell development take place(%$). 
$#
In the thymus selection takes place of T-cells expressing useful 
T-cell receptors (TCRs) able to engage self-HLA molecules(%$), and 
lineage commitment to either CD)+ helper or CD'+ cytotoxic 
T-cells(%"). First, the rearrangement of TCR genes leading to TCR-
cell surface expression is essential for progression during T-cell 
development. The TCR consists of a transmembrane heterodimer 
of TCR: and TCR; chains linked with a disul!de bond. Each TCR 
locus consists of variable (V), joining (J), and constant (C) region 
genes, and the ; chain locus also contains diversity (D) gene 
segments. Both TCR chains are the result of a complex process 
of random combination of di-erent gene segments (V-D-J-C). 
The rearrangement of !rst the TCR; and subsequently the TCR: 
genes result in the formation of TCRs with unique extracellular 
variable regions and a constant intracellular region(%(). During 
positive selection immature T-cells expressing TCRs with no or 
too low an a7nity for self-HLA die by neglect, whereas immature 
T-cells with a TCR with intermediate a7nity receive a survival 
signal. These immature T-cells subsequently commit to the CD) 
or CD' T-cell lineage with their precise lineage fate being deter-
mined by the HLA-restriction of their TCR. Immature T-cells that 
receive signals through HLA class II-restricted TCRs di-erentiate 
into CD)+ T-cells, whereas immature T-cells that receive signals 
through HLA class I-restricted TCRs di-erentiate into CD'+ 
T-cells. CD)+ and CD'+ T-cells then undergo negative selection 
resulting in elimination of T-cells with too high a7nity to self-
peptides in the context of self-HLA molecules. 
Generally, the T-cells that end up in the periphery rec-
ognize via their unique TCR a particular conformation of an HLA 
molecule and antigenic peptide. The antigen-binding surface of 
a TCR is formed by three complementarity-determining regions 
(CDR) contributed by the TCR: and three contributed by the 
TCR; chain. Whereas TCR CDR$ and CDR" are well conserved 
throughout di-erent TCR: and TCR; subfamilies, the CDR( 
region in contrast shows high diversity and plays a central role 
in peptide recognition(%)). The antigenic peptides that are rec-
ognized by T-cells, called epitopes, are derived from degraded 
proteins and can be presented in HLA class I or class II mol-
ecules(%%). The strength by which a T-cell binds to a target cell is 
called avidity. The T-cell avidity is determined by the a7nity of the 
TCR for the antigen in the context of an HLA molecule, and addi-
tional interactions between T-cell and target cell via adhesion and 
costimulatory molecules that interact with di-erent molecules on 
the target cells. 
CD! and CD" coreceptors
Two molecules that play a role in enhancing the interaction 
between T-cell and target cell are the CD) and CD' co-receptors. 
CD) and CD' co-receptors are transmembrane proteins with 
extracellular domains that promote TCR engagement of HLA-
ligands and, in addition, intracellular domains that enhance 
TCR signal transduction. The CD) molecule is a coreceptor that 
enhances the overall avidity of the interaction between the T-cell 
and the target cell by binding to the ;" domain of the HLA class II 
molecule(%5-%'). Whereas both the : and ; chain of CD' can coop-
erate to bind HLA class I molecules, the CD) corececptor consists 
of one chain of which the N-terminal variable-like region makes 
$$
contact with the HLA-molecule. The CD' co-receptor enhances 
binding between the T-cell and the target cell by binding to 
the alpha ( domain of the HLA class I molecules(%&,5#). While CD' 
on peripheral T-cells mostly consists of disul!de-linked CD':; 
heterodimers, intestinal T-cells, <= T-cells, and NK-cells express 
CD':: homodimers(5$-55). CD'; protein requires association with 
CD': for its stable expression at the cell surface. This is not due 
to the inability of>CD'; molecules to form homodimers, which 
can be formed intracellularly, but these are unstable and rapidly 
degrade(56-5&). When expressed as cell-surface molecules, however, 
the coordinated binding of CD':; with TCR-engaged HLA class 
I is much stronger as compared to membrane-bound CD'::(6#-6"). 
Both CD) and CD' are molecules that promote signaling by 
HLA-restricted TCRs. The intracellular domains of CD) and CD' 
associate with the protein tyrosine kinase LCK which initiates 
TCR signal transduction when it is enzymatically activated(%5,6(-66). 
By binding to the same peptide-HLA complexes that have 
engaged the TCR, CD) and CD' bring intracellular LCK, which 
is present in lipid rafts, into physical proximity with the cytosolic 
domains of the engaged TCR to initate signaling(%&,6'-'#). 
CD!+ and CD"+ T-cell functions
In response to antigen-recognition, several biological responses 
take place. The major e-ector functions of CD)+ helper T-cells 
are the secretion of cytokines acting on other T-cells and promot-
ing CD'+ T-cell e-ector functions('$,'"), as well as upregulation 
of CD)#L promoting B-cell activation('(). The major e-ector 
functions of CD'+ T-cells are the secretion of lytic granules that 
kill antigen positive target cells, as well as the production of 
cytokines(')). In addition, after antigen-recognition, T-cells down-
regulate their TCR resulting in a so called refractory period('%,'5). 
This refractory period enables T-cells to transcribe DNA, result-
ing in proliferation generating high numbers of antigen-speci!c 
T-cells and execution of di-erent e-ector functions.
As mentioned before, CD)+ T-cells recognize peptides 
bound to HLA class II molecules. The major source of peptides 
that bind in HLA class II molecules are extracellular proteins. 
The major source of peptides that bind in HLA class I molecules 
and can be recognized by CD'+ T-cells are intracellular proteins 
found in the cytosol of antigen-presenting cells (APCs) or target 
cells. Although most CD'+ T-cells are cytotoxic T-cells recogniz-
ing antigens in the context of HLA class I and most CD)+ T-cells 
are helper T-cells recognizing antigens in the context of HLA 
class II, the existence of CD)+ T-cells with cytolytic capacity has 
been demonstrated previously('6). In addition, CD'+ T-cells have 
been described recognizing an antigen in the context of HLA 
class I as well as an antigen in the context of HLA class II(''). 
T $ C E L L  D I F F E R E N T I AT I O N
Antigen-encounter results in di-erentiation of naïve CD)+ and 
CD'+ T-cells not yet activated by antigen into either short- or 
long-lived e-ector and memory T-cells. Although T-cell re-
sponses quickly contract once the antigen is eliminated, memory 
T-cells survive and initiate larger and more e7cient secondary 
$"
immune responses upon subsequent exposure to the antigen. 
The di-erent naïve, e-ector and memory subsets can be distin-
guished both by their di-erential expression of several cell sur-
face antigens and by their distinct functional properties('&-&$). 
In CMV- and EBV-speci!c immune responses di-erent 
memory subsets are raised(&",&(). Even within one virus-speci!c 
memory response distinct memory subsets can be found. For 
example, the CD'+ memory T-cells speci!c for EBV lytic anti-
gens predominantly have a more di-erentiated e-ector memory 
phenotype, consisting of mainly CD)%RO+, CD"6-, CD"'-, CCR6- 
and CD5"L- T-cells. CD'+ memory T-cells speci!c for EBV latent 
antigens predominantly have a central memory phenotype, con-
sisting mainly of CD)%RO+, CD"'+, CCR6+ and CD5"L+ T-cells(&)). 
Based on phenotypic characteristics CD'+ memory T-cells 
speci!c for CMV are mainly e-ector-type or late memory T-cells(&%). 
These experimental !ndings suggest that the memory phenotype 
re9ects the frequency in which T-cells encounter their antigen 
and thus re9ects the activation state in vivo of these T-cells .
MiHAs / HA-# and HA-$
After HLA-identical allo-SCT donor derived T-cells recogniz-
ing MiHAs may induce both GvL e-ects, as well as GvHD(()). 
Individuals are genetically disparate due to SNPs in the hu-
man genome that can result in small di-erences in amino acid 
sequence of several proteins. If these polymorphic peptides 
presented in the context of HLA on patient’s cells elicit a 
strong immune response of donor derived T-cells these anti-
gens are called MiHAs. Based on our current understanding of 
antigen-processing, di-erent mechanisms can explain the great 
immunogenicity of MiHAs. First, if single or multiple amino acid 
substitutions are present within the peptide that is processed and 
bound into the groove of the HLA molecules and presented on 
patient-derived cells, these polymorphisms can be recognized as 
“foreign” by donor T-cells(&5-$##). Second, polymorphisms in amino 
acids within the peptide that do not have direct contact with the 
TCR but are essential for binding of the peptide to the HLA class 
I molecules on the target cells may lead to di-erential expression 
of the peptide-HLA complex on the cell membrane between 
patient- and donor-derived cells($#$-$#)). If the peptide is not ap-
propriately processed in donor cells and therefore cannot be 
presented in HLA molecules by cells from the donor but only by 
cells from the patient, donor T-cells will not have been educated 
to recognize this antigen as self, and a T-cell response against 
the epitope presented on patient’s cells may occur. In addition, 
(partial) deletion of the gene coding for the protein involved has 
been described as a mechanism by which MiHAs can arise($#%). 
Polymorphic peptides of various lengths can also be presented in 
the context of HLA class II molecules. Although the mechanism 
by which peptides are processed and presented in HLA class II 
molecules is di-erent from that of HLA class I and less clearly 
understood, several mechanisms for the generation of MiHAs are 
similar($#5-$#&). 
After allo-SCT the hematopoietic system will be of donor 
origin, whereas other tissues will still be of patient origin. Donor 
T-cells recognizing MiHAs ubiquitously expressed on several 
tissues may induce both GvL and GvHD. In contrast, donor 
$(
T-cells recognizing MiHAs exclusively expressed on cells of the 
hematopoeitic system will selectively induce GvL by eliminating 
all patient hematopoietic cells, including the malignant cells, but 
not donor hematopoietic cells. MiHAs that are expressed only 
on cells of the hematopoietic system, and are also expressed on 
leukemic precursor cells are optimal target antigens for a cura-
tive strategy without induction of GvHD. HA-" and HA-$ were 
the !rst MiHAs described to be expressed solely on cells of the 
hematopoietic system and to be present on clonogenic leukemic 
precursor cells($#(,$$#,$$$). 
HA-" is a HLA-A*#"#$-restricted epitope with a popula-
tion frequency of 6#8- &%8($$"-$$)). HA-" is derived from a diallelic 
gene encoding a novel human class I myosin with selective high-
level expression on hematopoietic cells($#",$#(,$$#). Target cells recog-
nized by HA-"-speci!c T-cells contained a single A-to-G transition 
at nucleotide )& of the gene sequence that alters the sequence 
of the HA-" epitope from YIGEVLVSM (HA-"M) to the immuno-
genic YIGEVLVSV  (HA-"V). Although HA-"-speci!c T-cells are 
able to recognize both HA-"V and HA-"M variants when the 
synthetic peptides are exogenously pulsed onto HLA-A*#"#$+ 
target cells, experiments indicated that endogenously processed 
HA-"M peptide is not expressed on the cell surface($#(). It is not 
complete clear whether this failure of HA-"M to be presented is 
due to di-erently proteosomal cleavage or ine7cient translation.
HA-$ is an epitope presented in the context of 
HLA-A*#"#$(&6). HA-$ is derived from a diallelic gene with a yet 
unknown function with selective hematopoietic expression, and, 
in addition, shows expression on epithelial cancer cells($$#,$$$,$$%). 
HA-$ has a population frequency of (%-5&8(&6,$$(,$$)). A two nu-
cleotide di-erence alters the sequence of the HA-$ epitope from 
VLRDDLLEA (HA-$R) into the immunogenic VLHDDLLEA (HA-
$H)(&6). HA-$-speci!c T-cells required $#,### times the concentra-
tion of exogenously pulsed HA-$R peptide compared to HA-$H 
peptide for HA-$-speci!c TNF-: production, and in concordance 
with this !nding, HA-$H but not HA-$R transfected HeLa cells 
were recognized by HA-$-speci!c T-cells(&6). It was demonstrated 
that the HA-$R peptide is extremely rapidly dissociated from 
HLA-A*#"#$ when compared with the HA-$H peptide, and most 
likely, the HLA-A*#"#$/HA-$R complexes never reach the cell 
surface but already dissociate intracellularly($$5). 
Both MiHA HA-$ and HA-" induce high-a7nity T-cell 
responses and are shown to be induced frequently in vivo in 
HLA-A*#"#$+ patients that received allo-SCT($$),$$6-$$&). Previously 
in MiHA HA-$ and/or HA-" incompatible donor–recipient pairs 
a direct association between the emergence of MiHA HA-$ or 
HA-" tetramer+ cytotoxic T-cells and the complete disappear-
ance of malignant recipient cells was shown($"#). The observation 
that T-cell responses against HA-$ are capable of eliminating 
leukemic precursor cells capable of engrafting into immunode-
!cient NOD/SCID mice con!rmed the ability of these T-cells to 
prevent outgrowth of leukemia($"$). 
In conclusion, di-erential expression of HA-$ and HA-" 
in patients elicits high-a7nity donor-derived T-cell responses 
recognizing these MiHAs as “foreign”. Since HA-$ and HA-" are 
$)
exclusively expressed on cells of the hematopoietic system, these 
MiHAs are attractive target antigens for adoptive immunotherapy.
G E N E  T H E R A PY
TCR gene transfer
Adoptive transfer of T-cells is a strategy used to target both solid 
tumors and leukemia. Patients with relapsed hematological ma-
lignancies after allo-SCT can be successfully treated with donor 
lymphocyte infusion (DLI)("(,")), and patients with solid tumors can 
be e-ectively treated with tumor in!ltrating lymphocytes (TILs) 
cultured from tumor tissue($""). The bene!cial GvL e-ect of DLI 
mediated by the recognition of MiHAs is, however, often accom-
panied by GvHD. Furthermore, isolation and expansion of TILs is 
feasible only for a fraction of patients with solid tumors. Since the 
antigen-speci!city of a T-cell is purely de!ned by the TCR: and 
; chains, consequently, the transfer of TCR-chains into recipient 
T-cells can be used as a strategy to transfer T-cell immunity, as was 
demonstrated for the !rst time by the group of Steinmetz($"(). By 
introducing a well-characterized TCR, large numbers of T-cells 
with de!ned antigen-speci!city can be obtained.  Furthermore, 
TCR gene transfer allows the introduction of TCRs that have spe-
ci!cities that are not present in the endogenous T-cell repertoire 
of the recipient. 
Di-erent studies have shown the e-ectiveness of TCR 
transfer, both in vitro($"(-$"') and in vivo($"&-$($). Recently, patients 
with advanced melanoma have been treated by adoptive transfer 
of lymphocytes genetically modi!ed with a TCR speci!c for 
MART$(Melan-A)($(#,$(") and a TCR speci!c for gp$##($("). In the !rst 
clinical study, persistence of TCR gene-modi!ed T-cells in indi-
vidual patients was variable, and expression of the introduced 
MART-I-speci!c TCR was markedly lower than endogenous TCR 
expression ($(#). Perhaps because of this, with a response rate of 
)/($, clinical e-ectiveness of TCR gene transfer was clearly less 
than that of prior trials by the Rosenberg group that involved in-
fusion of ex vivo expanded tumor-in!ltrating lymphocytes (TILs)
($"",$((,$()). Also in the second clinical trial, although high a7nity 
TCRs were used in this study, clinical response rate was still lower 
compared to the use of TILs. Although the clinical response rate 
was lower than anticipated, the results support the therapeutic 
potential of TCR gene-modi!ed lymphocytes as an anti-tumor 
treatment.
Vector systems
Retroviral vectors based on Moloney Murine leukemia virus (Mo-
MuLV) were the !rst viral vectors to be used in gene therapy trials 
and although various tools have been developed to deliver genes 
into human cells, genetically engineered retroviruses continue 
to be mostly used. Retroviruses are logical tools for gene delivery, 
since they introduce genes into the host cell genome, resulting 
in stable expression of the gene of interest. This integration in 
the genome will ensure that also upon proliferation of host cells, 
daughter cells will continu to express the gene of interest. For 
retroviral transduction, proliferation of the host cell is required. 
Therefore, lentivirus-based vectors were developed because they 
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could be used to deliver genes into nondividing cells. However, 
cytokine stimulation of quiescent human T-cells is still needed to 
transduce the T-cells using lentiviral vectors($(%).
The most successful gene therapy trial using a Mo-
MuLV-based retroviral vector was by Alain Fischer on children 
su-ering from a fatal form of SCID, SCID-X$. This disease is an 
X-linked hereditary disorder characterized by an early block in 
the development of T- and NK-cells because of mutations in the 
<c cytokine receptor subunit. Hematopoietic stem cells (HSCs) 
from patients were stimulated and transduced ex vivo with a 
retroviral vector expressing the <c cytokine receptor subunit, 
and were then reinfused into the patients($(5). During a $#-month 
follow up, <c-expressing T- and NK-cells could be detected, and 
cell counts and function were comparable to age-matched 
controls. The selective proliferation advantage of the transduced 
lymphocyte progenitors due to expression of the <c cytokine 
receptor subunit contributed considerably to the success of this 
study. While & of $# patients were successfully treated, ) of the 
& children developed T-cell leukemia ($-5' months after gene 
therapy which were found to be due to insertional mutagen-
esis($(6). In " of these cases, blast cells contained activating vector 
insertions near the LIM domain-only " (LMO") proto-oncogene. 
In two other patients, integrations near the proto-oncogene 
BMI$ and CCND" were found. Chemotherapy led to sustained 
remission in ( of the ) cases of T-cell leukemia, but failed in the 
fourth. Successful chemotherapy was associated with restora-
tion of polyclonal transduced T-cell populations. As a result, the 
treated patients continued to bene!t from therapeutic gene 
transfer. Untill now, "# SCID-X$ patients have been treated, with 
% children developing T-cell leukemia and the immunode!ciency 
corrected in $6 of the "# patients($(').
Similarly, patients with adenosine deaminase (ADA)-
de!ciency SCID were treated with genetically corrected HSCs. 
ADA-SCID is a complex metabolic and immunological disorder, 
characterized by a severe immunode!ciency. Due to the absence 
of enzymatic activity of ADA, purine metabolites accumulate in 
plasma and cells, leading to lymphopenia, absent cellular and 
humoral immunity, failure to thrive, and recurrent infection. In $& 
of the "6 patients treated with transduced HSCs the immunode-
!ciency was corrected($(&). In contrast to the SCID-X$ trial, none 
of the "6 patiens with ADA-de!ciency treated with genetically 
modi!ed HSCs showed any adverse e-ects up to ' years after 
treatment($)#).
Although the risk of insertional mutagenesis in retro-
viral integration has been subject to debate, in contrast to 
hem atopoietic stem cells, retroviral vector integration into 
mature T-cells has been found to be safe. In the !rst clinical 
trial in the early nineties that attempted to treat patients su-er-
ing from ADA-de!ciency with retrovirally transduced mature 
T-lymphocytes long-term reconstitution from transduced pro-
genitor cells was observed at low levels, without in vivo clonal 
expansion or malignant transformation up to ) years after 
treatment($)$). However, multiple infusions of corrected T-cells 
were required. Various studies have demonstrated that retroviral 
vector integration into mature T-cells has no consequence on the 
biology and function of transplanted T-cells, as demonstrated by 
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long-term engraftment of donor lymphocytes genetically engi-
neered with the suicide gene thymidine kinase of herpes simplex 
virus (HSV-tk) after allo- SCT($)",$)(). In addition, gene transfer to 
T-cells using retroviral constructs con taining the marker gene 
truncated nerve growth factor receptor and subsequent infu-
sion of more than $#$$ transduced cells into ($ patients did not 
result in undesirable side e-ects($))). Recently, the susceptibility 
of mature T-cells and hematopoietic stem cells to transformation 
after retroviral gene transfer with potent T-cell oncogenes was di-
rectly compared in an animal model($)%). All animals that received 
transplants of hematopoietic stem cells transduced with a T-cell 
oncogene developed leukemia/lymphoma. In contrast, none of 
the animals that received transplants of mature T-cells transduced 
with a T-cell oncogene developed a hematological malignancy.
These studies indicate that introduction of therapeutic 
genes using retroviral integration into mature T-cells is a safe 
strategy.
High a%nity TCRs
TCRs introduced via gene transfer have to compete for cell 
surface expression with not only the endogenous TCR, but also 
with mixed TCR dimers that can be formed by pairing of the 
endogenous TCR chains with the introduced TCR chains (Figure 
$). Therefore, gene transferred TCRs need to exhibit high a7nity 
for their speci!c peptide-HLA complex. One strategy is to obtain 
TCRs that recognize foreign antigens in self-HLA. MiHA-TCRs 
like the HA-$- and HA-"-TCR derived from an immune response 
after allo-SCT of a HLA-A*#"#$ and HA-$/HA-" positive patient 
with stem cells from a HLA-A*#"#$ positive but HA-$/HA-" 
negative donor are examples of high-a7nity TCRs recogniz-
ing foreign antigens in self-HLA. In contrast, TCRs recognizing 
tumor associated antigens (TAA) are mostly derived from T-cell 
responses against solid tumors and are directed against self-HLA 
molecules presenting peptides derived from self-proteins over-
expressed in tumor tissue. Therefore, most of these TAA-speci!c 
TCRs are of low a7nity. Several strategies have been explored to 
increase the a7nity of TAA-speci!c TCRs, inducing variations in 
TCR: and ; sequences and screening for TCR:; complexes that 
exhibit improved binding a7nity for the speci!c MHC-peptide 
combination($)5-$%$). 
Alternatively, chimeric antigen receptors (CARs) can 
be engineered that combine antigen-speci!city with the high 
a7nity of an antibody and T-cell activating properties in a single 
fusion molecule($%"). Generally, !rst generation CARs consisted 
of a single-chain antibody-derived antigen-binding motif that is 
coupled to signalling modules that are normally present in the 
TCR complex, such as the CD(?-chain. First generation CARs 
e-ectively redirected T-cell cytotoxicity, but failed to enable T-cell 
proliferation and survival upon repeated antigen exposure. Since 
then di-erent second generation CARs have been engineered 
containing costimulatory signalling domains of CD"' or )-$BB to 
reduce activation induced cell death (AICD) and improve persis-
tence($%(-$%'). The value of second generation CARs has still to be 
validated in clinical trials. 
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Suicide genes
TCR gene transfer poses di-erent safety issues, that might war-
rant the inclusion of a suicide gene. First, di-erent strategies to 
improve a7nity of TCRs might pose the risk of unwanted on-tar-
get toxicity. Recently, it has been described that administration 
of high a7nity TAA-speci!c T-cells directed against the renal cell 
carcinoma antigen carboxy anhydrase IX (CAIX) resulted in se-
vere cholestasis based on the overlooked CAIX expression by the 
bile duct epithelial cells($%&). Likewise, in the second clinical study 
of Rosenberg and colleagues that used a high-a7nity MART-$-
speci!c TCR on-target autoimmune destruction of melanocytes 
in ear, skin and hair that required treatment was observed in 
several patients($("). Furthermore, in the case of unexpected o--
target reactivity, inclusion of a suicide gene as a safety switch can 
abrogate unwanted toxicity directed against healthy tissue.
Several suicide genes or safety switches have been 
reported. HSV-tk is a well-established suicide gene that has 
been successfully used to control GvHD following DLI after allo-
SCT($)",$5#,$5$). Transfer of HSV-tk to DLI preserved the bene!cial 
anti-tumor e-ect and allowed in vivo elimination of donor T-cells 
using ganciclovir if severe GvHD occured. In immunocompetent 
patients receiving HSV-tk gene modi!ed DLI late after transplan-
tion, however, gene modi!ed lymphocytes rapidly disappeared 
due to induction of HSV-tk-speci!c immunity($5",$5(). Another 
disadvantage of the HSV-tk suicide gene is that ganciclovir used 
to eliminate HSV-tk modi!ed T-cells is !rst line therapeutic agent 
used in transplanted patients with CMV reactivations, a common 
complication after allo-SCT. Administration of ganciclovir to 
control CMV replication to patients after allo-SCT who received 
anti-leukemic TCR and HSV-tk modi!ed T-cells will result in de-
pletion of the TCR modi!ed T-cells and terminate the bene!cial 
anti-leukemic immune response.
Another well-studied suicide gene is the CD"# cell 
surface molecule($5),$5%). CD"# is a transmembrane calcium chan-
nel that is believed to play a role in B-cell activation, prolifera-
tion and di-erentiation. It is !rst expressed on pre-B-cells and 
persists until later in di-erentiation, but is absent on terminally 
di-erentiated plasma cells. Since CD"# is already expressed on 
the cell surface of B-cells, it is unlikely that CD"# expressed on 
T-cells to function as a suicide gene will be immunogenic. We 
have demonstrated that human CD"# may be used as a safety 
switch in adoptive immunotherapy without a-ecting normal 
antigen-speci!c T-cell functions($55). Rituximab is a therapeutic 
anti-CD"# antibody, which is widely used in the clinic, and upon 
ligation of CD"# triggers various e-ector mechanisms, includ-
ing complement-dependent cytotoxicity (CDC). At present, only 
Rituximab and ganciclovir are available as clinical-grade thera-
peutic reagents. 
TCR make up of host cells
In most TCR gene transfer studies unselected peripheral blood 
T-cells were used as host cells. Transfer of TCRs into an unse-
lected pool of T-cells may lead to transduction into regulatory 
T-cells capable of impairing the anti-leukemic immune reaction. 
Furthermore, in a pool of T-cells with a diverse TCR repertoire, a 
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Figure !. Simpli"ed representation of TCR cell surface make up after TCR gene transfer in di#erent T-cells using 
di#erent strategies to improve cell surface expression of the introduced TCR.
Figure !: (A) Transfer of unmodi"ed TCR will result in 
cell surface expression of the endogenous TCR, the in-
troduced TCR and mixed TCR dimers composed of the 
introduced TCR$  chain pairing with the endogenous 
TCRß chain and the endogenous TCR$  chain pairing 
with the introduced TCRß chain. (B) T-cells with a 
weak competitor phenotype predominantly express the 
introduced TCR after TCR gene transfer, and to a lesser 
extent the endogenous TCR on their cell surface.  (C) 
T-cells with a strong competitor phenotype predomi-
nantly express their endogenous TCR after TCR gene 
transfer, and to a lesser extent the introduced TCR on 
their cell surface. (D) Codon optimization is a strategy 
that improves cell surface expression of the introduced 
TCR by changing the nucleotide sequence to obtain op-
timal codon usage. This optimal codon usage results in 
identical amino acid sequence of the TCR chains, how-
ever, improves mRNA stability and translation e%cacy 
of the introduced TCR chains, resulting in improved 
introduced TCR cell surface expression. (E) Inclusion 
of cysteine residues or murinization of the constant 
domains of the introduced TCR chains induces prefer-
ential pairing of the introduced TCR chains. Cell surface 
expression of the introduced TCR chains is improved 
since reduced numbers of mixed dimers are formed, 
resulting in less competition for cell surface expression. 
Additionally, forced preferential pairing might o#er 
advantages for the introduced TCR of capturing more 
CD&  complexes.
high number of di-erent mixed TCR dimers with un-
known speci!city can be formed due to pairing of the 
retrovirally introduced TCR chains with the endoge-
nously expressed TCR chains, increasing the probabil-
ity of the formation of autoreactive mixed TCR dimers. 
Theoretically, the introduction of a TCR into a T-cell 
will result in formation of two mixed TCR dimers, con-
sisting of the endogenous TCR: chain pairing with 
the introduced TCR; chain and vice versa (Figure $A). 
Therefore, usage of unselected PBMCs with a broad 
TCR repertoire as host cells for TCR transfer will in-
crease the risk of formation of mixed TCR dimers with 
a harmful o--target reactivity. An alternative strategy 
to prevent formation of mixed TCR dimers would be 
to transduce <=-T-cells, since the <=-TCR chains are 
not able to pair with :;-TCR chains($56). Human <=-T-
cells redirected with :;-TCRs were fully functional in 
vitro and were capable of recognizing chronic my-
eloid leukemic cells. In addition, in murine studies we 
were able to show functional activity in vivo and per-
sistence of the cells($5'). However, further analyses will 
be required to determine to what extent redirected 
<=-T-cells and :;-T-cells are di-erent with respect to 
homing properties and speci!city of the endogenous 
TCR. Another attractive strategy can be to transduce 
oligo- or monoclonal T-cell populations. Since most 
virus-speci!c T-cell populations consist of a restricted 
TCR repertoire($5&-$6"), the number of di-erent mixed 
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TCR dimers harboring harmful speci!cities will be limited. 
Another possible advantage of the use of virus-speci!c T-cells is 
the exclusion of regulatory T-cells from the pool of TCR modi-
!ed lymphocytes that can possibly disturb the immune reaction. 
Furthermore, adoptive immunotherapy with EBV-speci!c T-cells 
in patients with post-transplant proliferative disease and CMV-
speci!c T-cells as prophylaxis for CMV reactivation(5$-5() in patients 
after SCT has proven to be a therapeutic strategy without toxic-
ity or GvHD, and long-term persistence of these T-cells has been 
demonstrated())). Since EBV and CMV are examples of latent 
viruses, we hypothesize that due to frequent encounter with viral 
antigens and subsequent triggering of the endogenous TCR, 
TCR transferred virus-speci!c T-cells will survive for a prolonged 
period of time in vivo. Moreover, it was recently shown in a 
mouse model that tolerization of one TCR could be overcome by 
signaling via the other TCR. In this model the function of the tol-
erized self-tumor-reactive TCR of dual-T-cell receptor transgenic 
T-cells was rescued by proliferation induced via the virus-speci!c 
TCR, underlining the potency of TCR transfer into virus-speci!c 
T-cells($6(). In addition, expression of the transgene under regula-
tion of a viral promotor is enhanced upon T-cell activation($6)-$66). 
Using T-cells speci!c for latently present viruses may result in 
repetitive stimulation via the endogenous TCR and increased 
expression of the introduced TCR due to T-cell activation.
We have previously reported di-erences between TCRs 
in the capacity to compete for cell surface expression($6'), and we 
described weak competitor phenotype TCRs exhibiting low cell 
surface expression (Figure $B) and strong competitor phenotype 
TCRs (Figure $C) exhibiting high cell surface expression after 
gene transfer. Probably interchain pairing of the introduced 
TCR and competition for CD(-complex formation may both 
play a role. Because the TCR is expressed only at the cell surface 
when noncovalently bound to the CD( complex composed 
of CD(<, CD(@, CD(=, and CD(?, correct assembly of all these 
subunits with TCR:- and ;-chains is required to assure optimal 
membrane expression of the TCR-CD( complex in T-cells($6&-$'$). 
Single subunits and partial receptor complexes redundant for 
the assembly process retain in the ER where these products are 
highly susceptible to proteolysis($'",$'(). We speculate that weak 
and strong competitor phenotype can be explained by two 
mechanisms. Possibly, strong competitor phenotype TCRs have 
a higher interchain a7nity, which results in rapid formation of 
TCR:; complexes and hinders degradation of the single TCR: 
and ; chains. Alternatively, strong competitor phenotype re9ects 
the ability of particular TCR-chains to more e7ciently capture 
CD( and thus be preferentially transported to and expressed at 
the cell surface. Ideally, TCRs selected for the purpose of gene 
transfer should exhibit both high interchain a7nity and a high 
TCR-CD( intrinsic a7nity to generate T-cells that preferentially 
express the transferred-TCR, resulting in a strong competitor 
phenotype. Alternatively, weak competitor phenotype T-cells 
could be selectively used as host cells. Recently, we have de-
scribed that weak competitor phenotype of virus-speci!c T-cells 
is, to some extent, correlated with speci!city($55). However, se-
lection of host cells with a weak competitor phenotype would 
minimize the pool of host cells useful for TCR gene transfer. 
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Furthermore, to ensure persistence of TCR modi!ed T-cells, we 
would like to preserve the endogenous virus-speci!c TCR cell 
surface expression. Introduction of a strong competitor pheno-
type TCR into weak competitor phenotype virus-speci!c T-cells 
might result in loss of cell surface expression of the endogenous 
virus-speci!c TCR. Several strategies to improve expression of 
the introduced TCR have been described. mRNA and protein 
stability and translation e7cacy of the introduced TCR chains can 
be enhanced by codon optimization($')) (Figure $D). Furthermore, 
matched pairing of the introduced TCR chains can be facilitated 
by murinization($'%-$'6) or introduction of cysteine residues in the 
constant regions of the introduced TCR chains, resulting in for-
mation of an extra disul!de bond($'',$'&) (Figure $E).
In conclusion, TCR gene transfer is a promising strategy 
to rapidly engineer therapeutically relevant amounts of anti-tu-
mor speci!c T-cells. However, future application of TCR modi!ed 
T-cells in clinical trials might bene!t from increased knowledge 
how to improve cell surface expression of the introduced TCR 
and persistence of TCR modi!ed T-cells.
Aim of the study
TCR gene transfer is a strategy that enables the rapid engineer-
ing of anti-leukemic T-cells with de!ned speci!city, resulting in 
a so called ‘o- the shelf’ therapy. An elegant strategy to promote 
persistence of TCR modi!ed T-cells may be TCR gene transfer 
into CMV- and EBV-speci!c T-cells, which exhibit proper memory 
and e-ector phenotypes. Furthermore, these virus-speci!c T-cells 
do not induce GvHD after HLA identical allo-SCT, and can thus 
be safely administered. For e7cient anti-leukemic reactivity of the 
introduced TCR coinciding with enhanced in vivo survival, a bal-
ance between cell surface expression of the introduced and en-
dogenous TCR is required. The aim of this thesis was to optimize 
the e7cacy of TCR gene transfer, study possibilities and restric-
tions of virus-speci!c T-cells as host cells for TCR gene transfer 
and characterize the occurrence of potentially harmful mixed TCR 
dimers and strategies to prevent their formation.
Since the introduced TCR chains have to compete for 
cell surface expression with the endogenous TCR, the introduced 
TCR chains are under control of a strong viral promotor, which, in 
contrast to the endogenous promotor, is constitutively active. In 
Chapter ", we analyzed whether physiological TCR downregula-
tion resulting in a protective refractory period was preserved in 
TCR modi!ed T-cells. For this purpose, CMV- and EBV-speci!c 
T-cells were retrovirally transduced with the hematopoietic minor 
histocompatibility antigen HA-"-speci!c TCR (HA-"-TCR). TCR 
transduced T-cells were antigen-speci!cally triggered via either 
the introduced TCR or the endogenous virus-speci!c TCR. At 
various time points after stimulation TCR cell surface expression 
as well as TCR-responsiveness and activation induced cell death 
(AICD) was measured to analyze preservation of the protective 
refractory period.
TCR transfer into T-cells speci!c for persistent viruses 
may promote long-term persistence of TCR modi!ed T-cells. 
When frequent encounter of viral antigens would lead to selec-
tive survival of TCR modi!ed virus-speci!c T-cells predominantly 
expressing the endogenous TCR incapable of proliferating via 
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the introduced anti-leukemic MiHA-TCR, persistence in vivo of 
TCR modi!ed virus-speci!c T-cells capable of controlling the he-
matological malignancy may fall short. In Chapter (, we analyzed 
whether the dual-speci!city of the TCR transferred T-cells after 
repetitive stimulation via either the introduced anti-leukemic 
TCR or the endogenous virus-speci!c TCR was preserved. 
Puri!ed CMV-speci!c T-cells were transduced with the HA-"-TCR 
and either repetitively stimulated via the endogenous CMV-TCR 
to mimick a period of minimal residual disease (MRD) or via the 
introduced HA-"-TCR to mimic relapse, and preservation of dual-
speci!city was analyzed. 
It has been described that introduction of TCR chains 
into T-cells results in mixed TCR dimer formation, consisting of 
the introduced TCR chains pairing with the endogenous TCR 
chains. Since the speci!city of mixed TCR dimers is unpredict-
able, hazardous speci!cities may be formed. In Chapter ), we 
investigated whether TCR transfer can lead to the generation of 
mixed TCR dimers exhibiting new detrimental reactivities. To ad-
dress this issue we created T-cells expressing mixed TCR dimers. 
To be able to discriminate between the functionality of the en-
dogenous TCR, the introduced TCR as well as mixed TCR dimers, 
we transduced di-erent de!ned virus-speci!c T-cells with seven 
di-erent well characterized antigen-speci!c TCRs and tested 
these for newly acquired reactivities against an HLA-typed EBV-
LCL panel covering all prevalent HLA class I and II molecules, 
and against di-erent normal cell subsets. Furthermore, we 
explored the introduction of cysteine residues in the constant 
domains of the introduced TCR resulting in formation of an extra 
disul!de bond as a strategy to avoid expression of neoreactive 
mixed TCR dimers.
The MiHA HA-$ is an attractive candidate antigen for 
clinical study, as it is exclusively expressed on hematopoietic 
cells. However, previously it has been demonstrated that HA-$-
TCRs are poorly expressed after gene transfer. In Chapter % we 
therefore sought to improve HA-$-TCR expression after gene 
transfer. TCR-de!cient jurkat-cells were used to study pairing 
capacities of the HA-$-TCR chains. The role of the CDR$ region 
of the always identical HA-$-TCR BV5S) chain in low HA-$-TCR; 
expression was analyzed by exchanging this region. Furthermore, 
two well described strategies, namely the inclusion of cysteine 
residues in the TCR constant domains and codon optimization 
were explored for improvement of HA-$-TCR cell surface expres-
sion after gene transfer in virus-speci!c T-cells known to pos-
sess endogenous TCRs which strongly compete for cell surface 
expression. 
In Chapter 5 the results obtained in the studies are sum-




To broaden the applicability of cellular immunotherapy, adop-
tive transfer of T-cell receptor (TCR) transferred T-cells may be an 
attractive strategy. Using this approach, high numbers of de!ned 
antigen-speci!c T-cells can be engineered. Since the introduced 
TCR has to compete for cell surface expression with the en-
dogenous TCR, the introduced TCR chains are under control of 
a strong viral promotor, which, in contrast to the endogenous 
promotor, is constitutively active. We examined whether this 
di-erence in regulation would result in di-erences in TCR inter-
nalization and re-expression of the introduced and endogenous 
TCR on dual TCR engineered T-cells as well as the antigen-
responsiveness of both TCRs. We demonstrated comparable 
TCR downregulation of TCRs expressed under regulation of a 
retroviral promotor or the endogenous promotor. However, the 
introduced TCRs were rapidly re-expressed on the cell surface 
after TCR stimulation. Despite rapid re-expression of the intro-
duced TCR, T-cells exerted similar antigen-sensitivity compared 
to control T-cells, illustrating that cell mechanisms other than 
TCR cell surface expression are involved in antigen-sensitivity 
directly after antigen-speci!c stimulation. These results demon-
strate that TCR transduced T-cells are functionally not di-erent 
from non-transduced T-cells and can potentially be used as an 
e-ective treatment strategy. 
Rapid re-expression of retrovirally introduced 
versus endogenous TCRs in engineered 
T-cells after antigen-speci,c stimulation
J Immunother. "#$$ Mar;()("):$5%-6). Reprinted with permission.
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I N T R O D U C T I O N
Adoptive transfer of TCR transduced (td) T-cells may be an attrac-
tive strategy to obtain high numbers of de!ned antigen-speci!c 
T-cells for cellular immunotherapy without complicated isolation 
strategies and labour intensive culturing procedures($). Di-erent 
studies have shown the e-ectiveness of TCR transfer, both in 
vitro("-6) and in vivo('-$$), and recently the feasibility of this approach 
was demonstrated in clinical trials(',$#).
In TCR td T-cells, the introduced TCR has to compete 
for cell surface expression with the endogenous TCR. For optimal 
e7cacy of TCR modi!ed T-cells in vivo, the cell surface expression 
of the introduced TCR has to be high, allowing the TCR td T-cells 
to recognize clinically relevant target cells expressing endog-
enously processed antigen. One of the strategies to acquire high 
TCR cell surface expression on TCR gene modi!ed T-cells, is to 
use a strong retroviral promotor to regulate the introduced TCR. 
However, retroviral promotor regions are constitutively active, 
and in addition, it has been described that viral promotor activity 
will increase by T-cell activation($"-$)). In contrast, the endogenous 
promotor regions regulating the endogenous TCR expression 
have been demonstrated to be transiently inactivated after TCR 
triggering. TCR:; mRNA expression decreases within )-6h after 
TCR triggering, followed by normalization of mRNA levels ")h 
after activation($%,$5). In addition, T-cell activation induced by TCR 
triggering has been demonstrated to induce internalization of 
the TCR-CD(-complexes. It has been suggested that internaliza-
tion of TCR-CD(-complexes and transient inactivation of the 
promotor regions regulating the endogenous TCR result in a 
refractory period of activation in which all e-ector-target in-
teractions are terminated($6-"#). This latter e-ect is supported by 
the observation that TCR-CD( downregulation results in a loss 
of cellular sensitivity to subsequent stimulation for 6" hours or 
longer($',"#), and vice versa, the inhibition of receptor downregula-
tion leads to enhanced signaling($6,"$,""). Thus, the control of TCR 
expression by internalization of TCR-CD( complexes and degra-
dation of all its subunits("(-"%) is speculated to result in a refractory 
period important to prevent harmful hyperstimulation resulting 
in activation induced cell death (AICD).
Since the regulation of the endogenous and introduced 
TCRs di-er, TCR transfer may induce di-erences in the refractory 
period of TCR engineered T-cells, rendering these cells more sen-
sitive for AICD. In this study we therefore examined TCR internali-
zation and re-expression of the introduced and endogenous TCR 
on TCR td T-cells and antigen responsiveness via both TCRs. Our 
results demonstrate that TCR downregulation of the endogenous 
and introduced TCRs shortly after TCR triggering is identical. 
However, ")h after antigen-speci!c triggering the retrovirally in-
troduced TCR-CD( complexes are rapidly re-expressed at the cell 
surface, in contrast to the endogenous TCR which is still down-
regulated. Despite rapid re-expression of the introduced TCR-CD( 
complexes, the T-cells remained physiologically non-responsive 
to antigen, illustrating that cell mechanisms other than TCR-CD( 
cell surface expression are involved in providing a protective 
refractory period. 
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R E S U LT S
Rapid re-expression of the introduced TCR-CD& complex on TCR td 
T-cells 
To ensure high and stable expression of the introduced TCR, 
most TCR gene transfer studies to date use retroviral vectors for 
transgene delivery. Expression of the introduced TCRs in these 
studies will be regulated by the retroviral long terminal repeats 
(LTRs), whereas endogenous promotor regions will regulate 
the endogenous TCR expression. We assessed whether TCR-
triggering of TCR td virus-speci!c T-cells resulted in increased 
protein levels under regulation of the retroviral LTR by analyzing 
eGFP expression as a marker using 9ow cytometric analyses. As 
shown in Figure $, eGFP expression was increased at ")h after 
antigen-speci!c TCR triggering, and showed further increase up 
till )'h after TCR triggering, con!rming previous observations 
that protein levels under regulation of a viral promotor increase 
upon TCR stimulation($"-$)). To determine whether antigen-specif-
ic stimulation would result in changed TCR modulation between 
the introduced TCR under regulation of a viral promotor and 
the endogenous TCR, we sorted TCR td virus-speci!c T-cells 
based on double positivity for eGFP and truncated nerve growth 
factor receptor (NGF-R). These TCR engineered T-cells with 
dual-speci!city were stimulated antigen-speci!cally via their en-
dogenous or introduced TCR, and analyzed for TCR cell surface 
expression. We analyzed three di-erent TCR td T-cells; HA-"-TCR 
td or CMV-TCR td EBNA(A-speci!c T-cells, and HA-"-TCR td 
pp5%-speci!c T-cells. T-cells were stained at di-erent time points 
after antigen-speci!c stimulation with TCR:;-, CD(- or TCR;-
speci!c mAbs to determine the TCR-CD( cell surface expression 
and to dissect between the endogenous and introduced TCR; 
chains. Unfortunately no mAbs are available to stain for the 
endogenous or introduced TCR: chains. TCR downregulation of 
the di-erent TCR-CD( complexes in TCR td virus-speci!c T-cells 
was compared to TCR downregulation of mock td virus-speci!c 
T-cells. In Figure "A a representative example of the kinetics of 
TCR cell surface expression after antigen-speci!c stimulation 
is depicted. The HA-"-TCR td pp5% T-cells demonstrate down-
regulation of the cell surface expressed TCR:; complexes after 
)h of stimulation similar to mock td pp5% T-cells. With mAbs 
speci!c for the endogenous and introduced TCR; chain we 
observed after antigen-speci!c stimulation via the endogenous 
TCR (pp5% pep $ µM) downregulation of both the endogenous 
as well as the introduced TCR; chains. Likewise, we observed 
after antigen-speci!c stimulation via the introduced TCR (HA-" 
pep $ µM) downregulation of both the introduced as well as the 
















Figure !. Protein levels under regulation of a viral promotor increase after stimulation.
Figure !: Sorted virus-speci"c T-cells trans-
duced with vectors containing TCR$  chains 
in combination with the marker gene eGFP 
and TCR'  chains in combination with the 
marker gene NGF-R were stimulated via their 
endogenous TCR using peptide pulsed target 
cells and eGFP expression was measured us-
ing FACS as an indication of viral promotor 
activity. eGFP expression of T-cells without 
stimulation (black dotted line), (h after stim-
ulation (light grey line), )(h after stimulation 
(grey line), (*h after stimulation (dark grey 
line) and +)h after stimulation (black line) is 
shown. Data is representative for several TCR 
td as well as mock td T-cells in six independ-
ent experiments.
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Figure ). TCR td T-cells demonstrate fast TCR re-expression in comparison with mock td T-cells due to fast introduced TCR re-expression.
Figure ): (A) As an example, the kinetics of total TCR re-expression 
(TCR$'; black diamonds) or re-expression of the endogenous 
TCR-'  (CMV-TCR BV); grey triangles) or introduced TCR-'  (HA-
)-TCR BV!*; white circles) of mock and HA-) TCR td pp,- T-cells 
after stimulation with LCLs pulsed with either ! µM of pp,- or HA-) 
peptide is depicted. The cell surface expression of T-cells stimulated 
with unpulsed LCL (control) was set at !../. Per timepoint the 
percentage cell surface expression was calculated as follows: [MFI 
of T-cells with peptide pulsed LCL / MFI of control T-cells] * !... The 
average MFI of control stimulated mock td T-cells stained with anti-
TCR$'  = ,+&; anti-TCR-BV) = +&,.  The average MFI of control 
stimulated HA-)-TCR td T-cells stained with anti-TCR$'  = +((; 
anti-TCR-BV) = )0,; anti-TCR-BV!* = )0.
(B)/(C)/(D) Mock td pp,- and mock td EBNA&A T-cells (mock), HA-
)-TCR td pp,- and HA-)-TCR td EBNA&A T-cells and CMV-TCR 
td EBNA&A T-cells (TCR td) were stimulated with LCL-Z (control 
stim; white bars) or with either LCL-Z pulsed with pp,- peptide or 
HLA-B+ td LCL-Z pulsed with EBNA&A peptide, respectively (stim 
endogenous TCR; grey bars) or with LCL-Z pulsed with either HA-) 
or pp,- peptide (stim introduced TCR; black bars) and analyzed at 
the indicated time points for B) TCR$'  expression, C) CD&  expres-
sion, and D) endogenous and introduced TCR'  expression. The cell 
surface expression of T-cells stimulated with unpulsed LCL (control) 
was set at !../. Per timepoint the percentage cell surface expres-
sion was calculated as follows: [MFI of T-cells with peptide pulsed 
LCL / MFI of control T-cells] * !...  Reported P values were consid-
ered statistically di#erent if <...! and values statistically di#erent 
are indicated with an asterisk. Data from six independent experi-
ments were combined. 
"6
endogenous TCR; chains. HA-"-TCR td pp5% T-cells, however, 
re-expressed TCR:; complexes faster at their cell surface com-
pared to mock td T-cells, both when stimulated via their endog-
enous or introduced TCR. Already ")h after stimulation TCR:; 
complexes were re-expressed on TCR td pp5% T-cells, while 
TCR:; expression of mock td pp5% T-cells was still decreased 
6"h after TCR stimulation. Also TCR:; expression of the parental 
HA-"-speci!c T-cell clone was still decreased 6"h after TCR stimu-
lation (data not shown). Using mAbs speci!c for the endogenous 
and introduced TCR; chain we demonstrated that re-expression 
of TCR:; complexes ")h and )'h after TCR triggering correlated 
with recovery of the introduced TCR; chain, whereas the endog-
enous TCR; chain was still downregulated 6"h after stimulation. 
Moreover, recovery of the endogenous TCR; chain appeared to 
be even slower compared to mock transduced T-cells, indicating 
that the abundance of introduced TCR chains may compete for 
cell surface expression with the endogenous TCR chains. Since 
the introduced TCR: and TCR; chain are both regulated via a 
similar retroviral LTR, it seems plausible that the recovered TCR 
complexes that stained with the mAb speci!c for the introduced 
TCR; early after stimulation are primarily composed of the intro-
duced TCR: and TCR; chains. To demonstrate that the kinetics 
of TCR expression in dual TCR engineered T-cells is not in9u-
enced by the speci!city of the virus-speci!c T-cells or the trans-
ferred TCR, we performed similar experiments with HA-"-TCR or 
CMV-TCR td EBNA(A T-cells. Figure "B, "C and "D demonstrate 
that the TCR td pp5% and TCR td EBNA(A T-cells showed similar 
TCR expression kinetics using mAbs against TCR:;, CD( and 
against the endogenous and introduced TCR; chains, respec-
tively. Eventually, TCR make up as expressed by both mock and 
TCR td T-cells before stimulation was re-established 6 days after 
stimulation.
Based on these results, we conclude that although the 
retrovirally introduced and endogenous TCRs demonstrate a 
similar rapid downregulation after antigen-speci!c stimulation, 
the introduced TCR is re-expressed signi!cantly faster at the 
T-cell surface compared to the endogenous TCR.
Fast re-expression of introduced TCR is not re'ected in restored 
tetramer binding
Since the introduced TCR chains were re-expressed signi!cantly 
faster at the cell surface compared to endogenous TCR chains, 
tetramers were used to stain the introduced as well as the en-
dogenous TCRs at )h and )'h after stimulation (Figure (A and 
B). Consistent with the downregulation of TCR-CD( complexes 
)h after antigen-speci!c stimulation, we observed a marked 
reduction in the tetramer binding to both the introduced TCR 
as well as the endogenous TCR (Figure (A, B), and this reduc-
tion in tetramer binding resembled tetramer staining of mock 
td virus-speci!c T-cells after TCR-triggering (Figure (A, B). In 
contrast, whereas the cell surface expression of the introduced 
TCR was restored )'h after antigen-speci!c stimulation, no 
restored tetramer staining of the introduced TCR was observed. 
Since tetramer binding can be CD' dependent, CD' expression 
was analyzed at di-erent time points after stimulation of TCR td 
T-cells (Figure (A and C). Consistent with the downregulation 
"'
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Figure &. Restored introduced TCR expression is not coincided with restored tetramer staining, possibly due to low CD*  expression.
Figure &: The cell surface expression of CD&, 
CD*  and the endogenous and exogenous TCR 
using tetramers was analyzed (h and (*h 
after stimulation via either the endogenous 
or introduced TCR using speci"c peptide 
pulsed LCLs. (A) As a representative example 
histograms of CD&, CD*  and tetramer stain-
ings are depicted for mock td pp,- T-cells and 
HA-)-TCR td pp,- T-cells (h and (*h after no 
stimulation ("lled histograms), or stimulation 
via either the endogenous CMV-TCR (thick 
grey line) or introduced HA-)-TCR (dotted 
black line) by LCL-Z pulsed with pp,- or HA-) 
peptide, respectively. In addition, the experi-
ments were repeated with the same cells as 
well as mock td, HA-)-TCR td, and CMV-TCR 
td EBNA&A T-cells stimulated via their endog-
enous or introduced TCR using speci"c peptide 
pulsed LCLs. At the indicated time points mock 
and TCR td T-cells were stained for (B) the en-
dogenous or introduced TCR using tetramers 
or (C) CD*. The cell surface expression of T-cells 
stimulated with unpulsed LCL (no stim) was 
set at !../. Per timepoint the percentage cell 
surface expression was calculated as follows: 
[MFI of T-cells with peptide pulsed LCL / MFI 
of T-cells with unpulsed LCL] * !... Data from 
( independent experiments were combined.  
"&
of TCR-CD( complexes )h after antigen-speci!c stimulation a 
marked downregulation of the CD' complex on mock td and 
TCR td T-cells was observed. The expression of CD' increased 
gradually, however, )'h after stimulation, CD' expression 
was still diminished (#-)#8 compared to non-stimulated 
TCR td T-cells. This reduced CD' expression was compara-
ble with the CD' expression of mock td T-cells )'h after TCR 
triggering(Figure (A and C). These data indicate that although 
the introduced TCR is rapidly re-expressed at the cell surface this 
TCR-CD( complex is not able to bind the speci!c tetramer, prob-
ably due to downregulated CD' expression. 
Rapid TCR re-expression does not result in restored T-cell 
functionality
Tetramer binding after T-cell activation is described to re9ect the 
functional activity of the T-cells("5). Therefore, we investigated 
whether high TCR expression but low tetramer binding re9ected 
reduced or restored e-ector functions. For this purpose, HA-
"-TCR td pp5% T-cells were stimulated via the endogenous or 
introduced TCR and tested at di-erent time points for function-
ality via both TCRs in a cytotoxicity assay (Figure )). Early after 
TCR stimulation ()h) with pp5% peptide, mock and HA-"-TCR td 
pp5% T-cells were not able to recognize EBV transformed lym-
phoblastoid cell lines (LCLs) expressing endogenously processed 
pp5% antigen (Zpp5%), as well as LCLs expressing endogenously 
processed HA-" (LCL-RZ). Likewise, )h after TCR stimulation 
with HA-" peptide TCR td T-cells were unable to recognize HA-" 
positive LCL-RZ, as well as LCL-Zpp5%. Although the HA-"-TCR 
cell surface expression at ")h after stimulation with either pp5% 
peptide or HA-" peptide was restored to almost normal levels 
on the TCR td T-cells, no increase in cytotoxicity directed against 
LCL-RZ was observed, whereas some increased cytotoxic activity 
against LCL-Zpp5% was observed when T-cells were stimulated 
with HA-" peptide. Analyses of the cytotoxic activity after )'h 
of stimulation demonstrated that in contrast to what could be 
expected from the cell surface expression, the cytotoxic activ-
ity against LCL-RZ was still not restored. Comparable cytotoxix 
activity of TCR td T-cells and mock td T-cells was observed 
against LCL-Zpp5%. Eventually, when 6 days after stimulation the 
TCR make-up re-established to a comparable TCR make-up as 
expressed before stimulation, also functionality via both TCRs 
was restored (data not shown).
In conclusion, these results demonstrate that TCR cell 
surface expression is not accurately re9ected in functionality and 
restored expression of the introduced TCR on the cell surface 
does not necessarily result in restored T-cell functionality.
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Figure (. Despite rapid re-expression of the introduced TCR, T-cell functionality is not restored
Figure (: To determine the cytolytic activity after 
stimulation, mock (Mock td) and HA-)-TCR td 
pp,- T-cells (TCR td) were either control stimu-
lated with LCL-Z (control stim; white bars), or 
stimulated via the endogenous TCR with LCL-Z 
pulsed with pp,- peptide (stim pp,- pep; grey 
bars) or via the introduced TCR with LCL-Z 
pulsed with HA-) peptide (stim HA-) pep; black 
bars) and tested for cytotoxic reactivity at (h, 
)(h or (*h after stimulation as indicated above 
the panels. Targets used were pp,- positive LCL-
Zpp,- and HA-) positive LCL-RZ as indicated on 
the x-axis. Cytotoxic reactivity exerted by control 
and peptide stimulated mock and HA-)-TCR 
td T-cells after (h of co-incubation with either 
chromium labeled LCL-Zpp,- or LCL-RZ as 
target cells is depicted. The cytolytic reactivity of 
mock td and TCR td T-cells stimulated with un-
pulsed LCL (control stim) was set at !../. Per 
timepoint the percentage cell surface expression 
was calculated as follows: [/ lysis of T-cells with 
peptide pulsed LCL / / lysis of control T-cells] * 
!... The average / lysis of control stimulated 
mock td T-cells directed against LCL-Zpp,-  = 
,!/. The average / lysis of control stimulated 
TCR td T-cells directed against LCL-Zpp,- = 
--/ and directed against LCL-RZ = )-/.Data 
presented are representative for & independent 
experiments.
(#
No restored T-cell functionality despite su%cient expression of adhe-
sion molecules and lytic granules 
For restored functionality of e-ector T-cells, adhesion molecules 
at the cell surface like LFA-$ (CD$$a) and LFA-" (CD") are needed 
for optimal target cell interaction as well as cytotoxic capacity("6-"&). 
To test whether low expression of adhesion molecules could have 
hampered  restored lytic activity, HA-"-TCR td pp5% T-cells were 
stimulated and analyzed for expression of these molecules )h and 
)'h after stimulation using mAbs directed against CD$$a and CD" 
and as a control for staining artefacts resulting from T-cell activa-
tion also the corresponding ligand for CD", namely CD%' (ICAM-
(), that is normally functioning on antigen presenting cells and 
isotype controls were measured. Expression of these molecules 
was compared with expression of CD' (Figure %A). In contrast 
to clear downregulation of CD' after stimulation, no signi!cant 
decrease in cell surface expression of adhesion molecules is 
observed )h as well as )'h after stimulation (Figure %A). To test 
whether reduced intracellular amounts of cytolytic granules was 
hampering restored lytic activity, the level of intracellular gran-
zyme B was measured )h and )'h after stimulation. Although 
)h after stimulation the amount of cytolytic granules stored was 
slightly decreased, )'h after stimulation even higher amounts of 
granzyme B were present in the TCR td pp5% T-cells. These results 
demonstrate that restored T-cell functionality is not hampered 
due to low expression of adhesion molecules or low intracellular 
amount of lytic granules.
D I S C U S S I O N
In this study, we demonstrated that early after antigen-speci!c 
stimulation of TCR td T-cells both the endogenous and intro-
duced TCR complexes were downregulated irrespective of which 
TCR was triggered. The introduced and endogenous TCR were 
downregulated upon stimulation via the introduced TCR and 
likewise, the endogenous and introduced TCR were downregu-
lated upon endogenous TCR stimulation. In agreement with this, 
we demonstrated that the functional activity both via the stimu-
lated as well as the non-stimulated TCR was markedly reduced, 
indicating that stimulation via one TCR resulted in a period of 
non-responsiveness via both TCRs. Although TCR downregula-
tion shortly after TCR triggering was similar in TCR td T-cells 
compared to mock td T-cells, we demonstrate that the intro-
duced TCR under regulation of a retroviral promotor was rapidly 
re-expressed on the cell surface at ")h after TCR stimulation, 
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Figure -. Reduced lytic activity of introduced TCRs is not associated with loss of granzyme or expres-
sion of adhesion molecules
Figure -: HA-)-TCR td pp,- T-cells were 
stimulated with unpulsed LCL-Z (no stim; 
"lled histograms) or pulsed with pp,- and 
HA-) peptide, and analyzed (h (stim (h; 
thick grey line) and (*h (stim (*h; thick 
black line) thereafter for surface expression of 
CD*  coreceptor, adhesion molecules CD)  and 
CD!!a and for intracellular amount of gran-
zyme B. As a control, cell surface expression 
of the CD-*  molecule which is the ligand for 
CD)  and isotype controls (black hairline) are 
depicted. Data depicted are representative for 
) independent experiments.
($
whereas the CD' coreceptor as well as the endogenous TCR 
were still downregulated similar to mock td T-cells. Despite rapid 
re-expression of the introduced TCR, however, the T-cells were 
still physiologically non-responsive, similar to mock td T-cells. 
The T-cells exerted low cytolytic activity when stimulated via the 
endogenous or introduced TCR despite su7cient expression of 
adhesion molecules or intracellularly stored lytic granules. These 
results illustrate that cell mechanisms other than TCR cell surface 
expression are involved in providing a physiological period of 
non-responsiveness.
TCR cell surface expression is tightly controlled, 
and requires assembly of TCR:; with all CD( subunits((#-()). 
Unassembled TCR subunits and incomplete complexes are 
either rapidly degraded or retained in the ER((%-(6). We therefore 
assume that the lack of restored functionality despite restored 
re-expression of the introduced TCR is unlikely to be due to 
cell surface expression of inappropriate assembled TCR-CD( 
complexes. Our data on TCR downregulation of mock td T-cells, 
however, are in accordance with previous results showing that 
ligand-induced TCR degradation causes a prolonged reduction 
in the level of TCR expression and that over 6"h were required 
for normalization of the TCR cell surface expression("#,('). At the 
same time, the rapid re-expression of the introduced TCR chains 
after TCR-triggering of the TCR td T-cells indicates as proposed 
previously by others, that ")h after initial activation adequate 
levels of all CD( subunits("() are present and are not limiting TCR 
cell surface expression.
Although ")-)'h after TCR stimulation the introduced 
TCR is re-expressed at the cell-surface, we could hardly detect 
the TCR complexes using tetrameric complexes and, in addi-
tion, the TCR td T-cells remained physiologically non-responsive 
comparable to mock td T-cells. Previously, it has been reported 
that after antigen-speci!c stimulation, tetramer staining is im-
paired despite almost completely restored TCR expression("5) and 
T-cells with redistributed TCRs but no or low tetramer staining 
were unable to completely exert their e-ector functions("5). Our 
results demonstrate that the non-responsiveness of the TCR td 
T-cells could in part be due to reduced CD' coreceptor expres-
sion, since )'h after speci!c stimulation the CD' coreceptor 
expression was still downregulated. However, because a very 
small number of MHC-peptide complexes is su7cient to activate 
a T-cell((&-)"), we hypothesize that restoration of CD' expression 
levels )'h after stimulation to 5#-6#8 of normal expression 
levels should be su7cient to result in restored functionality via 
the HA-"-TCR. It has been described previously that CTLs with 
low e-ector function and a low ability to bind tetramers despite 
having normal amounts of TCR and CD' expressed on their cell 
surface lacked colocalization of TCR and CD' molecules ()(,))). 
Besides ine7cient colocalization of TCR and CD', other cell 
mechanisms may have provided the TCR td T-cells with a protec-
tive refractory period as well.
An alternative explanation for the discordance in TCR 
expression and the absence of tetramer staining as well as func-
tional activity could be the formation of mispaired TCR dimers. 
Theoretically, rapidly re-expressed TCR-complexes at the cell 
("
surface of TCR transferred T-cells can consist of the introduced 
TCR; chain pairing with either the introduced TCR: or endog-
enous TCR: chain. In this study we used mAbs against total 
TCR:;-complexes and mAbs speci!c for the TCR; chains of the 
endogenous or introduced TCRs. Unfortunatley, these mAbs do 
not allow analysis of mispaired TCR dimers. However, it is unlikely 
that restored TCR:;-complexes consist of mixed TCR dimers. 
Restored total TCR:; cell surface expression corresponded to 
the restored introduced TCR; expression but not to the still 
decreased endogenous TCR; expression. Both the endogenous 
TCR: and ; chain are under control of an endogenous promotor 
and it seems plausible that the endogenous TCR: chain will still 
be downregulated ")h after stimulation, similar to the endog-
enous TCR; chain. Furthermore, the introduced TCR: and TCR; 
chain are both regulated via a retroviral LTR, which is activated 
upon TCR triggering. This is demonstrated in Figure $ depicting 
increased eGFP expression after stimulation, which is in our stud-
ies linked to TCR: chain expression. Based on these arguments 
we assume that rapid re-expression of the introduced TCR; chain 
is coincided with rapid re-expression of the introduced TCR: 
chain.
We con!rmed comodulation of non-engaged TCRs as 
already observed by others()%-)'), although other studies failed to 
demonstrate comodulation()&,%#). Furthermore, we demonstrated 
that the functional activity both via the stimulated as well as 
the non-stimulated TCR was markedly reduced, indicating that 
stimulation via one TCR resulted in a protective refractory period 
comprising of non-responsiveness via both TCRs. 
Although the introduced and endogenous TCR are 
di-erently expressed directly after TCR stimulation, T-cells were 
completely functional again after %-6 days, both via the endog-
enous and introduced TCR. At that time, the cell surface expres-
sion of both TCRs could be visualized with tetramers (data not 
shown).
In this study we con!rmed that T-cell activation results 
in increased viral promotor activity and thus in increased intro-
duced TCR cell surface expression($"-$)). It has been postulated that 
for sustained optimal cell surface expression of the introduced 
TCR, TCR td T-cells must be repetitively activated. This could be 
achieved using speci!c vaccination strategies encoding antigens 
recognized by the introduced TCR to reactivate the viral promo-
tor regulating the introduced TCR(%$). However, if TCR td T-cells 
in a state of minimal residual disease encounter their antigen 
sporadically, cell surface expression of the introduced TCR will 
be low due the non-activated status of TCR td T-cells. Therefore, 
knowledge of the speci!city of the endogenous TCR could pro-
vide a tool to induce proliferation and increased activity of TCR 
engineered T-cells(%"). To minimize the risk of loss of expression 
of the introduced TCR, usage of TCR td EBV- and CMV-speci!c 
T-cells can be an attractive strategy. These T-cells will frequently 
encounter viral antigens due to the latent presence of these 
viruses and this triggering of the endogenous TCR may result in 
increased introduced TCR expression in vivo. We have previously 
demonstrated that TCR td CMV-speci!c T-cells remained dual 
reactive via both the endogenous and introduced TCR, also after 
repetitive stimulation via the virus-speci!c TCR(%().
((
In conclusion, we have demonstrated that irrespective 
of whether the endogenous or introduced TCR is triggered, 
both the endogenous and the introduced TCRs are downregu-
lated, resulting in a protective refractory period via both TCRs. 
Furthermore, we have shown that regulation of the introduced 
TCR by a viral promotor results in fast re-expression of TCR 
chains on the cell surface ")h after TCR triggering, but that this 
re-expression does not lead to immediate restored functionality, 
indicating a preserved protective refractory period. On bases of 
these results we conclude that TCR transduced T-cells can poten-
tially be an e-ective treatment strategy due to maintenance of 
a normal physiological protective refractory period via both the 
endogenous and introduced TCR despite rapid re-expression of 
the introduced TCR.
M AT E R I A L S  A N D  M E T H O D S
Construction of retroviral vectors and production of retroviral 
supernatant
The construction of retroviral vectors encoding for the TCR 
chains of the HA-"-speci!c T-cell clones HA-".5 and HA-".%, and 
the TCR-AV$' chain and TCR-BV$( chain of the CMV pp5%-
speci!c T-cell clone have been described previously(%). Brie9y, the 
HA-".5-TCR-AV"(, HA-".%-TCR-AV$% and CMV-TCR-AV$' were 
cloned into bicistronic retroviral vectors encoding for the marker 
gene eGFP. The HA-".5-TCR-BV$', HA-".%-TCR-BV$', and CMV-
TCR-BV$( were cloned in combination with the truncated nerve 
growth factor receptor (NGF-R)(%)). Retroviral vectors encoding 
eGFP or NGF-R only were used as control vectors. The Moloney 
murine leukemia virus-based retroviral vector LZRS and packag-
ing cells A-NX-A were used to obtain viral supernatant(%%). 
HLA Class I tetrameric complexes and 'ow cytometric analyses
PE- or APC-conjugated tetrameric complexes were constructed 
as previously described(%5) with minor modi!cations. The fol-
lowing tetramers were used; tetrameric HLA-A" molecules in 
complex with CMV-pp5% derived peptide NLVPMVATV (CMV 
tetramer) or HA-" peptide YIGEVLVSV (HA-" tetramer), and 
tetrameric HLA-B6 molecules in complex with EBV EBNA(A 
derived RPPIFIRRL (EBV tetramer). For 9ow cytometric analy-
ses cells were labeled with tetramers for $ h at )ºC in RPMI 
without phenol, supplemented with "8 FBS, and washed 
two times or labeled with monoclonal antibodies (mAb) di-
rected against various cell surface molecules for (# minutes at 
)ºC. The mAbs used were anti-BV$(, anti-BV6, anti-BV$' and 
anti-BV", all PE-conjugated (Beckman Coulter, Mijdrecht, The 
Netherlands), anti-TCR:; PE-Cy%-conjugated and CD( APC- or 
PE-conjugated (BD Pharmingen, San Diego, CA, USA) and CD' 
APC- or PE-conjugated (Invitrogen, Paisley, UK). For detection 
of BNGF-R, anti-human NGF-R mAbs were used either PE- (BD 
Pharmingen, San Diego, CA, USA) or APC-conjugated (Cedarlane 
Laboratories, Hornby, Ontario, Canada). For the di-erent adhe-
sion and costimulatory molecules PE-conjugated anti-CD%) 
(CLB, Amsterdam, The Netherlands), anti-CD%' (Southern 
Biotechnology Associates, Birmingham, AL, USA), anti-CD" , 
()
anti-CD$$a, and anti-CD%# (BD Pharmingen, San Diego, CA, USA) 
were used. For intracellular stainings, T-cells were stained with 
mAbs for "# minutes at )ºC and were subsequently !xated for 
$# minutes using paraformaldehyde. T-cells were permeabilized 
by washing " times using PBS containing saponine, stained for 
another "# minutes at )ºC, washed and analyzed using FACS.
Isolation, transduction and culture of T-cells and LCLs 
Puri!ed (>&%8 pure) HLA-A"-restricted CMV pp5% NLV-speci!c 
T-cells (pp5% T-cells) and HLA-B6-restricted EBV EBNA(A RPP-
speci!c T-cells (EBNA(A T-cells) were isolated from peripheral 
blood of EBV and CMV seropositive healthy individuals using 
tetramers. After informed consent, peripheral blood mononuclear 
cells (PBMCs) were harvested and labeled with tetramers for $ 
h at ) ºC in RPMI without phenol supplemented with "8 FBS, 
washed, and sorted at ) ºC using the FACS Vantage™ (Becton 
Dickinson, San Jose, CA, USA). Tetramer-positive T-cells were stim-
ulated with PHA (Murex Biotec Limited, Dartford, UK) and irradi-
ated feeder cells ((# Gy), and after " d of culture, the T-cells were 
transduced with retroviral supernatant. The transduction proce-
dure used for the peripheral blood T-cells has been described pre-
viously(%6). In brief, $x$#6 T-cells were cultured on CH-"&5-coated 
")-well non-tissue culture-treated plates (Falcon) together with 
$ ml thawed retroviral supernatant overnight at (6ºC, washed, 
and transferred to ")-well tissue culture plates. TCR transduced 
(td) virus-speci!c T-cells were sorted on bases of marker gene 
expression and cultured in IMDM supplemented with %8 FBS, 
%8 human serum and IL-" ($## IU/ml) (Chiron, Amsterdam, The 
Netherlands). T-cells were nonspeci!cally stimulated every " wk 
with feeder cell mixtures containing $x$#6/ml irradiated allogeneic 
PBMCs ((#Gy), $x$#5/ml irradiated EBV-transformed B cells (LCLs; 
%# Gy), and PHA ('## ng/ml).
For TCR internalization and re-expression assays di-er-
ent LCLs were used. LCL-Z and LCL-RZ originate from an HLA-
identical sibling pair with HA-" disparity. LCL-Z is HLA-A" positive 
but HA-" negative, while LCL-RZ is HLA-A" and HA-" positive. 
Both LCLs were transduced with HLA-B6, and pulsed with the 
EBNA(A peptide in particular experiments. To obtain LCLs 
presenting endogenously processed pp5%, LCL-Z was transduced 
with the lower matrix protein pp5% of HCMV AD$5& (Zpp5%). 
LCLs were maintained in IMDM supplemented with $#8 FBS. 
This study was approved by the Leiden University Medical Center 
institutional review board.
TCR internalization assay
"x$#4 TCR td and mock td T-cells were plated in &5-well 
U-bottomed microtiter plates. LCL-Z was used as stimulator cell, 
either unpulsed, or pulsed with $ µM of pp5% or HA-" peptide for 
$ h at (6ºC. In some assays, HLA-B6 td LCL-Z was pulsed with $ 
µM of EBNA(A peptide. At di-erent time points, "x$#4 LCLs were 
added to the T-cells in a !nal volume of "## µl in medium contain-
ing (# IU/ml of IL-". After a stimulation period of maximal 6" h 
at (6ºC and %8 CO", &5-well U-bottomed microtiter plates were 
spinned down, and T-cells were either tested functionally in a 
chromium release assay or cells were stained with di-erent mAbs 
and analyzed for cell surface expression by 9ow cytometry. Cell 
(%
surface expression was calculated as follows: [MFI of T-cells with 
stimulator / MFI of T-cells without stimulator] * $##.
Cytotoxicity assay
$x$#4 TCR td and mock td T-cells were plated in &5-well 
U-bottomed microtiter plates and stimulated using LCL-Z either 
unpulsed or pulsed with $ µM of pp5% or HA-" peptide. Target 
cells were labeled with 6# µCi Na"51CrO) for $ h at (6ºC, washed 
three times, and added at di-erent time points after antigen-
speci!c stimulation to the e-ector cells in a !nal volume of $%# 
µl IMDM supplemented with $#8 FBS in &5-well U-bottomed 
microtiter plates, resulting in a $#:$ e-ector-to-target-ratio. Target 
cells were pulsed with EBNA(A, pp5% or HA-" peptide ($ µM) 
during Na"51CrO) labeling. Targets incubated in medium or 
$8 Triton X-$## were used for determination of the spontane-
ous and maximum release, respectively. The tests were done in 
triplicate. After ) h of incubation at (6ºC and %8 CO", "% µl of 
the supernatant was harvested and measured in a luminescence 
counter (Topcount-NXT, Packard Instrument Company, Meriden, 
CT, USA). The percentage of speci!c lysis was de!ned as [(ex-
perimental release – spontaneous release) / (maximum release 
– spontaneous release)] * $##.
Statistics
Cell surface expression of the TCR chains and complexes, CD( 
and CD' of stimulated TCR and mock transduced virus-speci!c 
T-cells were evaluated in a paired fashion by use of the students’  
T-test at each time interval ()h, ")h and )'h). Reported P values 
are "-sided and were considered statistically di-erent if <#.#$. 
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Adoptive transfer of antigen speci!c T-cells is an attractive strat-
egy for the treatment of hematological malignancies. It has been 
demonstrated that T-cells recognizing minor histocompatibility 
antigens (mHags) selectively expressed on hematopoietic cells 
mediate anti-leukemic reactivity after allogeneic stem cell trans-
plantation (allo-SCT ). However, large numbers of T-cells with 
de!ned speci!city are di7cult to attain. An attractive strategy 
to obtain large numbers of leukemia-reactive T-cells is retroviral 
transfer of mHag-speci!c T-cell receptors (TCRs). TCR transfer 
into T-cells speci!c for persistent viruses may enable these T-cells 
to proliferate both after encountering viral antigens as well as 
mHags, increasing the possibility of in vivo survival. We analyzed 
whether the dual-speci!city of the TCR transferred T-cells after 
repetitive stimulation via either the introduced anti-leukemic 
HA-"-TCR or the endogenous CMV-TCR was preserved. We 
demonstrate that after repetitive stimulation, T-cells skew to 
a population predominantly expressing the triggered TCR. 
However, HA-"-TCR transferred CMV-speci!c T-cells with high 
anti-leukemic HA-"-TCR expression but low CMV-TCR expres-
sion were able to persist and proliferate after repetitive stimula-
tion with pp5%. Moreover, HA-"-TCR transferred CMV-speci!c 
T-cells remained dual-speci!c after repetitive stimulation and 
TCR expression could be reverted after additional stimulation via 
the previously non stimulated TCR, restoring high avidity inter-
actions. These data imply persistence of TCR transferred virus-
speci!c T-cells with both anti-leukemic and anti-virus reactivity 
in vivo.
Kinetic preservation of dual-speci,city of 
coprogrammed minor histocompatibility 
antigen-reactive virus-speci,c T-cells
Cancer Res. "##& Mar $;5&(%):"#()-)$. Epub "##& Feb $6. Reprinted with permission.
Marleen M. van Loenen, Renate S. Hagedoorn, Michel G.D. Kester, Manja Hoogeboom, Roel Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
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A B S T R AC T
('
I N T R O D U C T I O N
Patients with relapsed hematological malignancies after HLA-
matched allo-SCT can be succesfully treated with donor lympho-
cyte infusion (DLI)($,"). However, the bene!cial graft versus leuke-
mia (GVL) e-ect of donor lymphocytes is frequently accompanied 
by graft versus host disease (GVHD). GVL as well as GVHD appear 
to be caused by T-cells that are capable of recognizing mHags on 
patient cells((-%). mHags are immunogenic peptides derived from 
polymorphic proteins presented in the context of HLA molecules 
which are disparate between donor and recipient. T-cell respons-
es against ubiquitously expressed mHags may be responsible for 
both GVL and GVHD. T-cells reactive with mHags selectively ex-
pressed on cells of the hematopoietic lineage may solely mediate 
GVL reactivity. HA-" and HA-$ are examples of mHags selectively 
expressed in cells of the hematopoietic system and are presented 
in an HLA-class I-restricted fashion(5,6).
To separate the bene!cial GVL from GVHD, adop-
tive transfer of T-cells recognizing mHags selectively expressed 
on cells of the hematopoietic system is a promising strategy. 
However, therapeutic cell numbers of mHag-speci!c T-cells are 
di7cult to attain. An attractive alternative would be to equip 
T-cells with mHag-speci!c TCRs via retroviral gene transfer. 
Di-erent studies have shown the e-ectiveness of TCR transferred 
T-cells in vitro('-$") and in vivo($(-$%). Redirected T-cells were able 
to produce cytokines and exhibited Ag-speci!c cytolytic activ-
ity when triggered via the introduced TCR. Moreover, in mouse 
models it was shown that redirected T-cells could be activated 
via their introduced TCR, home to e-ector sites, and eradicate 
tumors. Recently, Rosenberg and colleagues demonstrated in a 
clinical trial the feasibility of adoptive transfer of TCR engineered 
T-cells in melanoma patients($)).
In most TCR gene transfer studies unselected periph-
eral blood T-cells were used as recipient T-cells. Transfer of TCRs 
into an unselected pool of T-cells may lead to transduction into 
regulatory T-cells capable of impairing the anti-leukemic immune 
reaction. Furthermore, in a pool of T-cells with a diverse TCR 
repertoire, a high number of di-erent mixed TCR dimers with 
unknown speci!city can be formed due to pairing of the retro-
virally introduced TCR chains with the endogenously expressed 
TCR chains, increasing the probability of the formation of auto-
reactive mixed TCR dimers. Therefore, we previously proposed 
TCR transfer into virus-speci!c T-cells($5), since selection of these 
Ag-speci!c CD'+ T-cells leads to exclusion of regulatory T-cells. In 
addition, virus-speci!c memory T-cells generally consist of an oli-
goclonal population with restricted TCR:; usage($6-"$), minimizing 
the number of di-erent mixed TCR dimers that can be formed. 
Furthermore, adoptive immunotherapy with EBV-speci!c T-cells 
in patients with post-transplant proliferative disease and CMV-
speci!c T-cells as prophylaxis for CMV reactivation(""-")) in patients 
after SCT has proven to be a therapeutic strategy without toxicity 
or GVHD. Since EBV and CMV are examples of latent viruses, we 
hypothesize that due to frequent encounter with viral antigens 
and subsequent triggering of the endogenous TCR, TCR trans-
ferred virus-speci!c T-cells will survive for a prolonged period of 
time in vivo. Moreover, it was recently shown in a mouse model 
(&
that tolerization of one TCR could be overcome by signaling via 
the other TCR. In this model the function of the tolerized self-
tumor reactive TCR of dual-T-cell receptor transgenic T-cells was 
rescued by proliferation induced via the virus-speci!c TCR, un-
derlining the potency of TCR transfer into virus-speci!c T-cells("%). 
We previously demonstrated that CMV-speci!c T-cells 
could be redirected into anti-leukemic T-cells by transfer of TCRs 
directed against the mHag HA-" without the loss of their original 
speci!city. T-cells were capable of exerting e-ector functions via 
their endogenous virus-speci!c TCR as well as via their intro-
duced HA-"-speci!c TCR($5). The TCR cell surface make up of HA-
"-TCR transferred CMV-speci!c T-cells, however, varied. T-cells 
either highly expressed the endogenous TCR with a low expres-
sion of the introduced TCR, or highly expressed the introduced 
TCR with a low expression of the endogenous TCR, or expressed 
both TCRs intermediately at the cell surface. Di-erent studies 
have shown that there is a threshold in expression of TCR com-
plexes and costimulatory molecules needed for TCR signaling 
leading to proliferation("5,"6). Although both the HA-"-TCR and 
CMV-TCR used in this study are high-a7nity TCRs, it is likely that 
di-erential TCR expression leads to di-erences in avidity and 
thus in proliferation. For long-term protection, we hypothesize 
that proliferative capacity via both TCRs will be important. When 
patients relapse, mHags will be abundantly present. However, 
when there is only minimal residual disease (MRD) it may be 
expected that HA-"-TCR transferred virus-speci!c T-cells will pri-
marily encounter viral antigens latently present in the recipient, 
as the HA-" antigen is only expressed by recipient hematopoietic 
cells. When frequent encounter of viral antigens would lead to 
selective survival of HA-"-TCR transferred CMV T-cells predomi-
nantly expressing the CMV-TCR incapable of proliferating via 
the HA-"-TCR, persistence in vivo of HA-"-TCR transferred CMV 
T-cells capable of controlling MRD may fall short. 
In this study we analyzed the TCR expression, cytolytic 
potential and proliferation of HA-"-TCR transferred CMV-speci!c 
T-cells after repetitive stimulation with the CMV-pp5% antigen or 
the HA-" antigen. We demonstrate that TCR-transferred virus-
speci!c T-cells repetitively stimulated skewed to T-cells predomi-
nantly expressing one TCR. However, HA-"-TCR transferred 
CMV-speci!c T-cells with high anti-leukemic HA-"-TCR expres-
sion but low CMV-TCR expression were able to persist after re-
petitive stimulation with pp5%. Moreover, HA-"-TCR transferred 
CMV-speci!c T-cells preserved their functional activity via both 
TCRs after repetitive stimulation, and TCR expression could be 
reverted after additional stimulation, restoring high avidity func-
tionality of both the endogenous CMV-TCR and the introduced 
anti-leukemic HA-"-TCR. 
M AT E R I A L S  A N D  M E T H O D S
Construction of retroviral vectors and production of retroviral 
supernatant
The construction of retroviral vectors encoding for pp5% of 
HCMV AD$5& and the TCR chains of the HA-" reactive T-cell 
clone HA".% has been described previously($5). Brie9y, the 
)#
HA-"-TCR AV$% and HA-"-TCR BV$' chains were cloned into bi-
cistronic retroviral vectors encoding the marker genes eGFP and 
BNGF-R("'), respectively. As control vectors, retroviral vectors were 
used containing eGFP or CNGF-R only. 
HLA Class I tetrameric complexes and sorting by 'ow cytometry
Tetrameric HLA-A" molecules in complex with CMV pp5% derived 
peptide NLVPMVATV (CMV tetramer) and the HA-" derived pep-
tide YIGEVLVSV (HA-" tetramer) either PE- or APC-conjugated 
were constructed as previously described("&) with minor modi!ca-
tions. For 9ow cytometric analyses as well as FACS sorting, cells 
were labeled with tetramers for $ hour at )ºC in RPMI without 
phenol, supplemented with "8 FBS, and washed two times or la-
beled with either anti-BV" PE (Immunotech, Marseille, France), or 
anti BNGF-R either PE- (PharMingen, San Diego, California, USA) 
or APC-conjugated (Cedarlane Laboratories, Hornby, Ontario, 
Canada) for (# minutes at )ºC. 
Cells 
For all stimulations and functional experiments EBV-transformed 
lymphoblastoid cell lines (EBV-LCLs) were used of an HLA-
identical sibling pair with HA-" disparity. EBV-LCL Z is HLA-A" 
positive but HA-" negative (EBV-Z), while EBV-LCL RZ is HLA-A" 
and HA-" positive (EBV-RZ HA-"). To obtain EBV-LCLs presenting 
endogenously processed pp5%, EBV-Z was transduced with the 
lower matrix protein pp5% of CMV (EBV-Z pp5%). EBV LCLs were 
maintained in IMDM supplemented with $#8 FBS.
Malignant cells used in this study were chronic myeloid 
leukemia mononuclear cells (CML) CML-Z which is HLA A" posi-
tive but HA-" negative and CML-T which is HLA A" and HA-" 
positive. CML cells were thawed $ day prior to testing and cul-
tured in IMDM supplemented with $#8 FBS.
Virus speci!c T-cells were isolated from peripheral 
blood of healthy individuals using CMV tetramers, as previously 
described($5), and expanded in T-cell medium containing IMDM 
supplemented with %8 FBS, %8 human serum and $## IU/ml IL-". 
T-cells were non speci!cally stimulated using '## ng/ml PHA 
(Murex Biotec Limited, Dartford, UK) and irradiated autologous 
feeder cells. The CMV-speci!c T-cells were subsequently sorted 
using anti-BV" PE, and non speci!cally restimulated, followed by 
retroviral transduction at day ". For the transduction procedure 
recombinant human !bronectin fragments CH-"&5((#,($) were used. 
HA-"-TCR transduced BV" positive T-cells were FACS sorted 
based on eGFP and NGF-R positivity, and the cells were ex-
panded in bulk. T-cells were cultured in T-cell medium and either 
stimulated non speci!cally every " weeks with feeder cell mix-
tures containing $x$#6/ml irradiated allogeneic PBMCs ("#Gy) and 
$x$#5/ml irradiated EBV-LCLs (%# Gy), or were repetitively stimu-
lated with $x$#6/ml irradiated HLA-A" negative allogeneic PBMCs 
and $x$#5/ml irradiated EBV-RZ HA-" or EBV-Z pp5%. Subsets of 
HA-"-TCR transduced virus-speci!c T-cells with various levels of 
TCR cell surface expression were sorted based on either high 
CMV-TCR and low HA-"-TCR expression using a combination 
of anti-BV" mAb and HA-" tetramer, or based on low CMV-TCR 
expression using only anti-BV" mAb. No tetramers were used for 
)$
positive selection, since tetramer binding to the TCR can lead to 
speci!c stimulation(("). Subsequently, sorted T-cells were tested 
functionally either directly after sorting, or after 6 days of stimula-
tion with pp5% or HA-". This study was approved by the Leiden 
University Medical Center institutional review board.
Cytotoxicity assay and PKH-$( based proliferation assay
Cytotoxicity assay was performed as previously described($5) us-
ing a standard ) hours 51Cr release assay at $#:$ e-ector-to-target 
ratios. The tests were done in duplicate. To test the capacity of 
T-cells to speci!cally proliferate in response to antigen, T-cells 
were labeled with PKH-"5 (St. Louis, Missouri, USA) according to 
manufacturer’s instructions, and stimulated with di-erent feeder 
cell mixtures containing $x$#6/ml irradiated allogeneic HLA-A" 
negative PBMCs in combination with $x$#5/ml target cells. The 
following targets were used: EBV-Z either unpulsed or pulsed 
with $ µg/ml CMV-NLV or HA-" YIG peptide, EBV-Z pp5% and 
EBV-RZ HA-". Alternatively, T-cells were stimulated non-specif-
ically by adding PHA. PKH dilution was analyzed at day ) after 
stimulation using 9ow cytometry.  
R E S U LT S
Skewing of TCR cell surface make-up upon speci)c TCR triggering
We hypothesize that for long-term protection the capacity of TCR 
transferred virus-speci!c T-cells to proliferate and exert e-ector 
functions in response to triggering via each TCR is important. 
Therefore, we studied whether repetitive Ag-speci!c stimula-
tion of these dual-speci!c T-cells resulted in skewing of T-cells to 
a population predominantly expressing one TCR, incapable of 
exerting e-ector functions via the other TCR. For this purpose, 
T-cells recognizing the pp5% protein of CMV in the context of 
HLA-A" (pp5%-NLV) were isolated from PBMCs of healthy CMV 
seropositive individuals, transduced with the mHag-speci!c 
HA-"-TCR, and sorted on basis of marker gene expression. 
These TCR transferred virus-speci!c T-cells showed di-erences 
in TCR cell surface make up, which was stable for months after 
repetitive non-speci!c TCR triggering. The T-cells expressed 
either both TCRs at intermediate levels at the cell surface, or 
the endogenous TCR was highly expressed with a low expres-
sion of the introduced TCR, or the introduced TCR was highly 
expressed with a low expression of the endogenous TCR (Figure 
$A). These HA-"-TCR transferred CMV T-cells exerted cytolytic 
activity directed against HA-" expressing EBV-LCLs, as well as 
HA-" expressing mononuclear CML cells (Figure $B). To test 
whether all di-erent T-cell subpopulations were able to persist 
after repetitive stimulation with either pp5% or HA-", the dual-
speci!c T-cells were stimulated with EBV-LCLs expressing either 
endogenously pp5% or HA-". Di-erences in TCR expression were 
measured at day 6 after stimulation using CMV and HA-" te-
tramers (Figure $C). A gradual decrease in HA-"-TCR expression 
was observed after repetitive stimulation with pp5%. Likewise, 
a gradual decrease in CMV-TCR expression was observed after 
repetitive stimulation with HA-", while HA-"-TCR expression 
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Figure !. Cell surface expression and functional activity of the introduced and endogenous TCR after repetitive antigen-speci"c 
stimulation.
Figure !.: (A)  CMV and HA-) tetramer staining was 
analyzed for mock and HA-)-TCR transferred puri-
"ed CMV T-cells previously sorted on eGFP en NGF-R 
marker gene positivity. Numbers indicate / T-cells 
per quadrant. (B) Mock CMV T-cells and HA-)-TCR 
transferred CMV T-cells were tested for anti-pp,- and 
anti-leukemic reactivity in an 51Cr release assay. Target 
cells were EBV-Z, EBV-Z pp,-, EBV-RZ HA-), HLA-A)+ 
HA-)- CML-Z (CML-Z) and HLA-A)+ HA-)+ CML-T 
(CML-T). (C) CMV and HA-) tetramer staining was 
analyzed for HA-)-TCR transferred CMV T-cells after 
every stimulation. T-cells were either stimulated three 
times with pp,- (black squares), or twice with pp,- and 
additionally with HA-) (grey squares), or T-cells were 
stimulated three times with HA-) (black circles) or twice 
with HA-) and additionally with pp,- (grey circles). The 
percentage of tetramer positive T-cells is shown. (D) The 
dot plots of CMV and HA-) tetramer staining of HA-)-
TCR transferred CMV T-cells after three rounds of stimu-
lation as indicated in (C) are depicted. Per quadrant / 
T-cells are indicated, numbers in brackets indicate MFI 
of the tetramer positive T-cell population. (E) HA-)-TCR 
transferred CMV T-cells stimulated three times with 
either pp,- or HA-), and mock CMV T-cells were tested 
for cytotoxic activity against HA-) and pp,- positive tar-
gets. The T-cells were tested at an E:T ratio of !.:! against 
EBV-Z, pp,- peptide pulsed EBV-Z (EBV-Z + pp,- pep-
tide), EBV-Z pp,-, HA-) peptide pulsed EBV-Z (EBV-Z 
+ HA-) peptide), and EBV-RZ HA-). Data shown is 
representative for two independent experiments.
reversed by changing the stimulation, T-cells 
that were stimulated twice with pp5% were 
stimulated alternatively with HA-". Likewise, 
T-cells that were stimulated twice with HA-" 
were stimulated alternatively with pp5%. The 
results demonstrate that by Ag-speci!c trig-
gering of the previously non triggered TCR the 
TCR expression rapidly reverted (Figure $C). 
On bases of the changed TCR make up (Figure 
$D) we tested the HA-" TCR transferred virus-
speci!c T-cells stimulated repetitively with 
either only pp5% or only HA-" for Ag-speci!c 
cytotoxic capacity (Figure $E). Both T-cell popu-
lations were capable of killing HA-" peptide 
loaded target cells, but the cytolytic activity 
of HA-"-TCR transduced T-cells repetitively 
stimulated with pp5% directed against target 
cells endogenously expressing HA-" (EBV-RZ 
HA-") was reduced. This was in accordance 
with the TCR expression, since in the T-cell 
population repetitively stimulated with pp5%, 
only low numbers of HA-" tetramer positive 
T-cells were present, while in the T-cell popu-
lation repetitively stimulated with HA-" still 
signi!cant numbers of CMV tetramer positive 
T-cells were present. 
These data illustrate that repeti-
tive stimulation of HA-"-TCR transferred 
)(
CMV-speci!c T-cells with either HA-" or CMV pp5% antigen 
resulted in preferential TCR expression of the triggered TCR, 
whereas expression of the non-triggered TCR gradually de-
creased. However, the T-cells with either predominant CMV or 
HA-"-TCR expression preserved their dual-speci!city, although 
the level of reactivity in response to activation of the triggered 
TCR was higher than via the non-triggered TCR. In addition, 
changes in TCR expression could rapidly be reverted by Ag-
speci!c triggering of the previously non-triggered TCR. 
Generation and functionality of opposing T-cell subsets
To be able to dissect whether the di-erence in TCR make up af-
ter reverting the stimulation of T-cells predominantly expressing 
one TCR was due to selective outgrowth or due to di-erential 
TCR distribution, these T-cells were sorted into opposing subsets 
with either high CMV-TCR expression based on high CMV-TCR 
BV" mAb staining and low HA-" tetramer staining (Figure "A; 
CMV-TCRhi), or low CMV-TCR expression based on low CMV-
TCR BV" mAb staining (!gure "A; HA-"-TCRhi). No tetramers 
were used for positive selection of the T-cells, since binding of 
the tetramers to the TCR would result in Ag-speci!c triggering 
via either the CMV or HA-"-TCR(("). Directly after sorting, TCR 
expression of the sorted T-cell populations was analyzed using 
HA-" tetramer and CMV-TCR BV" mAb staining (Figure "A). Both 
sorted T-cell subsets were positive for the marker genes eGFP 
and NGF-R (Figure "B). To investigate whether T-cells almost 
exclusively expressing one TCR were still able to exert both HA-" 
and pp5%-speci!c cytolytic activity, the T-cells were tested in a 
cytotoxicity assay directly after sorting (Figure "C). The CMV-
TCRhi T-cells exerted e7cient cytotoxic activity against both 
pp5%-peptide pulsed target cells and target cells endogenously 
expressing pp5%, that was comparable to the mock transduced 
CMV T-cells. Although no HA-"-TCR expression could be meas-
ured on these T-cells using HA-" tetramers (Figure "A), the cells 
were still cytotoxic against HA-" peptide pulsed target cells, but 
demonstrated marginal cytotoxic activity against target cells 
endogenously expressing HA-", indicating that these T-cells only 
exhibit low avidity HA-" reactivity (Figure "C). The HA-"-TCRhi 
T-cells e7ciently lysed both HA-" peptide pulsed target cells as 
well as the endogenous HA-" positive target cells. Only low CMV-
TCR expression could be measured on these T-cells, and the 
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Figure ). TCR cell surface expression and functional activity of opposing CMV-TCRhi or HA-)-TCRhi 
sorted T-cell populations.
Figure ): (A) HA-)-TCR transferred CMV 
T-cells were sorted on basis of CMV-TCR 
BV)high and HA-) tetramerlow ( CMV-TCRhi) 
or BV)low staining (HA-)-TCRhi), respectively. 
Directly after sorting, TCR expression of the 
sorted T-cell populations was analyzed us-
ing HA-) tetramer and CMV-TCR BV) mAb 
staining.  (B) Both sorted T-cell subsets were 
analyzed for marker gene expression (eGFP 
and NGF-R). Numbers in (A) and (B) indi-
cate / of cells per quadrant. (C) Mock CMV 
T-cells, CMV-TCRhi and HA-)-TCRhi sorted 
T-cell populations were tested for cytotoxic 
activity against HA-) and pp,- positive tar-
get cells. One representative experiment out 
of four is shown.
))
pulsed target cells, but only marginal cytotoxicity against target 
cells endogenously expressing pp5%.
To study whether the sorted opposing T-cell subsets 
were able to proliferate upon HA-" and pp5%-speci!c stimulation, 
the T-cells were labeled with PKH-"5 and analyzed using FACS at 
day ). Both the CMV-TCRhi and HA-"-TCRhi T-cells were able to 
proliferate after stimulation with pp5% peptide pulsed EBV-LCLs 
or EBV-LCLs endogenously expressing pp5% (Figure (A and B). 
Only a small percentage of the CMV-TCRhi T-cells were capable 
of proliferating after stimulation with HA-" peptide pulsed EBV-
LCLS or EBV-LCLs endogenously expressing HA-" (Figure (A and 
B). The proliferation of HA-"-TCRhi T-cells stimulated with HA-" 
positive EBV-LCLs was similar to the proliferation induced by 
pp5% positive EBV-LCLs. Since the HA-"-TCRhi T-cells were capa-
ble of proliferating both after HA-" and pp5%-speci!c stimulation, 
speci!c outgrowth as the main cause of reverting TCR make up 
was less plausible.
These results demonstrate that low CMV-TCR cell 
surface expression on HA-"-TCRhi T-cells was su7cient for these 
cells to exert pp5%-speci!c cytotoxic activity against pp5% pep-
tide pulsed target cells, as well as pp5%-speci!c proliferation. The 
low HA-"-TCR expression on CMV-TCRhi T-cells was su7cient for 
these cells to exert speci!c cytotoxic activity against HA-" peptide 
pulsed target cells, but was not enough for HA-"-speci!c prolifer-
ation. Therefore, it appears that the threshold of the endogenous 
TCR to induce proliferation and cytotoxic reactivity is more easily 
reached than the threshold of the introduced TCR, underlining 
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Figure &. Proliferation of CMV-TCRhi and HA-)-TCRhi sorted T-cells after pp,- and HA-)-speci"c 
stimulation. 
Figure &: (A) and (B) CMV-TCRhi and HA-)-
TCRhi sorted T-cell subsets and mock CMV 
T-cells were labeled with PKH-),, and stimu-
lated Ag-speci"cally with HLA-A) negative 
allogeneic feeders in combination with 
EBV-Z (Control), EBV-RZ HA-) (A; HA-)) or 
HA-) peptide pulsed EBV-Z (B;  HA-) pep) or 
EBV-Z pp,- (A: pp,-) or pp,- peptide pulsed 
EBV-Z (B; pp,- pep). Only a small subset of 
CMV-TCRhi sorted T-cells proliferate after 
HA-)-speci"c stimulation. One representa-
tive experiment out of four is shown.
Figure (. TCR re-expression after restimulation of the CMV-TCRhi and HA-)-TCRhi sorted T-cell 
subsets.
Figure (: CMV-TCRhi and HA-)-TCRhi 
sorted T-cell subsets were stimulated pp,- 
or HA-)-speci"cally, and TCR expression was 
analyzed using CMV and HA-) tetramers. 
(A) TCR expression of CMV-TCRhi and (B) 
TCR expression of HA-)-TCRhi sorted T-cells 
directly after sorting (after sort) or + days 
after stimulation with either EBV-Z pp,- 
(middle panel; pp,-) or EBV-RZ HA-) (lower 
panel; HA-)). Numbers indicate / of cells per 
quadrant. One representative experiment out 
of four is shown.
)%
that trigger their endogenous TCR in vivo to ensure persistence 
of TCR transferred T-cells.
Opposing T-cell subsets redistribute TCR expression on their cell 
surface after additional stimulation
To test whether also the CMV-TCRhi and the HA-"-TCRhi sorted 
T-cells were able to change their TCR make up after di-erent 
speci!c stimulations, CMV-TCRhi sorted T-cells (Figure )A) and 
HA-"-TCRhi sorted T-cells (Figure )B) stimulated with EBV-LCLs 
presenting either endogenously processed pp5% or HA-" were 
analyzed for TCR expression at day 6. After 6 days of Ag-speci!c 
stimulation CMV-TCRhi sorted T-cells re-expressed the HA-"-TCR 
after stimulation with pp5% or HA-" (Figure )A). Although stimu-
lation with HA-" was not robust enough to induce proliferation 
of the CMV-TCRhi sorted T-cells (Figure (), it resulted in restored 
HA-"-TCR expression. Similarly, HA-"-TCRhi sorted T-cells re-
expressed the CMV-TCR after stimulation with pp5% or HA-" 
(Figure )B). These results demonstrate that also in the sorted 
T-cell subsets with predominant CMV or HA-"-TCR expression, 
T-cells are still capable of upregulating their TCR expression after 
stimulation via either the endogenous or introduced TCR.
Since we observed redistribution of TCR cell surface 
expression one week after stimulation (Figure )), we investigated 
in a cytotoxicity assay whether cytolytic activity of CMV-TCRhi or 
HA-"-TCRhi sorted T-cells was improved (Figure %A). After addi-
tional stimulation, only marginal di-erences in cytotoxic activ-
ity against HA-" and pp5% positive target cells were observed 
between the CMV-TCRhi and HA-"-TCRhi T-cells (Figure %A), 
corresponding with the restored co-expression of the HA-"- and 
CMV-TCR (Figure )). All subsets displayed high cytotoxic activity 
against HA-" positive and pp5% positive target cells, illustrating 
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Figure -. Comparable HA-) and pp,- reactivity of CMV-TCRhi and HA-)-TCRhi sorted T-cells 
stimulated once after sorting.
Figure -: (A) CMV-TCRhi and HA-)-TCRhi 
sorted T-cell subsets stimulated either pp,- 
or HA-)-speci"cally and mock CMV T-cells 
were analyzed for their pp,- and HA-) reac-
tivity + days after stimulation in a cytotoxic-
ity assay.  (B) Concurrently, the proliferative 
capacity of mock CMV T-cells, CMV-TCRhi 
and HA-)-TCRhi sorted T-cells was analyzed 
+ days after their "rst speci"c stimulation. 
CMV-TCRhi and HA-)-TCRhi sorted T-cells 
stimulated directly after sorting with EBV-Z 
pp,- (upper panel; !st stim pp,-) or EBV-RZ 
HA-) (lower panel; !st stim HA-)) were either 
stimulated additionally with negative control 
EBV-Z (No )nd stim; shadowed line), or with 
EBV-RZ HA-) ()nd stim HA-); black line), or 
with EBV-Z pp,- ()nd stim pp,-; grey line). 
One representative experiment out of two is 
shown.
)5
To test whether the restored HA-" and CMV-TCR co-
expression also led to improved proliferation after stimulation via 
either endogenous or introduced TCR, the CMV-TCRhi and the 
HA-"-TCRhi T-cells were labeled with PKH-"5, stimulated again 
with HA-" or pp5% and analyzed using FACS at day ) (Figure 
%B). All CMV-TCRhi T-cells and HA-"-TCRhi T-cells stimulated with 
pp5% or HA-" were able to proliferate vigorously after a second 
stimulation with pp5% positive EBV-LCLs. In contrast to the 
minimal amount of proliferation after HA-"-speci!c stimulation 
directly after sorting (Figure (), most CMV-TCRhi T-cells stimu-
lated once with HA-" were capable of proliferating after a second 
HA-"-speci!c stimulation. A small part of the CMV-TCRhi T-cells 
stimulated once with pp5% was not able to proliferate upon HA-"-
speci!c stimulation. 
In conclusion, opposing T-cell populations are able 
to redistribute their TCRs at the cell surface after an additional 
Ag-speci!c stimulation, leading to restored functionality via both 
TCRs. These data imply that no loss of dual-speci!city is likely to 
occur due to skewing of T-cells to a population predominantly 
expressing one TCR.
D I S C U S S I O N
In this study, we demonstrate that TCR transferred virus-speci!c 
T-cells repetitively stimulated via one TCR remained dual reac-
tive in response to triggering via both the endogenous and the 
introduced TCR. After repetitive stimulation of one TCR, TCR 
transferred T-cells preferentially expressed the triggered TCR, 
losing high avidity interaction via the previously non-triggered 
TCR. However, after a single stimulation via the previously non-
triggered TCR, TCR expression reverted within one week. When 
the dual-speci!c T-cells were sorted in opposing CMV-TCRhi 
T-cells and HA-"-TCRhi T-cells, both subsets still demonstrated cy-
totoxic activity against HA-" peptide pulsed target cells and CMV 
peptide pulsed target cells, respectively, but limited cytotoxic 
activity against targets presenting endogenously processed an-
tigen, indicating loss of high avidity interactions. After additional 
stimulation, both subsets were able to re-express the HA-" and 
CMV-TCR, respectively. When TCR expression was redistributed 
on the T-cells, high avidity functionality via both the endogenous 
and the introduced TCR was restored. Therefore, we speculate 
that also HA-"-TCRhi T-cells are capable of persisting during MRD 
when HA-"-TCR transferred CMV T-cells will predominantly en-
counter viral antigens. Furthermore, we anticipate that HA-"-TCR 
transferred CMV T-cells after a long period of MRD are still able 
to gain anti-leukemic e-ector functions when the patient would 
relapse.
Directly after sorting T-cells predominantly expressed 
the CMV-TCR (CMV-TCRhi) or the HA-"-TCR (HA-"-TCRhi). 
However, after an additional stimulation TCR re-expression was 
observed. Surprisingly, HA-"-TCR re-expression was observed on 
CMV-TCRhi TCR T-cells both after stimulation with HA-" as well as 
with pp5%, and CMV-TCR re-expression was observed on HA-"-
TCRhi T-cells both after stimulation with pp5% as well as with HA-
". TCR make up on transduced T-cells appears to be activation 
)6
dependent, however, a trend of preferential redistribution of the 
TCR being triggered was observed. It has been described that 
upon activation, T-cells enlarge and increase TCR expression(((-(5) 
which is accompanied with restructuring compartmentaliza-
tion of plasma membrane molecules("6,(6,('). Possibly, because of 
both increased TCR expression and localized high TCR density, 
HA-"-TCR on CMV-TCRhi T-cells could be visualized using HA-" 
tetramer staining after an additional stimulation, whereas this 
is not possible when HA-"-TCR is equally distributed along the 
cell membrane. Another possibility is that initial downregulation 
of the triggered TCR enabled surface expression of intracellular 
TCRs consisting of both the endogenous and introduced TCRs, 
whereas later on TCR expression will be dominated by newly 
synthesized previously triggered TCR. This would result in the 
preferential but not exclusive re-expression of the triggered TCR. 
It is evident that despite low CMV-TCR expression, HA-"-TCRhi 
T-cells are capable of persisting during repetitive stimulation 
with pp5%, although they do not proliferate as vigorously after 
stimulation with pp5% as CMV-TCRhi T-cells. Even in a stringent 
selection of T-cells with predominant expression of either the 
introduced or the endogenous TCR, re-expression of the other 
TCR was observed, implying that TCR expression on these 
T-cells is dynamic rather than static.
Our results indicate that the threshold of the endog-
enous TCR to induce proliferation and cytotoxic reactivity is 
more easily reached than the threshold of the introduced TCR, 
underlining the importance of targeting T-cells which will en-
counter antigens that trigger their endogenous TCR in vivo 
to ensure persistence of TCR transferred T-cells. EBV and CMV 
are viruses which latently persist after initial infection and have 
to be continuously controlled by the immune system. Both in 
immunocompetent and immunocompromised hosts, immune 
responses result in viral containment in latent stage rather 
than virus eradication((&-)$). Therefore, we propose to use EBV or 
CMV-speci!c T-cells as host cells for TCR transfer. When there is 
only minimal residual disease it may be expected that HA-"-TCR 
transferred virus-speci!c T-cells will primarily encounter viral 
antigens latently present in the recipient, as the HA-" antigen is 
only expressed by recipient hematopoietic cells. We hypothesize 
that low dose triggering of the endogenous TCR due to the 
persistence of the virus will also boost the anti-leukemic immune 
response mediated via the HA-"-TCR.
To ensure persistence and correct homing of trans-
duced virus-speci!c T-cells it is discussed that di-erent memory 
subsets should be used()",)(), or virus-speci!c T-cells responsi-
ble for the immunodominant response in the donor should 
be selected("$,))). Recent studies demonstrated that distinct 
memory subsets are raised in di-erent viral infections()%,)5). Even 
within one virus-speci!c memory response distinct subsets 
of virus-speci!c CD'+ T-cells can be found. For example, the 
CD'+ memory T-cells speci!c for EBV lytic antigens predomi-
nantly have a more di-erentiated e-ector memory phenotype, 
whereas CD'+ memory T-cells speci!c for EBV latent antigens 
predominantly have a central memory phenotype()#). Therefore 
it is hypothesized that phenotype of CD'+ memory T-cells could 
well be dictated by di-erent routes of antigen exposure. Based 
)'
on phenotypic characteristics CD'+ memory T-cells speci!c for 
CMV are mainly e-ector-type or late memory T-cells()$). However, 
studies have demonstrated that CD'+ memory T-cells speci!c for 
CMV are able to respond with renewed clonal expansion upon 
viral reactivation("(,)6), suggesting that phenotypic classi!cation 
alone is not indicative for functional characteristics. We therefore 
would like to use for clinical application a pool of CMV or EBV-
speci!c T-cells with distinct phenotypic characteristics, resulting 
in virus-speci!c T-cells with di-erent functional characteristics 
and homing capacities.
In conclusion, although after repetitive stimulation 
HA-"-TCR transferred CMV-speci!c T-cells skew to populations 
predominantly expressing one TCR, all subsets are able to persist 
and repopulate after stimulation via the previously non-triggered 
TCR. Therefore we conclude that TCR transduced virus-speci!c 
T-cells behave favorably in view of future clinical applications.
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Adoptive transfer of TCR transduced T-cells may be an attractive 
strategy to target both hematological malignancies and solid 
tumors. By introducing a TCR, large numbers of T-cells with de-
!ned antigen (Ag) speci!city can be obtained. However, by intro-
duction of a TCR, mixed TCR dimers can be formed. Besides the 
decrease in TCR expression of the introduced and endogenous 
TCR, these mixed TCR dimers could harbor potentially harmful 
speci!cities. In this study, we demonstrate that introduction of 
TCRs resulted in formation of neoreactive mixed TCR dimers, 
composed of the introduced TCR chains pairing with either the 
endogenous TCR: or ; chain. Neoreactivities observed were 
HLA class I or class II restricted. Most neoreactive mixed TCR 
dimers were allo-HLA reactive, however, neoreactive mixed 
TCR dimers with autoreactive activity were also observed. We 
demonstrate that inclusion of an extra disul!de bond between 
the constant domains of the introduced TCR markedly reduced 
neoreactivity, whereas enhanced e-ectiveness of the introduced 
TCR was observed. In conclusion, TCR transfer results in the 
formation of neoreactive mixed TCR dimers with the potential to 
generate o--target e-ects, underlining the importance of search-
ing for techniques to facilitate preferential pairing.
A B S T R AC T
Mixed TCR dimers harbor potentially 
harmful neoreactivity 
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I N T R O D U C T I O N
Adoptive transfer of T-cells is a strategy used to target both 
solid tumors and leukemia. Patients with relapsed hematologi-
cal malignancies after allogeneic stem cell transplantation can 
be successfully treated with donor lymphocyte infusion (DLI)
($,"), and patients with solid tumors can be e-ectively treated with 
tumor in!ltrating lymphocytes (TILs) cultured from tumor tis-
sue((). The bene!cial graft-versus-leukemia e-ect of DLI mediated 
by the recognition of minor histocompatibility antigens (mHags) 
is, however, often accompanied by graft-versus-host disease. 
Furthermore, isolation and expansion of TILs is feasible only for 
a fraction of patients with solid tumors. The adoptive transfer of 
T-cells transduced with TCRs recognizing tumor associated anti-
gens or mHags may be an attractive alternative strategy to target 
hematological malignancies and solid tumors. By introducing a 
TCR, large numbers of T-cells with de!ned antigen (Ag) speci!city 
can be obtained without long in vitro culture periods. Di-erent 
studies have shown the e-ectiveness of TCR transfer, both in 
vitro()-') and in vivo(&-$$). Recently, the in vivo e7cacy of adoptively 
transferred TCR transduced (td) T-cells was demonstrated in 
melanoma patients($#,$").
The introduction of an exogenous TCR into T-cells has 
several consequences for the TCR make-up of the cell. The intro-
duced TCR has to compete for cell surface expression with the 
endogenous TCR, and with mixed TCR dimers consisting of an 
endogenous TCR chain pairing with an introduced TCR chain($(). 
Because of competition of these di-erent TCR complexes for 
binding with CD(, the frequency of TCRs at the cell surface will 
be lower in TCR td T-cells than in parental T-cells. Therefore, a 
prerequisite of the introduced TCR is that it exhibits high af-
!nity for its antigen, and is able to e7ciently compete with the 
endogenous TCR for cell surface expression($(). Di-erent studies 
have attempted to improve TCR surface expression and subse-
quently biological activity, by facilitating matched pairing of the 
introduced TCR chains. Exchange of the human constant regions 
for murine constant regions was described to improve TCR ex-
pression and functionality($),$%). Another strategy that resulted in 
preferential pairing of the introduced TCR chains and increased 
TCR surface expression is the introduction of a disul!de bond in 
the extracellular constant domain($5,$6).
Not only the decrease in TCR expression of the intro-
duced Ag-speci!c TCR, but also the formation of mixed TCR 
dimers with unknown speci!city is an additional potential draw-
back of clinical application of TCR gene transfer($(,$',$&). Because 
the speci!city of mixed TCR dimers is unpredictable, hazard-
ous speci!cities may be formed. In this study, we investigated 
whether TCR transfer can lead to the generation of mixed TCR 
dimers exhibiting new detrimental reactivities. To address this is-
sue we created T-cells expressing mixed TCR dimers. To be able to 
discriminate between the functionality of the endogenous TCR, 
the introduced TCR as well as mixed TCR dimers, we transduced 
di-erent de!ned virus-speci!c T-cells with 6 di-erent well char-
acterized Ag-speci!c TCRs and tested these for newly acquired 
reactivities against an HLA-typed LCL panel covering all preva-
lent HLA class I and II molecules.
%$
Our results demonstrate that pairing of endogenous 
TCR chains with introduced TCR chains can result in the for-
mation of mixed TCR dimers with new potentially hazardous 
speci!cities recognizing allo-antigens as well as auto-antigens, 
both HLA class I and class II restricted.
R E S U LT S
Introduction of di*erent TCRs into several virus-speci)c T-cells elicits 
neoreactivity mediated via mixed TCR dimers
To study whether TCR transfer can lead to mixed TCR dimers 
with new detrimental reactivities, we transduced various virus-
speci!c T-cell lines from ) healthy donors with di-erent Ag-
speci!c TCRs. HLA-A$ restricted pp%#- or pp5%-speci!c T-cells 
and HLA-B' restricted IE-$- or BZLF-$-speci!c T-cells were sorted, 
resulting in % di-erent virus-speci!c T-cell lines (Table S$). These 
T-cell lines were transduced with 6 di-erent TCRs, consisting of 
) di-erent HA-"-speci!c TCRs (HA".%-TCR, HA".5-TCR, HA".$&-
TCR, and HA."."#-TCR), " di-erent HA-$-speci!c TCRs (HA$.
M"-TCR, HA$.M6-TCR) and the CMV-TCR. The transduced virus-
speci!c T-cells were sorted based on high eGPF and NGF-R posi-
tivity, and tested for neoreactivity against the LCL panel (Table 
S") covering all prevalent HLA class I and class II molecules. 
Introduction of di-erent TCRs resulted in newly acquired reac-
tivities against di-erent LCLs, of which representative examples 
are shown in Figure $. Some LCLs were excluded from analysis, 
as the non td virus-speci!c T-cells already recognized the LCLs, 
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Figure !. TCR td virus-speci"c T-cells demonstrate neoreactivity.
Figure !: T cells were tested against a broad 
LCL panel. IFN-1 production of & of the - 
di#erent virus-speci"c T-cell populations 
transduced with & di#erent TCRs is depicted, 
namely of (A) pp-.-speci"c T-cells isolated 
from donor CVO, (B) pp-.-speci"c T-cells of 
donor UKL and (C) IE-!-speci"c T-cells isolat-
ed from donor MBX.  As a control for the reac-
tivity of the endogenous and introduced TCR, 
LCLs with the restricting HLA molecules were 
pulsed with the relevant peptides (endo-TCR 
and intro-TCR, respectively). IFN-1 produc-
tion depicted is representative of & separate 
experiments performed in duplo.
%"
indicative for alloreactivity of the virus-speci!c T-cells rather than 
neoreactivity via mixed TCR dimers (Table S$). We could exclude 
alloreactivity of the introduced TCRs, as the parental T-cell clones 
of which these TCRs were derived were not reactive against the 
LCLs present in the panel. In each of the % di-erent virus-speci!c 
T-cell lines, transfer of at least " out of 6 TCRs induced neoreac-
tivity (Table S$). As illustrated in Figure $A, pp%#-speci!c T-cells 
of donor CVO (CVO pp%# T-cells) transferred with the CMV-TCR 
exhibited strong reactivity particularly against ZIL. This reactiv-
ity was not seen with HA".5-TCR td or HA$.M6-TCR td CVO 
pp%# T-cells. HA$.M6-TCR transfer resulted in strong reactivity 
directed against LSR, which was not observed with HA".5-TCR 
td or CMV-TCR td CVO pp%# T-cells. Introduction of the HA".5-
TCR into pp%#-speci!c T-cells of donor UKL (UKL pp%# T-cells) 
resulted in clear neoreactivity (Figure $B), whereas low neoreac-
tivity was observed after introduction of the HA$.M6-TCR or the 
CMV-TCR into these T-cells. Introduction of the HA".5-TCR and 
HA$.M6-TCR into IE-$-speci!c T-cells of healthy individual MBX 
(MBX IE-$ T-cells) resulted in neoreactivity against di-erent LCLs 
(Figure $C). Strikingly, some neoreactivities were as robust as 
reactivity via the introduced or endogenous TCR against peptide 
pulsed target cells. To determine whether the observed neore-
activities against LSR after HA$.M6-TCR transfer and against ZIL 
after CMV-TCR transfer (Figure $A) were mediated via mixed TCR 
dimers, we transduced CVO pp%# T-cells with either the HA$.
M6-TCR: or ; chain (Figure "A), or either the CMV-TCR: or ; 
chain (Figure "B). Transduction of only the HA$.M6-TCR; and 
not : chain (Figure "A) resulted in neoreactivity directed against 
LSR. Transduction of only the CMV-TCR: chain and not ; chain 
(Figure "B) into these T-cells resulted in neoreactivity directed 
against ZIL. In addition, to test whether the observed neoreactivi-
ties of MBX IE-$ T-cells after HA".5-TCR transfer (Figure $C) were 
mediated via mixed TCR dimers, we transduced these T-cells with 
either only the HA".5-TCR: or ; chain. As shown in Figure "C 
only HA-".5-TCR; td T-cells demonstrated neoreactivity directed 
against IZA. Furthermore, we deliberately created mixed TCR 
dimers by recombining HA-"-speci!c TCR: and TCR; chains of 
) di-erent HA-"-TCRs, namely the HA".%-TCR, the HA".5-TCR, 
the HA".$&-TCR and the HA"."#-TCR and transducing all pos-
sible combinations into monoclonal CVO pp%# T-cells. Taking into 
account that also the introduced HA-"-TCR chains can pair with 
the endogenous TCR of the pp%# T-cells, this resulted in poten-
tially "# mixed TCR dimers. Of these "# mixed TCR dimers, the 
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Figure ). Neoreactivities caused by mixed TCR dimers.
Figure ):  pp-. T-cells from CVO were trans-
duced with (A) HA!.M+-TCR$  or ' chains or 
with (B) CMV-TCR$  or ' chains, and IE-! 
T-cells from MBX were transduced with (C) 
HA).,-TCR$  or ' chains and tested against 
the LCL panel for neoreactivity. As a control 
for the reactivity of the endogenous TCR, 
LCLs with the restricting HLA molecules of the 
endogenous virus-speci"c TCR were pulsed 
with the viral peptides (A, B, C; endo-TCR). 
The IFN-1 production depicted is representa-
tive of ) separate experiments.
%(
S$A; mixed TCR dimer) resulted in signi!cant IFN-< production 
against DMD, whereas the parental HA".$&-TCR and HA".5-TCR 
demonstrated only HA-"-speci!c reactivity against HA-" peptide 
pulsed target cells. These results indicate that each recombina-
tion of TCR chains after TCR transfer can potentially result in a 
harmful new reactivity.
These results demonstrate that neoreactivities can 
occur in multiple virus-speci!c T-cells after transfer of di-erent 
TCRs. The neoreactive mixed TCR dimers can be composed of 
introduced TCR chains pairing with either the endogenous TCR: 
chain or the endogenous TCR; chain.
Mixed TCR dimers can acquire both HLA class I and class II restrict-
ed allo- and autoreactivities
To study whether neoreactivities of the mixed TCR dimers were 
HLA restricted, blocking experiments were performed. Because 
in oligoclonal virus-speci!c T-cell lines theoretically di-erent 
mixed TCR dimers can be formed and this can potentially hinder 
analysis of HLA-restriction, as well as functional activity of the 
individual-speci!cities, monoclonal CVO pp%# T-cells and MBX 
IE-$ T-cells were sorted on bases of TCR usage. By transfer of 
the di-erent TCRs we could con!rm that the most prominent 
TCR-BV$ positive population present in CVO pp%# T-cells was 
responsible for the neoreactivity against LSR after HA$.M6-TCR 
transfer, and the neoreactivity against ZIL after HA".5-TCR 
transfer. Likewise, of the oligoclonal populations of MBX IE-$ 
T-cells only the TCR-BV$ positive T-cells transduced with HA".5-









































































































Figure &. Neoreactivity of mixed TCR dimers is both HLA class I and II restricted.
Figure &:  HLA restriction of neoreactive 
mixed TCR dimers of (A) BV!+ HA!.M+-TCR' 
td CVO pp-. T-cells, (B) BV!+ CMV-TCR$  td 
CVO pp-. T-cells, or (C) BV!+ HA).,-TCR'  td 
MBX IE-! T-cells was tested in IFN-1 produc-
tion assay using blocking antibodies.
Relevant HLA typing of the LCLs is indicated, 
with the HLA typing of the blocked LCL in 
bold. IFN-1 production depicted is represent-
ative of & separate experiments performed 
in triplo. 
%)
HA$.M6-TCR; td BV$+ CVO pp%# T-cells against LSR (Figure 
$A, "A) could be blocked by HLA class I and HLA-B/C blocking 
antibodies, indicating HLA-B or HLA-C restricted recognition, 
as demonstrated in Figure (A. LSR expressed HLA-B(%, B%" 
and Cw$". Additional experiments using various LCLs express-
ing one of these HLA restriction molecules demonstrated 
that this neoreactivity was HLA-B%" mediated (Figure (A). In 
addition, the neoreactivity of CMV-TCR: td BV$+ CVO pp%# 
T-cells against ZIL (Figure $A, "B) was also HLA-B or HLA-C 
restricted, as the reactivity could be blocked with HLA class I 
and HLA-B/C antibodies (Figure (B). ZIL expressed HLA-B%5, 
B%', and Cw$, and additional testing against LCLs covering 
these di-erent HLA restriction molecules demonstrated this 
neoreactivity to be HLA-B%' restricted (Figure (B). The neo-
reactivity of the HA".5-TCR; td MBX IE-$ T-cells (Figure $C, 
"C) was demonstrated to be HLA-DR$6 restricted, based on 
blocking with HLA class II and HLA DR mAbs and testing with 
an additional LCL panel (Figure (C). The neoreactivity of the 
HA".$&-TCR: and HA".5-TCR; mixed TCR dimer could be 
blocked with HLA class II and HLA-DQ mAbs, and testing on 
an additional LCL panel demonstrated that this neoreactiv-
ity was HLA-DQ(('/&) restricted (Figure S$B). In conclusion, 
mixed TCR dimers derived from HLA class I restricted T-cells 
can acquire neoreactivities that can be both HLA class I and 
HLA class II restricted.
In Figure (C we demonstrate that the HA".5-TCR; 
chain in combination with the TCR: chain of the endogenous 
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Figure (. Neoreactivity also directed against normal human cell subsets.
Figure (: (A) CMV-TCR$  td and non td CVO 
pp-. T-cells were tested against HLA-B-*+ 
LCL ZIL and HLA-B-*- LCL from CVO and 
CD!(+, CD!0+ and CD(+ MACS-isolated 
cell subsets derived from HLA-B-*+ healthy 
individual IGN. HA-).,-TCR'  td and non td 
MBX IE-! T-cells were tested against LCLs and 
CD!(+, CD!0+ and CD(+ MACS-isolated 
cell subsets derived from (B) HLA-DR!++ 
MBX or (C) HLA-DR!++ NGI. HLA-DR!+- 
LCL EBM was included in the experiment as 
a control. T-cells were tested against resting 
cell subsets (ex vivo) or activated cell sub-
sets. CD!(+ cells were either activated into 
immature DCs (iDC) or mature DCs (mDCs) 
using activating cytokines. CD!0+ cells were 
activated using activating cytokines and 
CD(.L (B act). CD(+ cells were activated 
using PHA (T act). IFN-1 production depicted 
is representative of ) separate experiments. 
%%
neoreactivity. Because MBX was also HLA-DR$6 positive, we 
tested these neoreactive T-cells for recognition of autologous 
LCLs derived from MBX. Mixed TCR dimers produced IFN-< 
(Figure )B left panel, Figure S"A) and were cytolytic (Figure S"B) 
against HLA-DR$6+ LCLs including MBX, and reactivity against 
all LCLs could be blocked using HLA class II and HLA-DR mAbs 
(Figure S"C). 
These results indicate that mixed TCR dimers may 
lead not only to newly acquired alloreactivity, but also to 
autoreactivity.
Mixed TCR dimers are neoreactive against normal human cell 
subsets
To study whether the observed neoreactivities directed against 
LCLs were predictive for reactivity against normal human cell 
subsets, we tested both HLA class I and class II restricted neo-
reactive mixed TCR dimers against di-erent MACS isolated cell 
subsets. Neoreactive HLA-B%' restricted CMV-TCR: td CVO 
pp%# T-cells and HLA-DR$6 restricted HA".5-TCR; td MBX IE-$ 
T-cells were tested against freshly isolated and in vitro activated 
CD)+, CD$&+ and CD$)+ cell subsets isolated from PBMCs of 
an HLA-B%'+ or an HLA-B%'- individual (Figure )A, Figure S(A) 
or HLA-DR$6+ individuals (Figure )B and C, Figure S(B). The 
HLA-B%' restricted neoreactive T-cells were able to recognize 
all di-erent cell subsets directly ex vivo (Figure )A). The HLA-
DR$6 restricted neoreactive T-cells did not recognize the cell 
subsets directly ex vivo but recognized the autologous activated 
CD$&+ and CD$)+ cell subsets of MBX as well as the allogeneic 
activated CD$&+, CD$)+ and CD)+ cell subsets of NGI (Figure 
)B and C). The absence of IFN-< production against autologous 
activated CD)+ T-cells derived from MBX was not surprising, as 
no signs of self-reactivity of the HA".5-TCR; td MBX IE-$ T-cells 
were observed, and these T-cells could be easily expanded using 
feeder cells and PHA. Cytolytic capacity of CMV-TCR: td CVO 
pp%# T-cells (Figure S(A) corresponded with the IFN-< produc-
tion against these cell subsets (Figure )A). The HA".5-TCR; td 
MBX IE-$ T-cells, however, exerted cytolytic activity against allo-
geneic nonactivated CD$&+ and CD)+ cell subsets derived from 
NGI, whereas no IFN-< production was observed after stimula-
tion with these cell subsets, indicating that the threshold for 
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Figure -. Neoreactivities are markedly diminished using cysteine modi"ed TCRs.
Figure -: (A) BZLF-! T-cells from healthy 
individual UKL were transduced with two 
separate retroviral vectors encoding either the 
unmodi"ed HA!.M+-TCR$  and ' chains (HA!.
M+-TCR WT; black bars) or cysteine modi"ed 
HA!.M+-TCR$  and ' chains (HA!.M+-TCR SS; 
grey bars), sorted on bases of high eGFP and 
2NGF-R expression and tested against sev-
eral LCLs for neoreactivity in duplo.  (B) CVO 
pp-. T-cells were transduced with retroviral 
vectors containing T)A linked unmodi"ed 
HA!.M+-TCR$  and ' chain (HA!.M+-TCR )A 
WT; black bars) or T)A linked cysteine modi-
"ed HA!.M+-TCR$  and ' chain (HA!.M+-TCR 
)A SS; grey bars), sorted on high 2NGF-R ex-
pression and tested in duplicate against sev-
eral LCLs for neoreactivity.  As a control, non 
td UKL BZLF-! T-cells and CVO pp-. T-cells 
(non td; white bars) were tested against the 
same LCL panel. IFN-1 production depicted 
is representative of & separate experiments.
%5
cytolytic activity is easier reached than the threshold for cytokine 
production. The T-cells did not exert cytolytic activity against the 
nonactivated autologous cell subsets from MBX (Figure S(B) 
corresponding with the IFN-< production (Figure )B). These 
results demonstrate that the observed neoreactivities against the 
LCL panel are predictive for reactivity against normal human cell 
subsets.
In conclusion, T-cells expressing neoreactive mixed TCR 
dimers can recognize normal cell subsets, and are capable of both 
producing cytokines and demonstrating cytolytic activity. 
Transfer of cysteine modi)ed TCRs reduces neoreactivity
To determine whether strategies facilitating matched pairing 
could reduce potentially harmful neoreactivities, we modi!ed 
the HA$.M6-TCR by inclusion of extra cysteine residues in the 
constant domains of the TCR chains. UKL BZLF-$ T-cells that 
exhibited HLA-DR) restricted neoreactivity after transduction 
with the HA$.M6-TCR (Figure S)) were either transduced with 
retroviral vectors encoding the unmodi!ed HA$.M6-TCR: and ; 
chains (HA$.M6-TCR WT ) or with cysteine modi!ed HA$.M6-TCR: 
and ; chains (HA$.M6-TCR SS), sorted on bases of high eGFP 
and BNGF-R expression and tested against the LCL panel for 
neoreactivity. Whereas the HA$.M6-TCR WT td T-cells exhibited 
neoreactivity against the HLA-DR)+ EBM, the HA$.M6-TCR SS 
td T-cells showed limited neoreactivity (Figure %A). In contrast to 
reduced neoreactivity, the HA$.M6-TCR SS td T-cells exhibited 
increased HA-$-speci!city (Figure %A). In addition, we studied 
whether HLA-B%" restricted neoreactivity of HA$.M6-TCR td 
BV$+ CVO pp%# T-cells (Figure $A, "A, (A) could be reduced by in-
clusion of cysteine residues in the HA$.M6-TCR. CVO pp%# T-cells 
were transduced with retroviral vectors encoding both the HA-$-
TCR: and ; chain linked with a self-cleaving "A sequence (T"A) 
that were either unmodi!ed (HA$.M6-TCR T"A WT ) or cysteine 
modi!ed (HA$.M6-TCR T"A SS), sorted on bases of high BNGF-R 
expression and tested against the LCL panel for neoreactivity. As 
can be observed in Figure %B, CVO pp%# T-cells transduced with 
the HA$.M6-TCR T"A WT demonstrated neoreactivity directed 
against HLA-B%"+ LSR and SAV. However, also this HLA-B%" 
restricted neoreactivity was markedly reduced by cysteine modi-
!cation of the HA$.M6-TCR (Figure %B), whereas the reactivity 
against HA-$+ target cells increased.
The results indicate that inclusion of an additional 
disul!de bond between the introduced TCR chains markedly 
decreased neoreactivity and, in addition, increased the e-ective-
ness of the introduced TCRs.
D I S C U S S I O N
In this study, we investigated whether TCR gene transfer can 
lead to the generation of new detrimental reactivities by creat-
ing T-cells that express mixed TCR dimers. For this purpose, we 
introduced 6 di-erent TCRs into % virus-speci!c T-cell populations 
derived from healthy donors, and tested these transduced T-cell 
populations against an LCL panel covering the most prevalent 
HLA class I and II molecules. Per virus-speci!c T-cell line, at least 
%6
" out of 6 TCR-transductants demonstrated neoreactivities. 
We could demonstrate that introduction of only TCR: or TCR; 
chains resulted in neoreactivity, and that this neoreactivity could 
be HLA class I or class II mediated. Furthermore, we not only ob-
served neoreactive mixed TCR dimers harbouring alloreactivity, 
but also autoreactivity. Therefore, we conclude that mixed TCR 
dimers formed will frequently harbour new, potentially harmful 
speci!cities.
Relatively high frequencies of neoreactive mixed TCR 
dimers were found. Normally, during development, T-cells un-
dergo thymic selection resulting in a T-cell repertoire consisting 
of T-cells capable of binding to self-peptide-self-MHC complexes 
with adequate a7nity. Potentially autoimmune T-cells that have 
high a7nity for self-peptide-self-MHC complexes are deleted. 
Alloreactivity refers to the ability of T-cells to recognize peptide-
allogeneic-MHC complexes that were not encountered during 
thymic development, and we have recently described that allo-
reactivity by virus-speci!c T-cells is frequently observed("#). In the 
case of the mixed TCR dimers no thymic selection has occurred 
at all, and by chance both allo- and autoreactive mixed TCR di-
mers can be engineered. TCR td T-cells harbouring autoreactive 
mixed TCR dimers will only be able to survive when the peptide 
recognized is not expressed on the T-cells themselves, since this 
may lead to fratricide of these T-cells.
In our model we measured T-cell reactivity against an 
LCL panel covering a large spectrum of di-erent HLA molecules 
expressing di-erent peptides. Theoretically, by using this model 
it is more likely that we pick up neoreactive mixed TCR dimers 
recognizing either a peptide in the context of allo-HLA than in 
the context of self-HLA, since a maximum of $" self-HLA al-
leles will be shared with the LCLs in the panel, whereas up to 66 
HLA molecules will be foreign to the T-cells. However, we also 
identi!ed a neoreactive mixed TCR dimer recognizing peptides 
bound to self-HLA, namely the HLA-DR$6 reactive HA".5-TCR; 
td MBX IE-$ T-cells. These selfreactive T-cells were capable of 
recognizing only autologous DCs and activated B cells, and not 
activated autologous CD)+ T-cells, whereas both activated and 
resting allogeneic cell subsets (NGI) were recognized. This lack 
of reactivity against activated autologous CD)+ T-cells was not 
surprising, as these HLA-DR$6 neoreactive MBX IE-$ T-cells could 
be easily expanded using feeder cells and PHA. Furthermore, 
NGI derived target cells were always better recognized (Figure 
)B/C, S", S(), indicating that the target antigen might be higher 
expressed in NGI derived CD)+ T-cells compared with MBX de-
rived CD)+ T-cells. In addition, HLA-DR expression on activated 
T-cells is lower than on LCLs and DCs, and, in combination with 
lower antigen expression on MBX derived target cells, possibly 
the threshold for activation of the autoreactive T-cells by MBX 
derived CD)+ T-cells is not reached. We cannot conclude from 
these data whether the mixed TCR dimers recognize di-erent 
antigens expressed by MBX and NGI, although IFN-< production 
against both LCL MBX and LCL NGI could be blocked using HLA 
class II and HLA-DR blocking mAbs, or whether they recognize 
possibly di-erentially expressed antigens by these two LCLs.
In a pp%#-speci!c T-cell clone, we observed neoreactiv-
ity in ( out of 6 TCR transductions. Theoretically, the introduction 
%'
of 6 TCRs into a monoclonal virus-speci!c T-cell population will 
result in $) mixed TCR dimers. Of these $) mixed TCR dimers, ( 
were demonstrated to be neoreactive, indicating that approxi-
mately $ out of % mixed TCR dimers will harbour a new speci!c-
ity. Furthermore, deliberately creating mixed TCR dimers by 
recombining ) di-erent HA-"-TCRs into BV$+ CVO pp%# T-cell 
clone resulted in $ neoreactive mixed TCR dimer out of "#. On 
average, we conclude that approximately $ out of $# mixed TCR 
dimers will harbor potentially hazardous neoreactivity. The results 
demonstrate that selecting strong competitor TCRs could not 
avoid occurence of neoreactive mixed TCR dimers, as has been 
proposed previously as a strategy to acquire single TCR expres-
sion on transduced T-cells("$). For example, introduction of a 
strong competitor CMV-TCR into weak competitor pp%#-speci!c 
T-cells resulted in HLA-B%' restricted neoreactive mixed TCR 
dimers. Also, the introduction of a strong competitor HA".5-TCR 
into strong competitor IE$-speci!c T-cells resulted in HLA-DR$6 
restricted neoreactive mixed TCR dimers. These results imply that 
TCR transfer will frequently result in the formation of neoreactive 
mixed TCR dimers.
To date however, no o--target toxicity has been ob-
served in clinical trials treating in total %$ patients with either 
MART-$-TCR td or gp$##-TCR td T-cells($#,$"). While no evidence 
of mixed TCR dimer induced autoimmunity was observed in 
earlier murine experiments and these !rst clinical trials, in a 
recent set of experiments an often lethal autoimmune pathology 
was observed under conditions that promote the expansion of 
adoptively transferred T-cells more strongly, and this pathology 
appeared dependent on the action of mixed TCR dimers("").
There are di-erent techniques described that facilitate 
matched pairing of the introduced TCR chains. Exchange of 
the human constant regions for murine constant regions was 
described to improve TCR expression and functionality($),$%). 
However, murine constant regions can be potentially immuno-
genic in vivo. Another strategy that facilitated matched pairing 
and increased TCR surface expression is the introduction of an 
extra disul!de bond in the constant domains of the introduced 
TCR chains($5,$6). In this study, we demonstrate that cysteine 
modi!cation of the potentially clinical useful HA$.M6-TCR con-
siderably reduced the neoreactivity of two TCR td virus-speci!c 
T-cell populations tested. Potentially, the stochiometric produc-
tion of TCR: and ; chains, when linked with a self-cleaving "A 
peptide("(), could also result in increased preferential pairing of the 
TCR chains and lower expression of mixed TCR dimers. However, 
CVO pp%# T-cells transduced with HA$.M6-TCR chains linked 
with a T"A sequence still demonstrated marked neoreactivity 
(Figure %B), indicating that stochastic expression of the TCR: and 
; chain does not rule out the generation of mixed TCR dimers. 
Next to decreased neoreactivity using cysteine modi!ed TCRs, 
increased HA-$-speci!city was observed, making the cysteine 
modi!ed HA-$.M6-TCR more attractive than the unmodi!ed HA$.
M6-TCR for future clinical trials. Whether the results obtained 
with the cysteine modi!ed HA$.M6-TCR are predictive for other 
TCRs potentially useful for clinical therapy has yet to be tested.
%&
To completely rule out formation of harmful mixed TCR-
dimers, another option would be to transduce <=-T-cells, as the 
<=-TCR chains are not able to pair with :;-TCR chains($&). Human 
<=-T-cells redirected with :;-TCRs were fully functional in vitro($&) 
and in vivo(")). However, further analyses will be required to 
determine to what extent redirected <=-T-cells and :;-T-cells are 
di-erent with respect to homing properties and speci!city of the 
endogenous TCR. We therefore propose to limit the diversity of 
the TCR repertoire of the recipient T-cells by transducing virus-
speci!c T-cell populations. Because virus-speci!c T-cell popula-
tions consist of a restricted TCR repertoire("%,"5), the amount of 
di-erent mixed TCR dimers formed will be limited. In addition, 
the reactivity of these T-cells is known, allowing detection of 
harmful neoreactivities by introducing into these virus-speci!c 
T-cells as controls only the TCR: or TCR; chain of interest and 
subsequent testing against di-erent patient-derived cell types. 
By this procedure TCR td virus-speci!c T-cells can be selected 
that show no o--target toxicity.
In conclusion, in this study we demonstrated that TCR 
transfer results in neoreactive mixed TCR dimer formation. This 
formation of neoreactive mixed TCR dimers is not a feature of a 
speci!c TCR, because we observed this in all virus-speci!c T-cells 
tested, with di-erent introduced TCR: or ; chains. We therefore 
underline the importance of facilitating matched pairing of 
introduced TCR chains, and diminishing the chance of formation 
of harmful neoreactive mixed TCR dimers by using T-cell popula-
tions with restricted TCR repertoire as host cells for TCR transfer.
M AT E R I A L S  A N D  M E T H O D S 
Retroviral vector construction and production of retroviral 
supernatant
TCRAV and TCRBV gene usage of the di-erent Ag-speci!c T-cell 
clones was determined as previously described(6). All TCR AV and 
BV chains derived from di-erent high a7nity mHAg- (HA-" and 
HA-$) and virus-speci!c T-cell clones (CMV) were cloned sepa-
rately into the Moloney murine leukemia virus-based LZRS retro-
viral vector and are described in detail in the supporting informa-
tion. In addition, cysteine modi!ed HA-$.M6-TCR chains were 
constructed as previously described by introducing cysteine 
residues at positions )' of the TCR: and position %6 of the TCR; 
constant domains($5,$6). TCR-AV chains were always combined via 
the IRES sequence with the marker eGFP, and the TCR-BV chains 
with the truncated nerve growth factor receptor (CNGF-R). The 
retroviral vectors used in Figure %B contained either the unmodi-
!ed or cysteine modi!ed HA$.M6 TCR: and ; chains linked with 
picornavirus-derived self-cleaving "A sequence (T"A)("() and 
were combined via the IRES sequence with the marker BNGF-R. 
Retroviral supernatant was generated using A-NX-A as previ-
ously described("6). 
HLA Class I tetrameric complexes, 'ow cytometric analyses and cell 
sorting
PE-or APC-conjugated tetrameric complexes were constructed 
as previously described("') with minor modi!cations. The follow-
ing tetrameric complexes were constructed: tetrameric HLA-A$ 
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complexes in combination with CMV-pp%# VTE (pp%#) or CMV-
pp5% YSE (pp5%) peptide, and tetrameric HLA-B' complexes in 
combination with CMV-IE-$ ELR (IE-$) or EBV-BZLF-$ RAK (BZLF-
$). For 9ow cytometric analyses as well as 9ow cytometry-based 
sorting, cells were labeled with tetramers for $ hour at )ºC and 
during the last (# mins, mAbs directed against the various cell 
surface molecules were added. Sorting was performed at )ºC. 
mAbs used are described in the supporting information. 
Cells
All studies were conducted with approval of the institutional 
review board at Leiden University Medical Center. After informed 
consent, virus-speci!c T-cells were isolated from di-erent healthy 
individuals (UKL, MBX, CVO, UGW) using di-erent virus-speci!c 
tetramers (>&%8 purity). Tetramer positive T-cells were restimu-
lated every two weeks as described previously($() and expanded. 
Retroviral transduction was performed as described previously(') 
using recombinant human !bronectin fragments CH-"&5("6). TCR 
transduced (td) virus-speci!c T-cells were sorted based on eGFP 
and BNGF-R positivity (>&&8 purity), and the cells were expand-
ed in bulk. To analyze the reactivity of TCR td T-cells, a panel of 
HLA typed EBV-transformed lymphoblastoid cell lines (LCLs) was 
used (Table S"). LCLs were maintained in Iscoves modi!ed dul-
becco’s medium (IMDM) supplemented with $#8 FBS. 
Analysis of Ag-speci)c IFN-+ production
TCR td virus-speci!c T-cells were tested for IFN-< production 
against the HLA typed LCL panel. To determine IFN-< production, 
%.### T-cells were cocultured with "#.### LCLs, and after over-
night incubation supernatant was harvested and tested in a 
standard ELISA (CLB, Amsterdam, The Netherlands). As positive 
control for the activity of the endogenous and introduced TCRs, 
the T-cells were stimulated with LCLs pulsed for one hour at (6ºC 
with the di-erent viral and mHag peptides at a !nal concentration 
of $ µg/ml. To determine the HLA restriction molecules essential 
for recognition of the mixed TCR dimers, blocking studies were 
performed and antibodies used are described in the supporting 
information.
TCR td virus-speci!c T-cells were tested for IFN-< pro-
duction against normal human cell subsets and for this purpose 
CD)+, CD$&+ and CD$)+ cell subsets were MACS-isolated from 
peripheral blood mononuclear cells (PBMC) as described in the 
supporting information. TCR td virus-speci!c T-cells were tested 
against these di-erent puri!ed (>&#8) CD)+, CD$&+ and CD$)+ 
cell subsets directly ex vivo, and after in vitro activation of these 
cell subsets, as described in the supporting information. 
Chromium release assay and CFSE based cytotoxicity assay
To test the capacity of T-cells to speci!cally lyse Ag positive target 
cells, a standard ) h chromium release assay using di-erent 
e-ector-to-target ratios was performed as previously described('). 
Furthermore, to be able to analyse cytotoxicity after several days, 
we used a CFSE based cytotoxicity assay("&) as described in the 
supporting information. 
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Construction of retroviral vectors and production of retroviral 
supernatant
The TCR AV and BV chains used in this study are: AV$%S$; BV$'S$ 
(HA".%-TCR), AV"(S$; BV$'S$ (HA".5-TCR), AV(#S$; BV$'S$ 
(HA".$&-TCR), and AV"(S$; BV5S"A$ (HA"."#-TCR) derived from 
) di-erent T cell clones recognizing the HA" YIGVEVLVSV pep-
tide in the context of HLA-A" ($),  AV'S$; BV5S) (HA$.M"-TCR), 
AV("S$; BV5S) (HA$.M6-TCR) derived from " di-erent T cell 
clones recognizing the HA$ VLHDDLLEA peptide in the context 
of HLA-A" and AV$'S$; BV$(S$ (CMV-TCR)(") derived from a T cell 
clone speci!c for the CMV-pp5% derived NLVPMVATV peptide 
presented in the context of HLA-A".
mAbs used in this study 
To obtain more oligoclonal or monoclonal cell subsets, cells 
were labeled with tetramers and with either anti-TCR-BV$ or 
anti-TCR-BV$) PE (Immunotech, Marseille, France). To obtain the 
transduced cells, cells were labeled with anti BNGF-R either PE- 
(PharMingen, San Diego, CA, USA) or APC-conjugated (Cedarlane 
Laboratories, Hornby, Ontario, Canada) for (# minutes at )ºC and 
were subsequently sorted.
To determine the HLA restriction molecules essential 
for recognition of the mixed TCR dimers, blocking studies were 
performed using W5.(" (anti-HLA class I), B$."(." (anti-HLA-B/C), 
PdV%." (anti-HLA class II), B'.$$." (anti-HLA-DR), SPV-L( (anti-
HLA-DQ) or B6."$ (anti-HLA-DP) mAbs (kindly provided by A. 
Mulder from the LUMC). LCLs were preincubated with saturating 
concentrations of mAbs for $ hour at RT before addition of T cells.
mAbs used in the CFSE based cytotoxicity assay are anti-
CD$& and anti-HLA-DR or anti-CD) (Beckman Coulter, Fullerton, 
CA, USA) and anti-HLA-DR mAbs (PharMingen, San Diego, CA, 
USA).
MACS-enrichement and activation of isolated cell subsets 
PBMC of healthy donors were thawed, incubated with 
DNAse for $% minutes at (6 ºC, washed and stained with either 
anti-CD), anti-CD$& or anti-CD$) MACS beads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and isolated according to manufac-
turer’s instructions. The CD)+ cell subset was activated for a week 
(T act) using PHA ('## ng/ml), the CD$&+ fraction was activated 
Supporting information
M AT E R I A L S  A N D  M E T H O D S 
5(
for ( days (B act) by culturing them on CD)#L transduced mu-
rine !broblasts(() in medium containing CpG ($# µg/ml) and IL-) 
(%## IU/ml) (Schering-Plough, Innishammon, Cork, Ireland). The 
CD$)+ fraction was activated into immature DCs (iDC) by cultur-
ing in medium containing GM-CSF ($## ng/ml) (Novartis, Basel, 
Switzerland) and IL-) (%## IU/ml). After ( days of culturing, im-
mature DCs were activated for ( days into mature DCs()) (mDC) 
by culturing them in medium containing GM-CSF ($## ng/ml), 
TNF-: ($# ng/ml), IL-$ß ($# ng/ml), IL-5 ($# ng/ml) (Cellgenix, 
Freiburg, Germany), PGE-" ($ µg/ml) (Sigma-Aldrich, St Louis, MO, 
USA) and IFN-< (%## IU/ml) (Immukine, Boehringer Ingelheim, 
Alkmaar, The Netherlands).
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Figure S!. Each recombination of TCR chains after TCR transfer can potentially 
result in a HLA-restricted harmful new reactivity.
Figure S!: (A) To gain more insight into the frequency of neoreactive 
mixed TCR dimers and to analyze whether mixed TCR dimers consisting 
of conserved TCRs with the same speci"city could acquire new harmful 
reactivity, we deliberately created mixed TCR dimers by recombining 
HA-)-speci"c TCR$  and TCR'  chains of ( di#erent HA-)-TCRs, namely 
the HA).--TCR, the HA).,-TCR, the HA).!0-TCR and the HA).).-TCR. 
For this purpose, we sorted pp-.-speci"c T cells derived from healthy 
individual CVO using tetramers and BV!-staining, con"rmed mono-
clonality, and transduced all possible combinations into these T cells. 
Taking into account that also the introduced HA-)-TCR chains can pair 
with the endogenous TCR of the pp-. T cells, this resulted in poten-
tially ). mixed TCR dimers. BV!+ CVO pp-. T cells consisting of these 
deliberately created mixed TCR dimers were also tested against the LCL 
panel for neoreactivity; here, reactivity of CVO pp-. T cells transduced 
with the HA).!0-TCR$  and HA).,-TCR'  chains is depicted (A; mixed 
TCR-dimer). As a control, the parental HA).!0-TCR (TCR HA).!0) and 
the parental HA).,-TCR (TCR HA).,) combinations were included in the 
experiment. In addition, as a control for the reactivity of the introduced 
TCR, IZA was pulsed with HA-) peptide (A; intro-TCR). The experiments 
were performed in duplicate. IFN-1 production depicted is a representa-
tive experiment out of ) experiments. (B) To elucidate HLA restriction of 
the neoreactive mixed TCR dimer, blocking experiments were performed. 
Neoreactivity directed against DMD could be blocked by HLA class II and 
HLA-DQ blocking antibodies. DMD expressed HLA-DQ-, and DQ0, as 
indicated in bold. Additional experiments using various LCLs expressing 
one of these HLA restriction molecules demonstrated that this neoreac-
tivity was DQ&(*/0) mediated. Blocking experiments were performed in 
triplicate. IFN-1 production depicted is a representative experiment out 























Figure S). Cytokine production and cytotoxic activity of 
HLA-DR restricted autoreactive mixed TCR dimer.
Figure S): (A) HA).,-TCR$, HA).,-TCR' 
and HA).,-TCR$'  td MBX IE-! T cells were 
tested for IFN-1 production against HLA-
DR!++ LCLs IZA, NGI and MBX and against 
HLA-DR!+- EBM.  (B) In a (h cytoxicity 
assay, HA).,-TCR$  (white symbols), HA).,-
TCR'  (black symbols) and HA).,-TCR$'  td 
MBX IE-! T cells (grey symbols) were tested 
against HLA-DR!++ LCLs IZA (diamonds), 
MBX (triangles) and NGI (squares) in several 
e#ector-to-target ratios in triplo. As a nega-
tive control, HA).,-TCR$, HA).,-TCR'  and 
HA).,-TCR$'  td T cells were tested against 
HLA-DR!+- EBM (white, black and grey 
circles, respectively). Cytotoxicity depicted 
representative for ) separate experiments. (C) 
To con"rm that neoreactivity against MBX 
and NGI cells was also HLA-DR restricted, 
blocking experiments were performed. 
Neoreactivity directed against MBX and 
NGI cells could be blocked using class II and 
HLA-DR blocking antibodies, indicating that 
neoreactivity directed against these LCLs was 
also HLA-DR!+ restricted. The experiments 
were performed in triplo and IFN-1 depicted 



































































































































































































































Figure S&. Mixed TCR dimers are able to exhibit cytolytic activity against normal human cell subsets.
Figure S&: To analyze whether TCR td T cells were able to lyse the target cell sub-
sets directly ex vivo,  (A) HLA-B-* restricted neoreactive CMV-TCR$  td CVO pp-. 
T cells and 
(B) HLA-DR!+ restricted neoreactive HA).,-TCR'  td MBX IE-! T cells were tested 
using a CFSE cytotoxicity assay. T cells were labeled with - µM of CFSE (Molecular 
Probes Europe, Leiden, the Netherlands), and coincubated with either HLA-B-*- 
(NGI) or HLA-B-*+ (IGN) or HLA-DR!++ (NGI, MBX) PBMCs or LCLs. Control cul-
tures with T cells only or target cells only were included. Cultures were stained after 
)(h of coincubation with a combination of either anti-CD!0  and anti-HLA-DR or 
anti-CD(  and anti-HLA-DR mAbs, and the di#erent samples were analyzed using 
3ow cytometry. Propidium iodide (PI) (! µg/ml) was added to exclude dead cells. 
Percentage of lysis per cell subset (CD!0+ or CD(+) was calculated as follows: 
[(cell counts of PIneg cell subset with e#ector cells) / (cell counts of PIneg cell sub-
set without e#ector cells)] * !../. Percentage of lysis of LCLs, CD!0+ and CD(+ 
cells is depicted. The experiment was performed in duplicate, and a representative 


































Figure S(. Neoreactivity of HA!.M+-TCR td UKL BZLF! T cells directed against LCL EBM is HLA-DR 
restricted.
Figure S(: HA!.M+-TCR td but not non td UKL BZLF! T cells demonstrated reactivity 
directed against EBM. This reactivity could be blocked using class II and HLA-DR 
blocking antibodies.  Because EBM is homozygous HLA-DR( positive, this indicat-
ed that this neoreactivity was HLA-DR( restricted. HLA-DR( negative IZA was not 
recognized. The experiment was performed in duplicate, and representative IFN-1 
production for ) independent experiments is depicted.
55
56
Background: To increase the e7cacy of adoptive immunotherapy 
with TCR-modi!ed T-cells, high expression of the introduced TCR 
is necessary. TCRs directed against the minor histocompatibility 
antigen (MiHA) HA-$ are good candidates for TCR gene transfer 
to treat hematological malignancies because of the hematopoie-
sis-restricted expression of HA-$. Previously it has been demon-
strated, however, that gene transferred HA-$-TCRs are poorly 
expressed at the cell surface. In this study several strategies were 
explored to improve expression of transferred HA-$-TCRs.
Design and Methods: To investigate the underlying 
problem of low HA-$-TCR cell surface expression, TCR-de!cient 
jurkat cells were used to analyze pairing properties of the HA-
$-TCR chains and HA-$-TCR mRNA and cell surface expression 
levels were determined in parental HA-$-speci!c T-cell clones. To 
improve HA-$-TCR expression, HA-$-TCR chains were modi!ed 
using sequence speci!c modi!cations, codon optimization or 
inclusion of cysteine residues and analyzed.
Results: Low HA-$-TCR expression was already apparent 
in parental HA-$-speci!c T-cells, and was demonstrated not to be 
due to impaired pairing properties of the speci!c HA-$-TCR: and 
ß chains but due to intrinsic properties of the HA-$-TCRß chain. 
Of di-erent strategies explored, the most marked improve-
ment in HA-$-TCR expression and functionality was observed 
after TCR transfer of a codon optimized and cysteine modi!ed 
HA-$-TCR.
Conclusions: T-cells transduced with a codon optimized 
and cysteine modi!ed HA-$-TCR ef!ciently recognized target 
cells that endogenously process and present HA-$, independent 
of whether the recipient T-cells were strong or weak competi-
tor T-cells. Based on these results, these modi!ed HA-$-TCRs 
will be used for an HA-$-TCR gene therapy trial in patients with 
leukemia. 
Optimization of the HA---speci,c T-cell receptor for 
gene therapy of hematological malignancies
Haematologica. "#$# Nov "%. [Epub ahead of print]. Published as brief report. Reprinted with permission.
M.M. van Loenen, R. de Boer, R.S. Hagedoorn, H.M. van Egmond, J.H.F. Falkenburg, M.H.M. Heemskerk
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I N T R O D U C T I O N
Patients with hematological malignancies can be successfully 
treated with allogeneic stem cell transplantation (allo-SCT ). After 
allo-SCT relapse of the hematological malignancy can occur 
that can be successfully treated with donor lymphocyte infu-
sion (DLI) from the original stem cell donor inducing complete 
remissions($,"). It has been demonstrated that T-cells recognizing 
minor histocompatibility antigens (MiHAs) selectively expressed 
on hematopoietic cells mediate anti-leukemic reactivity after 
allo-SCT without causing graft versus host disease (GvHD)((,)). 
MiHAs are derived from genetically polymorphic proteins that 
can be di-erentially expressed between donor and recipient(%). 
The MiHA HA-$ is exlusively expressed on hematopoietic(5) and 
carcinoma cells(6), making it an attractive target antigen to treat 
hematological malignancies relapsing after allo-SCT when the 
patient is HA-$+ and the donor is HA-$-. The emergence of CD'+ 
T-cells recognizing the hematopoiesis-restricted MiHA HA-$ was 
observed to be associated with anti-leukemic responses in combi-
nation with no or only mild GvHD()). HA-$ is presented in the con-
text of HLA-A*#"#$(') and has a favorable population frequency(&), 
thus the chance that donor and patient are disparate for HA-$ 
expression is relatively high. Therefore, adoptive transfer of donor 
T-cells directed against HA-$ is an attractive strategy to induce 
anti-leukemic responses without GvHD. However, large numbers 
of T-cells with de!ned speci!city are di7cult to attain. To obtain 
large numbers of leukemia-reactive T-cells without long culture 
periods MiHA-speci!c T-cell receptors (TCRs) can be retrovirally 
transferred. From patients with anti-leukemic responses without 
GvHD high-a7nity HA-$- and HA-"-speci!c T-cells have been iso-
lated($#) and their TCRs have been characterized. Functional T-cells 
with redirected anti-leukemic reactivity have been generated by 
HA-$-TCR or HA-"-TCR gene transfer to donor lymphocytes($$,$").
To broaden the applicability of adoptive T-cell therapy 
in hematological malignancies, we aim to start a clinical study 
using HA-$-TCR transferred virus-speci!c T-cells. For optimal 
anti-leukemic reactivity, high cell surface expression of the in-
troduced TCR and persistence of the gene modi!ed T-cells are 
important. However, HA-$-TCR modi!ed T-cells expressed the 
HA-$-TCR at low levels at the cell surface($"), requiring optimiza-
tion of the strategy. A strategy to promote expression of the 
introduced TCR could be the selection of host T-cells with weak 
competitor phenotype. Recently, we have described that weak 
and strong competitor phenotype of virus-speci!c T-cells is, to 
some extent, correlated with speci!city($(). Based on the speci!c-
ity of the virus-speci!c T-cells, selectively the weak competitor 
phenotype virus-speci!c T-cells may be isolated and used for TCR 
gene transfer. However, this selection would also reduce the pool 
of host T-cells useful for TCR gene transfer. Therefore, we set out 
to optimize the HA-$-TCR to the extent that also TCR modi!ed 
strong competitor phenotype virus-speci!c T-cells expressed the 
introduced HA-$-TCR on their cell surface. In previous studies we 
observed low HA-$-TCR expression due to low HA-$-TCRß cell 
surface expression($"). Since there is exclusive TCRBV chain usage 
of HA-$-speci!c T-cells($),$%), possibly because parts of the variable 
region of the ß chain are crucial for HA-$-speci!city, this ruled out 
5&
the possibility to select for other HA-$-TCRs for use in clinical 
studies, and led to the hypothesis that sequence speci!c proper-
ties resulted in low HA-$-TCRß cell surface expression. There are 
several possible explanations for sequence speci!c low HA-$-
TCRß cell surface. Potentially, the HA-$-TCR; chain is not able to 
be e7ciently expressed on the cell surface in combination with 
the HA-$-TCR: chain. In addition, low mRNA levels due to low 
promotor activity, instable mRNA, or instability of the protein 
could be the underlying problem of low HA-$-TCRß cell surface 
expression.
In this study, we demonstrate using TCR-de!cient J65 
cells that the HA-$-TCR; chain is not able to be e7ciently ex-
pressed on the cell surface with any TCR: chain. In addition, on 
the parental HA-$-speci!c T-cell clones the HA-$-TCR complex 
is also relatively lowly expressed despite normal TCR: and ß 
chain mRNA levels. Sequence speci!c modi!cation to improve 
HA-$-TCRß expression by exchange of the CDR$ region did 
not result in improved HA-$-TCRß expression, but completely 
abolished HA-$-speci!c reactivity. Modi!cation of the HA-$-TCR 
using a combination of codon optimization described to en-
hance translation of the introduced TCR chains($5) and inclusion 
of cysteine residues described to facilitate matched pairing of 
the introduced TCR chains($6-$&) led to improved TCR cell surface 
expression. Moreover, using this modi!ed HA-$-TCR for TCR 
transfer, even virus-speci!c T-cells exhibiting a strong competitor 
phenotype expressed the introduced HA-$-TCRs e7ciently and 
transduced T-cells exerted robust HA-$-speci!c functionality.
D E S I G N  A N D  M E T H O D S
Construction of HA-#-TCR encoding retroviral vectors
TCRAV and TCRBV gene usage of the HA-$-speci!c, the HA-"-
speci!c and the CMV-speci!c T-cell clones was determined as 
previously described("#). TCR: and TCR; chains were cloned 
separately into the retroviral vector LZRS. The HA-$-TCR; chain 
was also cloned into the retroviral vector MP6$. The TCR: chains 
were always linked via IRES with the marker eGFP("$), and the 
TCR; chains were always linked via IRES with the truncated 
nerve growth factor receptor (NGF-R)(""), except for the HA-$-TCR 
chains linked with a T"A sequence("() which were either ex-
pressed in the pLZRS vector combined with the NGF-R marker-
gene or in the MP6$ vector without markergenes. The HA-$-TCR; 
chain comprising of the HA-"."#-TCR CDR$ region (construct A), 
and the HA-"."#-TCR; chain comprising of either only the HA-
$-TCR; CDR$ region (construct B) or both the HA-$-TCR; CDR$ 
and CDR( region (construct C) were obtained by two-step poly-
merase chain reactions (PCR). For construct C, the plasmid cDNA 
of construct B was used as template. Constructs were inserted in 
the pLZRS vector using restriction sites EcoR$ and XhoI. Primers 
used are depicted in Table $. Codon-modi!ed TCR genes were 
designed and produced by GENEART (Regensburg, Germany). In 
addition, cysteine modi!ed HA-$-TCR chains were constructed 
as previously described by introducing cysteine residues at 
positions )' and %6 of the TCR: and TCRß constant domains, 
respectively($6-$&). HA-$-TCR chains with incorporated cysteine 
residues linked with a self-cleaving "A sequence of porcine 
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teschovirus (T"A) sequence with or without codon optimization 
were produced by GENEART. Using the retroviral vectors LZRS 
or MP6$ ("),"%) and packaging cells A-NX-A("5) viral supernatant was 
generated as previously described($(,"6).
Tetrameric HLA class I-peptide complexes, 'ow cytometric analyses
PE- or APC-conjugated tetrameric complexes were constructed 
as described with minor modi!cations("'). Tetrameric HLA-A" 
molecules in complex with HA-$ peptide VLHDDLLEA (HA-
$ tetramer), HLA-A$ molecules in complex with CMV-pp%# 
peptide VTEHDTLLY (pp%# VTE), HLA-B6 molecules in com-
plex with CMV-pp5% TPRVTGGAM (pp5% TPR) or CMV-pp5% 
RPHERNGFTVL (pp5% RPH) and tetrameric HLA-B' molecules 
in complex with EBV-EBNA(A FLRGRAYGL (EBNA(A FLR) were 
constructed. For 9ow cytometric analyses or cell sorting experi-
ments, cells were labeled with tetramers for $ h at )ºC. During 
the last (# min mAbs directed against CD) FITC-conjugated 
(Beckton Dickinson [BD], San Diego, CA, USA), CD)# FITC-
conjugated (Bio-connect, Huissen, The Netherlands) or NGF-R 
PE-conjugated [BD] or APC-conjugated (Cedarlane Laboratories, 
Hornby, Ontario, Canada) were added. Cell surface staining with 
anti-TCR:; PE-Cy%-conjugated (Beckman Coulter, Mijdrecht, The 
Netherlands) or anti-CD( APC-conjugated (BD Pharmingen, San 
Diego, CA, USA) was performed for (# minutes at )ºC.
 qRT-PCR
A qRT-PCR was performed to measure the mRNA level of TCR: 
chain and TCRß chain. Total RNA was isolated from #.% to $x$#6 
T-cells, including % di-erent HA-$-T-cell clones, ( di-erent CMVB7 
T-cell clones, 5 di-erent HA-" T-cell clones, " di-erent CMVA2 
T-cell clones, " di-erent PHA blasts and as a negative control 
Mesenchymal stem cells (MSCs), using the RNeasy mini kit 
(Qiagen). First strand cDNA synthesis was performed with oligo 
dT primers using M-MLV reverse transcriptase (Invitrogen). PCRs 
were started with a hotstart $# min &%°C followed by %# cyles of 
(# sec &%°C, (# sec 5#°C and (# sec 5#°C. Samples were run on 
a 6&##HT Fast Real-Time PCR System of Applied Biosystems. 
Primers used are depicted in Table $. Probes used TET as a dye 
and TAMRA as a quencher and were chosen over an intron/
exon boundary. Each sample was run in duplo with $ and $# ng 
cDNA from " µg of total RNA and normalized to the internal 
Porphobilinogen Deaminase (PBGD) gene. The normalized Ct 
value of PHA blasts was set at $ and expression of other samples 
was shown referenced to that sample using the following formula 
[(Ca or CbTCR Ct sample – PBGD Ct sample)/ (Ca or CbTCR Ct  
pha – PBGD Ct pha)].
Isolation of T-cell clones, selection of virus-speci)c T-cells using 'ow 
cytrometry-based cell sorting and retroviral transduction
All studies were conducted with approval of the institutional 
review board at Leiden University Medical Center. The following 
T-cell clones were used in this study; HLA-A" restricted HA".$, 
HA".%, HA".5, HA".$&, HA"."# and HA"."6 T-cell clones speci!c 
for the MiHA HA-" (),$#), HLA-A" restricted T-cell clones HA-$.
M", HA-$.M6, HA-$.6, HA-$.$" and HA-$.'( speci!c for the MiHA 
HA-$($#), HLA-B6 restricted T-cell clones CMVB7.&#, CMVB7.$#' en 
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CMVB7.$$( speci!c for pp5% TPR("&), and HLA-A" restricted CMVA2.
AV" and CMVA2.AV$( T-cell clones speci!c for pp5% NLV((#). 
Virus-speci!c T-cells were isolated from PBMCs of CMV and 
EBV seropositive persons. After informed consent, PBMCs were 
harvested and labeled with the relevant tetramers for $ h at )ºC 
in RPMI without phenol, supplemented with "8 FBS, washed 
" times, and sorted at )ºC using the FACS Vantage (BD) into 
weak competitor phenotype pp%# VTE or pp5% RPH speci!c 
T-cells and strong competitor phenotype EBNA(A FLR or pp5% 
TPR speci!c T-cells with >&%8 purity. Virus-speci!c T-cells were 
stimulated with $x$#6 cells/ml irradiated allogeneic PBMCs ((# 
Gy), '## ng/ml PHA, and $## IU/ml IL-" (Chiron, Amsterdam, The 
Netherlands). After " days of culture T-cells were transduced with 
retroviral supernatant using recombinant human !bronectin 
fragments CH-"&5(($) and this procedure has been described pre-
viously(("). Markergene eGFP and NGF-R double positive T-cells 
were subsequently sorted. TCR:;-/- Jurkat clone 65($$) (J65) 
needed no stimulation prior to transduction.
Cytokine secretion assay and cytotoxicity assay
To test HA-$-speci!c functionality, %.### puri!ed TCR transduced 
or mock transduced T-cells were cocultured with "#.### di-erent 
target cells and after overnight incubation speci!c IFN-< produc-
tion was measured by standard ELISA(((). In addition, %#.### vi-
rus-speci!c T-cells were tested one week after transduction with 
the clinical vector against "#.### target cells. In the cytotoxicity 
assay puri!ed TCR transduced or mock transduced T-cells were 
cocultured with di-erent target cells at an $#:$ e-ector-to-target 
ratio and cytotoxic reactivity was determined after )h($(). The 
tests were done in triplicate. Targets used were HLA-A"+ HA-
$+ or HA-$- EBV-transformed lymphoblastoid cell lines (LCLs), 
and acute myeloid or lymphoblastoid leukemia (AML and ALL, 
respectively) primary cells.
R E S U LT S
Low HA-#-TCR cell surface expression due to intrinsic properties of 
HA-#-TCR, chains
The HA-$-speci!c TCR would be a good candidate for TCR gene 
transfer to treat hematological malignancies after allo-SCT be-
cause of the hematopoiesis-restricted expression of this MiHA. 
Based on the low cell surface expression of HA-$-TCRs after gene 
transfer as described by us previously($"), we investigated whether 
this low expression was due to the inability of the TCR chains to 
pair e7ciently with each other or due to intrinsic properties of 
the TCR chains. TCR:ß-de!cient jurkat J65 cells($$) were trans-
duced (td) with individual HA-$-TCR: and HA-$-TCR; chains in 
combination with di-erent TCR: and TCR; chains and TCR cell 
surface expression was measured using anti-TCR:; mAbs. In 
Figure $A, TCR cell surface expression is shown for HA-$-TCR:ß, 
CMVB7-TCR:ß, HA-"-TCR:ß, CMVA2-TCR:ß and mixed TCR: 
and ß chain combinations. HA-"-TCR:ß td J65 cells (MFI ((#) 
and CMVA2-TCR:ß td J65 cells (MFI "6)) demonstrated high TCR 
expression. TCR expression of HA-$-TCR:ß td J65 cells (MFI 
$"&) was low compared to HA-"-TCR:ß td J65 cells. Moreover, 
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no restored TCR cell surface expression was observed when 
J65 cells were transduced with combinations of the HA-$-TCRß 
with either the HA-"- or CMVA2-TCR: (Figure $A). In addition, 
no restored TCR expression could be observed in any of the 
transductions of the HA-$-TCR; chain with one of the $) other 
TCR: chains (data not shown). Also four other HA-$-TCRß chains 
derived from di-erent HA-$-speci!c T-cell clones expressing a 
similar TCR BV5S) variable domain (BV6S& according to IMGT 
nomenclature) but di-erent CDR( regions exhibited a similar 
expression pattern (data not shown). In contrast, the HA-$-TCR: 
chain in combination with HA-"- or CMVA2-TCRß chains resulted 
in comparable TCR cell surface expression as parental HA-"- and 
CMVA2-TCR complexes, indicating that reduced HA-$-TCR cell 
surface expression was not due to the HA-$-TCR: chain but due 
to the HA-$-TCRß chain. Since the TCR cell surface expression of 
the HA-$-TCRß with all $) other TCR: chains tested remained low 
we concluded that low HA-$-TCR cell surface expression was not 
due to ine7cient pairing of speci!cally the HA-$-TCR: with the 
HA-$-TCRß chain. To exclude that the LZRS vector used to intro-
duce the TCR chains caused selectively low expression of the HA-
$-TCR, the HA-$-TCR; gene was inserted into the MP6$ vector 
which was described to mediate high transgene expression in T 
lymphocytes(()). As can be seen in Figure $A, HA-$-TCR cell surface 
expression was not improved using the MP6$ vector encoding 
the HA-$-TCR; chain, indicating that the low HA-$-TCR cell sur-
face expression of td J65 cells was not due to vector speci!c prop-
erties. To investigate whether transfer of the HA-$-TCR; chain 
resulted in low cell surface expression due to sequence speci!c 
properties of the always identical variable region of the HA-$-
TCR BV5S) chain, cell surface expression of the CMVB7-TCRß 
with an identical variable BV5S) region as the HA-$-TCRß chain 
but a completely di-erent CDR( region was analyzed. As shown 
in Figure $A, the parental CMVB7-TCR complex demonstrated 
comparably low cell surface expression as the parental HA-$-TCR 
complex. This low TCR expression was also not restored when 
the CMVB7-TCR; chain was combined with either the HA-"- or 
CMVA2-TCR: chain, whereas CMVB7-TCR: chains in combina-
tion with HA-"- or CMVA2-TCRß chains resulted in high TCR cell 
surface expression that was comparable to the expression of the 
parental HA-"- or CMVA2-TCRs. These results imply that low HA-$- 
and CMVB7-TCRß chain expression was due to sequence speci!c 
properties of the variable region. 
These data together indicate that low HA-$-TCR cell 
surface expression is due to intrinsic properties of the HA-$-TCRß 
chain.
Low HA-#-TCR cell surface expression already apparent in parental 
HA-#-speci)c T-cell clones
To con!rm that the sub-optimal cell surface expression of the 
HA-$-TCR after gene transfer was due to intrinsic properties of 
the TCR; chain, the HA-$-TCR cell surface expression and HA-$-
TCR: and ; chain mRNA levels of di-erent parental HA-$-speci!c 
T-cell clones were determined. As demonstrated in Figure $B, 
FACS analyses with antibodies directed against the TCR:; and 
CD( complex demonstrated that the HA-$-speci!c T-cell clones as 
well as the CMVB7-speci!c T-cell clones expressed lower levels of 
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TCR-CD( complexes at the cell surface compared to HA-"- and 
CMVA2-speci!c T-cell clones. The HA-$-speci!c T-cell clones, how-
ever, stained with similar intensity with their respective tetramer 
compared to other T-cell clones (Figure $C), and were on basis 
of cytokine production and cytotoxicity fully functional T-cells 
(data not shown). To exclude that the low TCR:ß expression was 
due to lower transcriptional activity, TCR: and ß mRNA levels of 
the HA-$-speci!c T-cell clones were determined and compared 
to TCR: and ß mRNA levels of other T-cell clones. As demon-
strated in Figure $D, no signi!cant di-erences in HA-$-TCR: or ; 
mRNA expression levels compared to other T-cell clones could 
be detected. In addition, no di-erences between TCR: and ; 
mRNA expression within individual HA-$-speci!c T-cell clones 
could be detected. In conclusion, the parental HA-$-speci!c T-cell 
clones demonstrate lower TCR cell surface expression despite 
normal TCR:ß mRNA levels. These results indicate that the low 
HA-$-TCR expression observed in HA-$-TCR transferred T-cells is 
an intrinsique feature of the HA-$-TCR, since already TCR expres-
sion of the parental HA-$-speci!c T-cell clones is low.
CDR# region of HA-#-TCR, chain partly responsible for low cell 
surface expression, but indispensable for HA-# speci)city
To be able to improve HA-$-TCR expression after gene 
transfer, we investigated whether we could determine the spe-
ci!c region of the HA-$-TCRß responsible for this low TCR cell 
surface expression and improve HA-$-TCR expression by modi-
!cation of this region. For this purpose, the sequences of several 
TCRß chains belonging to the BV5 variable domain family and 
























































































































































































































































Figure !. Low HA-!-TCR cell surface expression due to intrinsic properties of the 
HA-!-TCRß chain.
Figure !: (A) The pairing properties of HA-!-TCR$  and ß 
chains were analyzed by transducing the J+, cells with com-
binations of the HA-!-TCR$  or TCR'  chains with !( other 
antigen-speci"c TCR$  and TCRß chains. TCR cell surface 
expression of these di#erent combinations was measured by 
staining with anti-TCR$ß mAbs and analyzing eGFP/NGF-R 
double positive J+, cells using 3ow cytometry - days after 
transduction. Here depicted are the mean 3uorescence inten-
sity (MFI) of the TCR$ß expression of all the TCR$  chains of 
the HA-)-, HA-!-, CMVB7, and CMVA2-speci"c TCRs combined 
with all the TCRß chains of these TCRs. All TCR chains are 
encoded by pLZRS retroviral vectors with the exception of the 
HA-!-TCRß chain that is in addition also encoded, as indi-
cated, by the MP+! retroviral vector. Non td J+, cells showed 
little background staining with anti-TCR$ß mAbs (MFI = !,). 
Parental TCR combinations are indicated with an asterisk. 
(B) Several T-cell clones including - di#erent HA-!-speci"c 
T-cell clones, , di#erent HA-)-speci"c T-cell clones, and ) dif-
ferent CMV-A)-speci"c T-cell clones were stained with anti-
TCR$ß and anti-CD&  mAbs and analyzed using 3ow cytom-
etry. MFIs shown are means of the di#erent T-cell clones. (C) 
The di#erent T-cell clones were stained with their respective 
tetramers and MFI is depicted in the dot plots. (D) mRNA lev-
els of TCR$  (closed symbols) and TCR'  chains (open symbols) 
were analyzed for the di#erent T-cell clones using q-RT-PCR. 
As a negative control, cDNA of MSCs was included. Stainings 
were performed in duplo, and data shown are representative 
for ) independent experiments.
6)
known to exhibit high cell surface expression after 
gene transfer, namely the HA-"-TCR BV5S", the 
JBBun-TCR BV5S(, and the $#G%-TCR BV5S6, were 
aligned with the sequences of the HA-$ and CMVB7-
TCR BV5S). In total, (# shared di-erences were 
scattered throughout the (#& amino acids (aa) long 
variable region, of which & nucleotide di-erences 
clustered in the $' nucleotide-long CDR$ region, 
as depicted in Figure "A. Based on these results, 
we hypothesized that primarily the CDR$ region 
of HA-$-TCR BV5S) may be in9uencing cell sur-
face expression of the HA-$-TCR; chain. To study 
this, di-erent constructs were made in which the 
HA-$-TCR; CDR$ region was exchanged with the 
HA-"-TCR; CDR$ region and vice versa. J65 cells 
transduced with modi!ed HA-$- and HA-"-TCRs 
were analyzed for TCR cell surface expression using 
an anti-TCR:;-speci!c mAb. As demonstrated in 
Figure "B, exchange of the HA-$-TCR; CDR$ region 
with the CDR$ region of the HA-"-TCR; did not re-
sult in marked improvement of TCR cell surface ex-
pression on J65 cells. Likewise, the exchange of the 
HA-"-TCR; CDR$ region with the HA-$-TCR; CDR$ 
region did not result in signi!cantly decreased TCR 
cell surface expression on J65 cells. These results 
indicate that the CDR$ region is not solely respon-
sible for the low TCR cell surface expression. In 
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Figure ). CDR! region not responsible for low HA-!-TCR expression, but indispensable for 
HA-!-speci"city.
Figure ): (A) Di#erent TCR-BV, chains that demonstrate high cell surface expres-
sion after TCR gene transfer and the HA-!-TCR BV,S( chains that demonstrate 
low cell surface expression after TCR gene transfer were aligned and di#erences 
in nucleotide sequences were analyzed. &. shared nucleotide di#erences were 
observed in the &.0 aa long variable region between the highly expressed HA-)-
TCR BV,S), the JBBun-TCR BV,S& and the !.G--TCR BV,S+ and the marginally 
expressed HA-!-TCR BV,S(. Sequences shown are from amino acid (! to *. of the 
BV, chains (total aa &.0) containing the CDR!- and CDR)-region of the HA-!-TCRß 
and the HA-)-TCRß chain. The shared di#erences between all the other BV, TCR 
chains and the HA-!-TCRß chain are indicated with arrows. (B) To test the role 
of the HA-!-TCR'  CDR! region in low HA-!-TCR expression, J+, cells were trans-
duced with combinations of the HA-!-TCR$  or HA-)-TCR$  with several constructs 
encoding for either the HA-!-TCRß chain unmodi"ed or exchanged with the HA-
)-TCRß CDR! region, or the HA-)-TCRß chain unmodi"ed or exchanged with the 
HA-!-TCRß CDR! region only or exchanged with the HA-!-TCRß CDR! and CDR& 
region. Using 3ow cytometry TCR cell surface expression was analyzed for the 
eGFP/NGF-R double positive J+, cells. Non td J+, cells showed little background 
staining with anti-TCR$ß mAbs (MFI = !,). Parental TCR combinations are in-
dicated with an asterisk. Stainings were performed in duplo, and data shown are 
representative for ) independent experiments (C) To test the role of the HA-!-TCR' 
CDR! region in HA-!-speci"city, virus-speci"c T-cells were transduced with several 
constructs encoding unmodi"ed HA-!-TCR$  chains combined with either unmodi-
"ed HA-!-TCR'  chains or exchanged with the HA-)-TCRß CDR! region or the 
HA-)-TCRß chain exchanged with the HA-!-TCRß CDR! region only or with the 
HA-!-TCRß CDR! and CDR& region. Cells were sorted based on eGFP and NGF-R 
double positivity and subsequently tested in a standard IFN-1 ELISA. Targets used 
were: HLA-A)pos and HA-!neg LCL-IZA, HLA-A)pos and HA-!pos LCL-BDV and LCL-
IZA pulsed with di#erent HA-!-peptide concentrations, as indicated in the "gure. 
6%
virus-speci!c T-cells with the di-erent modi!ed TCR chains that 
exchange of the CDR$ region of the HA-$-TCRß with the CDR$ 
region of the HA-"-TCRß resulted in a complete abolishment of 
HA-$-speci!c IFN-< production (Figure "C), illustrating that the 
HA-$-TCRß CDR$ region is crucial for HA-$-speci!city. However, 
exchange of the HA-"-TCRß CDR$ region with the HA-$-TCRß 
CDR$ region demonstrated that exchange of only this region 
was not enough to transfer HA-$-speci!city. Exchange of both 
the HA-"-TCRß CDR$ and CDR( region with the regions of the 
HA-$-TCRß resulted in HA-$-speci!city (Figure "C). However, 
these td T-cells were still less e7cient compared to the parental 
HA-$-TCR td T-cells, since only low recognition of endogenously 
processed HA-$ (LCL-BDV) was observed (Figure "C).
In conclusion, the HA-$-TCR; CDR$ region seems to 
play a modest role in low TCR cell surface expression, but is 
crucial for HA-$-speci!city.
Introduction of cysteine residues combined with HA-#-TCR codon 
optimization leads to highly improved HA-#-TCR expression after 
gene transfer
Since HA-$-TCR expression could not be improved by modi-
!cation of speci!c sequences of the HA-$-TCRß chain, other 
strategies described to improve TCR cell surface expression 
of gene transferred TCRs were explored. We studied whether 
TCR codon optimization or inclusion of cysteine residues in the 
constant domains of both the HA-$-TCR: and ß chain resulted 
in potent HA-$-speci!c T-cells after gene transfer. We analyzed 
the HA-$-TCR cell surface expression after transfer of the 
di-erent constructs into virus-speci!c T-cells known to possess 
endogenous TCRs which weakly compete for cell surface expres-
sion (weak competitor; pp%# VTE speci!c T-cells, Figure () and 
virus-speci!c T-cells known to possess endogenous TCRs which 
strongly compete for cell surface expression (strong competi-
tor; EBNA(A FLR speci!c T-cells, Figure (). As demonstrated in 
Figure (A, transfer of the unmodi!ed HA-$-TCR complex into 
weak competitor T-cells resulted in )#8 of HA-$ tetramer positive 
T-cells, whereas after transfer of the unmodi!ed HA-$-TCR com-
plex into strong competitor T-cells no clear HA-$-TCR expression 
could be measured using tetramers after transfer of the unmodi-
!ed HA-$-TCR complex. The inclusion of cysteine residues in 
both HA-$-TCR chains improved HA-$-TCR expression especially 
in the strong competitor virus-speci!c T-cells. As expected, inclu-
sion of cysteine residues in only one of the two HA-$-TCR chains 
signi!cantly diminished HA-$-TCR expression. Codon optimiza-
tion, in addition, improved HA-$-TCR expression both in weak 
and strong competitor virus-speci!c T-cells. The increased HA-$-
TCR expression, however, appeared not to be due to improved 
HA-$-TCR; chain expression, but due to improved HA-$-TCR: 
chain expression, since T-cells transferred with the codon op-
timized HA-$-TCR: chain in combination with the wild type 
HA-$-TCR; chain showed a similar improvement in percentage 
of HA-$-tetramer positive T-cells compared to T-cells transferred 
with both codon optimized HA-$-TCR: and ß chain. In both the 
weak and strong competitor virus-speci!c T-cells a combination 
of codon optimized and cysteine modi!ed HA-$-TCR: chain with 
65
cysteine modi!ed HA-$-TCRß chain improved HA-$-TCR expres-
sion most prominent (Figure (A). 
To test whether the improved HA-$-TCR expression re-
sulted in improved HA-$-speci!c functionality, HA-$-TCR td weak 
and strong competitor virus-speci!c T-cells were tested against 
HA-$ peptide loaded target cells as well as target cells endoge-
nously expressing the HA-$ antigen (Figure (B). In weak competi-
tor virus-speci!c T-cells, the combination of codon optimized and 
cysteine modi!ed HA-$-TCR: chain with the cysteine modi!ed 
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Figure &A. Analysis of HA-!-TCR expression of virus-speci"c T-cells transduced with di#erent modi-
"ed HA-!-TCRs.
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Figure &B. Analysis of HA-!-speci"c functionality of virus-speci"c T-cells transduced with di#erent 
modi"ed HA-!-TCRs.
Figure &: The di#erent modi"cation strategies 
were tested for their potential to optimize 
HA-!-TCR expression and functionality. (A) 
Weak (pp-. VTE T-cells) and strong competi-
tor phenotype (EBNA&A FLR T-cells) virus-
speci"c T-cells were transduced with either 
unmodi"ed HA-!-TCR$  chains (AV&) WT ), 
cysteine modi"ed HA-!-TCR$  chains (AV&) 
SS), codon optimized HA-!-TCR$  chains 
(AV&) opt) or codon optimized and cysteine 
modi"ed HA-!-TCR$  chains (AV&) opt SS) 
in combination with either unmodi"ed (BV, 
WT ), cysteine modi"ed (BV, SS), or codon 
optimized (BV, opt) HA-!-TCRß chains. Dot 
plots are depicted of eGFP and NGF-R double 
positive virus-speci"c T-cells. (B) All these 
modi"ed HA-!-TCR td weak competitor and 
strong competitor virus-speci"c T-cells were 
tested in a standard IFN-1 ELISA. Numbers 
in the "gures correspond with the num-
bers indicated in the dot plots of A. Targets 
used were HLA-A)pos HA-!neg LCL-IZA, 
HLA-A)pos HA-!pos LCL-MRJ and LCL-IZA 
pulsed with di#erent concentrations of HA-
!-peptide. The experiment was performed 
in duplo. Data shown are representative 
for & independent experiments using virus-
speci"c T-cells of ) di#erent healthy donors. 
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HA-$-TCR; chain (combination D') demonstrated highest IFN-< 
production against peptide loaded target cells as well as against 
target cells presenting endogenously processed HA-$ antigen. 
Most evidently, in strong competitor T-cells, this TCR combina-
tion was the only one able to exert signi!cant HA-$-speci!c 
reactivity.  
In conclusion, the combination of cysteine modi!cation of the 
HA-$-TCR chains with codon optimization of the HA-$-TCR: 
chain resulted in e7cient HA-$-TCR expression after gene 
transfer, even in strong competitor T-cells, and resulted in robust 
HA-$-speci!c functionality.
T-cells transduced with codon optimized and cysteine modi)ed HA-
#-TCR recognize HA-#+ malignant cells
To con!rm the generality of these data, polyclonal peripheral 
CD'+ T-cells, as well as other weak and strong competitor T-cells 
were transduced with single retroviral vectors encoding both the 
unmodi!ed or codon optimized and cysteine modi!ed HA-$-
TCR: and ß chain linked with a picorna virus derived self-cleav-
ing "A sequence and tested for HA-$-TCR cell surface expression 
(Figure )A). Also the HA-$-TCRß chain was codon optimized, 
although we did not observe improved cell surface expression 
of codon optimized HA-$-TCRß chains, to warrant that mRNA 
stability of the TCRß chain was not negatively in9uencing TCR: 
chain expression. Correspondingly, transduction with the modi-
!ed HA-$-TCR resulted in most e7cient cell-surface expression 
in both weak and strong competitor T-cells. The polyclonal 
CD'+ T-cells demonstrated similar to strong competitor T-cells !iigguurree 44AABBCC    MMMM    vvaann    LLooeenneenn
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Figure (. Introduction of codon optimized and cysteine modi"ed HA-!-TCR generally results in 
e%cient HA-!-TCR expression and robust HA-!-speci"c functionality.
Figure (: (A) Weak competitor phenotype 
(pp,- RPH) T-cells, strong competitor phe-
notype (pp,- TPR) T-cells and polyclonal 
peripheral CD*+ T-cells were transduced 
with either a single construct encoding the 
unmodi"ed (WT td) or the codon optimized 
and cysteine modi"ed HA-!-TCR chains (opt 
SS td) and HA-! tetramer staining was ana-
lyzed. Dot plots depict HA-! tetramer stain-
ing of NGF-R positive virus-speci"c T-cells 
and percentages of HA-! tetramer positive 
T-cells are indicated. Dot plots depicted are 
representative for ) independent experiments 
using T-cells of & di#erent healthy individuals. 
(B/C) pp,- RPH and pp,- TPR T-cells trans-
duced with a single construct encoding either 
HA-!-TCR WT or HA-!-TCR opt SS, or empty 
vectors were tested against di#erent targets 
for HA-!-speci"c (B) cytotoxic reactivity in a 
chromium release assay and (C) IFN-1 pro-
duction. Targets used were HLA-A)pos LCLs, 
AML and ALL primary cells that were either 
positive or negative for HA-!. Data presented 
is representative for ) independent experi-
ments using T-cells of & di#erent healthy 
individuals. 
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signi!cant HA-$-TCR cell-surface expression after transfer of the 
modi!ed HA-$-TCR (Figure )A).    
To study whether this improved HA-$-TCR cell-surface expression 
was coincided with clinically relevant HA-$-speci!c functionality, 
weak and strong competitor phenotype T-cells transduced with 
either the unmodi!ed or codon optimized and cysteine modi!ed 
HA-$-TCR were analyzed for HA-$-speci!c cytotoxic activity 
(Figure )B) and IFN-< production (Figure )C). Whereas weak com-
petitor T-cells transduced with the unmodi!ed HA-$-TCR exerted 
HA-$ speci!c cytotoxic reactivity and IFN-< production against 
AML and ALL, introduction of the modi!ed TCR enhanced HA-
$-speci!c reactivity (Figure )B and C, respectively).  In addition, 
strong competitor T-cells transduced with the modi!ed HA-$-TCR 
were able to demonstrate signi!cant cytotoxic activity and IFN-< 
production directed against HA-$+ malignant cells (Figure )B and 
)C, respectively).
In conclusion, these results con!rm the generality of im-
proved HA-$-TCR expression of introduced modi!ed HA-$-TCRs 
into both weak as well as strong competitor phenotype T-cells, 
thus generating potent redirected HA-$-speci!c T-cells. 
For use in clinical therapy the introduced TCR has to be encoded 
by a retroviral construct without potentially immunogenic 
marker genes. Therefore, we constructed a MP6$ vector without 
marker gene encoding the modi!ed HA-$-TCR: and ß chain, and 
analyzed whether weak and strong competitor T-cells (Figure %) 
transduced with this clinically useful vector demonstrated simi-
larly improved anti-leukemic reactivity. One week after trans-
duction weak and strong competitor T-cells were analyzed for 
HA-$-speci!c reactivity against malignant target cells using IFN-< 
ELISA (Figure %). Transduction e7ciency of the pLZRS and MP6$ 
vector were based on NGF-R or HA-$-tetramer staining, and was 
demonstrated to be $% and "8, respectively. Whereas malignant 
cells were equally well recognized by weak competitor T-cells 
transduced with either the unmodi!ed or the modi!ed HA-$-TCR 
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Figure -. Strong competitor phenotype virus-speci"c T-cells transduced with MP+! HA-!-TCR opt 
SS demonstrate more robust HA-!-speci"c IFN1 production against AML and ALL malignant cells 
compared to HA-!-TCR WT transduced T-cells. 
Figure -.: To improve the vector for clinical 
use, the modi"ed HA-!-TCR chains linked 
with a T)A sequence were expressed in the 
MP+! vector without marker gene. pp-. VTE 
and EBNA&A FLR virus-speci"c T-cells were 
transduced with pLZRS vectors encoding un-
modi"ed HA-!-TCR chains linked with a T)A 
sequence and linked with an IRES sequence 
to a marker gene (WT TCR) or with MP+! 
vector without markergene encoding HA-!-
TCR opt SS or empty vectors (mock td) and 
one week after transduction tested for HA-
!-speci"c IFN1 production against di#erent 
HLA-A)pos AML and ALL primary cells that 
were either positive or negative for HA-! as 
indicated in the "gure. The experiment was 
performed in duplo and is representative for 
) independent experiments.
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(Figure %), strong competitor T-cells transduced with the modi-
!ed HA-$-TCR demonstrated markedly improved IFN< produc-
tion against AML en ALL target cells as compared to unmodi!ed 
HA-$-TCR transduced T-cells.
In conclusion, TCR transfer with a codon optimized 
and cysteine modi!ed HA-$-TCR resulted in e7cient expression 
of introduced HA-$-TCRs and robust HA-$-speci!c functionality 
against clinically relevant target cells, both in weak as well as in 
strong competitor virus-speci!c T-cells. 
D I S C U S S I O N
To broaden the applicability of adoptive T-cell therapy in he-
matological malignancies, we aim to start a clinical study using 
MiHA-TCR transferred virus-speci!c T-cells. The MiHA HA-$-
speci!c TCR is an attractive candidate for TCR gene transfer to 
treat hematological malignancies based on the hematopoiesis-
restricted expression of HA-$, and the favorable population 
frequency. However, as previously described, HA-$-TCR cell 
surface expression after gene transfer is low($"). In this study, we 
attempted to improve cell surface expression of the HA-$-TCR 
after gene transfer. HA-$-TCR expression appeared to be mostly 
hampered due to intrinsic properties of the HA-$-TCR; chain, 
also re9ected in low TCR cell surface expression on the paren-
tal HA-$-speci!c T-cell clones. By using a combined strategy of 
codon optimization and introduction of cysteine residues, we 
demonstrated a substantial improvement of the HA-$-TCR cell 
surface expression, resulting in TCR modi!ed T-cells exhibiting 
clinically relevant HA-$-speci!c functional activity.
Since the transferred TCR has to compete for cell 
surface expression with the endogenous TCR and mixed TCR di-
mers, gene transferred TCRs need to exhibit high a7nity for their 
speci!c peptide-HLA complex. Although the HA-$-TCR is known 
to exhibit high a7nity for the HA-$-peptide-HLA-A" complex, 
we anticipate that for optimal e7cacy of the HA-$-TCR trans-
ferred T-cells the cell surface expression of the HA-$-TCR has to 
be high, allowing the HA-$-TCR modi!ed virus-speci!c T-cells to 
also recognize clinically relevant target cells expressing endog-
enously processed HA-$ antigen. Di-erential TCR cell surface 
expressions after gene transfer have been described previous-
ly((%,(5). Which properties of the TCR chains in9uences cell surface 
expression has been subject to debate((#), and it has been postu-
lated that interchain pairing and competition for CD(-complex 
formation may both play a role. In this study, we demonstrate 
that on the parental HA-$-speci!c T-cell clones the HA-$-TCR 
complex is relatively lowly expressed despite normal TCR: and ß 
chain mRNA levels, although here competition for CD(-complex 
formation does not play a role. From these results we conclude 
that low TCR expression is a characteristic of the HA-$-TCR that 
is also transferred into T-cells using retroviral transduction. We 
hypothesized that this characteristic is based upon mRNA or 
protein instability of the HA-$-TCR; chain. Codon optimization 
is described to increase RNA stability as well as translational 
e7cacy by knockout of cryptic splice sites and RNA destabiliz-
ing sequence elements, and optimization of codon usage and 
'#
GC content, resulting in substantially increased expression of the 
introduced TCRs($5). Since codon optimization did not change the 
expression of the HA-$-TCRß chain at the cell surface, we antici-
pate that the underlying problem of low HA-$-TCRß cell surface 
expression is downstream of translation. When di-erences in 
sequence between highly expressed and ine7ciently expressed 
TCR-BV5 chains after gene transfer were analyzed, most con-
spicuous di-erences were found in the CDR$ region. It has been 
postulated that the CDR$ region is important for HA-$-speci!city, 
since all the HA-$-speci!c T-cell clones described thus far selec-
tively use the TCR-BV5S) chain($),(6). Based on these results, we 
hypothesized that potentially the CDR$ region could be involved 
in ine7cient expression of the HA-$-TCRß chain. Upon exchange 
of this CDR$ region with the HA-"-TCR; CDR$ region, however, 
HA-$-speci!city was abrogated, underlining the importance of 
the CDR$ region for HA-$-speci!c reactivity. Exchange of the HA-
$-TCRß CDR$ region with the CDR$ region of the HA-"-TCR, in 
addition, did not improve HA-$-TCR cell surface expression.
For optimal TCR expression, selection of strong com-
petitor phenotype TCRs for TCR gene transfer purposes is neces-
sary. Alternatively, host T-cells with weak competitor phenotype 
TCRs can be selected. We have previously described that based 
on speci!city permissive virus-speci!c T-cells exist that allow high 
expression of the transferred TCR at the cell surface($(). Selection 
of these permissive virus-speci!c T-cells therefore would be a 
strategy to obtain su7cient expression of the introduced TCR. 
However, this would reduce the pool of host T-cells useful for 
HA-$-TCR gene transfer. Therefore, we aimed to !nd a strategy 
to obtain high HA-$-TCR expression both in virus-speci!c T-cells 
with weak and strong competitor phenotype. Codon optimiza-
tion is described to increase RNA stability as well as translational 
e7cacy by knockout of cryptic splice sites and RNA destabilizing 
sequence elements($5). Inclusion of cysteine residues is described 
to facilitate matched TCR chain pairing by formation of an extra 
interchain disul!de bond($6-$&). Most notably forced preferential 
pairing of the HA-$-TCR chains by inclusion of cysteine residues 
resulted in high HA-$-TCR expression. In addition, we have previ-
ously reported that forced preferential pairing reduced mixed TCR 
dimer formation, as measured by reduced neoreactivity exerted 
by mixed TCR dimers(((). Combining the two strategies increased 
the HA-$-TCR expression even more in both the weak and strong 
competitor phenotype T-cells, resulting in high numbers of high-
avidity T-cells capable of recognizing primary AML and ALL cells.
Currently, we are starting up a phase I/II clinical trial to 
treat HLA-A*#"#$+ HA-$+ patients with refractory hematological 
malignancies for whom no other therapies are available with co-
don optimized and cysteine modi!ed HA-$-TCR td virus-speci!c 
T-cells. Using this modi!ed HA-$-TCR, selection for weak competi-
tor phenotype T-cells for HA-$-TCR gene transfer might still result 
in the highest yield of high-avidity TCR modi!ed T-cells, but also 
without prior selection, high numbers of high-avidity TCR modi-
!ed T-cells can be obtained, allowing for a simple strategy to 
isolate and transduce the most dominantly present CMV- or EBV-
speci!c T-cell populations, without the need for another selection 
based on high HA-$-TCR cell surface expression.
'$
In conclusion, the combination of codon optimization 
and inclusion of cysteine residues in HA-$-TCR chains resulted 
in high HA-$-TCR expression after gene transfer. Even strong 
competitor phenotype virus-speci!c T-cells transduced with the 
clinical vector encoding the modi!ed HA-$-TCR highly expressed 
the HA-$-TCR on their cell surface, resulting in robust HA-$-
speci!city against clinically relevant target cells. Therefore, for 
future clinical HA-$-TCR gene transfer studies, the MP6$ vector 
encoding the codon optimized and cysteine modi!ed HA-$-TCR 
will be used.
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TCR gene transfer is an attractive strategy to equip T-cells with 
de!ned antigen-speci!c TCRs using short-term in vitro proce-
dures. Selection of host cells with a known speci!city and intro-
duction of a well characterized TCR may result in an o--the shelf 
therapy that combines high anti-leukemic reactivity with a mini-
mal risk of GvHD. However, some potential drawbacks to TCR 
gene transfer exist. The introduced TCR is under regulation of a 
retroviral promotor to ensure high cell surface expression, and it 
is unknown whether this interferes with physiological downregu-
lation and re-expression of the TCR after antigen-speci!c stimu-
lation. TCR transfer leads to lower expression of the introduced 
TCR compared to parental T-cell clone due to competition for 
cell surface expression with the endogenous TCR. T-cells ex-
pressing di-erent amounts of introduced and endogenous TCRs 
on their cell surface may skew after repetitive stimulations via 
one TCR to populations predominantly expressing the triggered 
TCR, resulting in loss of dual-speci!city. TCR transfer may in ad-
dition lead to the formation of mixed TCR dimers, composed of 
introduced TCR chains pairing with the endogenous TCR: or ; 
chain, harboring potentially harmful new reactivities. This thesis 
focused on bene!ts and threats of TCR gene transfer and pos-
sible solutions. 
TCRs that are introduced in T-cells using gene transfer 
are mostly under regulation of a strong viral promotor to ensure 
high introduced TCR cell surface expression. For e-ective reac-
tivity and in vivo survival of the TCR transduced T-cells, physi-
ological stimulation via the introduced TCR is important. The 
internalization of CD( complexes induced by TCR stimulation 
resulting in termination of all cellular interactions and T-cell non-
responsiveness seems to be vital to provide a so called refrac-
tory period of activation. In chapter " we investigated whether 
speci!c stimulation of either the introduced or endogenous TCR 
of dual TCR engineered T-cells resulted in comodulation of the 
non-triggered TCR. In addition, we examined the impact of regu-
lation via either the endogenous or retroviral promotor on re-ex-
pression of the introduced and endogenous TCR on TCR trans-
duced T-cells and antigen-responsiveness via both TCRs. For this 
purpose, virus-speci!c T-cells were retrovirally transduced with 
several TCRs. We demonstrated that early after antigen-speci!c 
stimulation of TCR transduced T-cells both the endogenous and 
introduced TCR complexes were downregulated irrespective 
of which TCR was triggered and this resulted in marked reduc-
tion of functional activity both via the stimulated as well as the 
non-stimulated TCR. These results indicate that stimulation via 
Summary and discussion 6
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one TCR results in a protective refractory period comprising of 
non-responsiveness via both TCRs. TCR downregulation shortly 
after TCR triggering was not changed in TCR transduced T-cells, 
however, the introduced TCR under regulation of a retroviral 
promotor was rapidly re-expressed on the cell surface at ")h after 
TCR stimulation independent of which TCR was triggered. This 
rapid re-expression of the introduced TCR, however, did not lead 
to immediate restored functionality or activation induced cell 
death (AICD), illustrating that cell mechanisms other than TCR 
cell surface expression are also involved in providing a protective 
refractory period.
We suggest that in the case of rapid expression of the 
introduced TCR CD' downregulation is involved in providing a 
protective refractory period. We conclude that TCR transduced 
virus-speci!c T-cells can be potentially useful for clinical purposes, 
since a protective refractory period is maintained in these T-cells 
even though the introduced TCR is rapidly re-expressed after 
TCR-triggering.
Persistence of TCR modi!ed T-cells is important for a 
potent continuous anti-leukemic response. TCR transfer into 
T-cells speci!c for latent viruses may achieve persistence of TCR 
modi!ed T-cells, since repetitive encounter with viral antigens 
latently present in the recipient may activate the TCR engineered 
T-cells via their endogenous TCR, and thereby increase in vivo 
survival. However, when frequent encounter of viral antigens 
would lead to selective survival of TCR modi!ed virus-speci!c 
T-cells with predominant expression of the endogenous virus-
speci!c TCR, this may result in loss of dual-speci!city of the T-cells 
and eventually in relapse of the leukemia. In Chapter (, we dem-
onstrate that HA-"-TCR transduced virus-speci!c T-cells repeti-
tively stimulated via one TCR remained dual reactive in response 
to triggering via both the endogenous and the introduced TCR. 
After repetitive stimulation of one TCR, HA-"-TCR transduced 
virus-speci!c T-cells preferentially expressed the triggered TCR, 
losing high avidity interaction via the previously non-triggered 
TCR. However, TCR expression reverted within one week after a 
single stimulation via the previously non-triggered TCR. When 
the dual-speci!c T-cells were sorted in opposing CMV-TCRhi 
T-cells and HA-"-TCRhi T-cells, both subsets still demonstrated 
cytotoxic activity against HA-" peptide pulsed target cells and 
CMV peptide pulsed target cells, respectively. However, CMV-
TCRhi T-cells demonstrated only cytotoxic activity against target 
cells presenting endogenously processed pp5% and not HA-", and 
vice versa, HA-"-TCRhi T-cells recognized only target cells present-
ing endogenously processed HA-", but not pp5%. After additional 
stimulation, both subsets were able to re-express the HA-" and 
CMV-TCR, respectively. When TCR expression was redistributed 
on the T-cells, high avidity functionality via both the endogenous 
and the introduced TCR was restored. In conclusion, after re-
petitive stimulation HA-"-TCR transduced CMV-speci!c T-cells 
appeared to skew to populations predominantly expressing the 
triggered TCR. However, populations predominantly express-
ing the triggered TCR were able to revert their TCR make up 
and redistribute the previously non-triggered TCR after a single 
stimulation. These results indicate that TCR transduced virus-
speci!c T-cells maintain co-expression of both the endogenous 
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and introduced TCR after several stimulations and can therefore 
be implemented in future clinical studies.
Transfer of TCRs into T-cells will not only result in cell 
surface expression of both the endogenous TCR and the in-
troduced TCR, but also in cell surface expression of mixed TCR 
dimers consisting of introduced TCR chains pairing with endog-
enous TCR chains. The speci!city of these mixed TCR dimers 
is unknown, and therefore harmful reactivities can not be ex-
cluded.  In chapter ), we investigated whether TCR gene transfer 
can lead to the generation of new detrimental reactivities by 
creating T-cells that express mixed TCR dimers. We demonstrate 
that transfer of TCR:; complexes as well as only TCR: or TCR; 
chains into virus-speci!c T-cells resulted in new reactivities. The 
observation that transfer of only TCR: or ; chains resulted in 
neoreactivities showed that mixed TCR dimers were responsible 
for these new speci!cities. The observed neoreactivities could 
be either HLA class I or class II restricted. Furthermore, we not 
only observed neoreactive mixed TCR dimers harboring allore-
activity, but also autoreactivity. Cysteine modi!cation to induce 
preferential pairing of the introduced TCR: and ; chain reduced 
the neoreactivity of TCR td virus-speci!c T-cells considerably. We 
conclude that the formation of neoreactive mixed TCR dimers 
is not a feature of a speci!c TCR, since we observed this in all 
virus-speci!c T-cells tested, with di-erent introduced TCR: or 
TCR; chains. We therefore underline the importance of facilitat-
ing matched pairing of introduced TCR chains, for example by 
cysteine modi!cation of the introduced TCR, and in addition, 
diminishing the chance of formation of harmful neoreactive 
mixed TCR dimers by using T-cell populations with restricted 
TCR repertoire as host cells for TCR transfer.
TCRs directed against MiHA HA-$ are good candi-
dates for TCR gene transfer to treat hematological malignancies 
because of the hematopoiesis-restricted expression of the HA-$ 
MiHA. For optimal e7cacy of adoptive immunotherapy with 
TCR modi!ed T-cells, high introduced TCR expression is neces-
sary. However, it has been described previously that HA-$-TCR 
cell surface expression after gene transfer is low. In chapter %, we 
analyzed what caused this low expression and studied di-erent 
strategies to improve HA-$-TCR expression after gene transfer. 
We demonstrate that poor TCR cell surface expression was 
already present in parental HA-$-speci!c T-cell clones. The low 
HA-$-TCR expression after gene transfer was not due to speci!c 
pairing properties of the HA-$-TCR: and ; chain, but due to 
intrinsic properties of the HA-$-TCR; chain. Of di-erent strate-
gies explored to improve cell surface expression of the intro-
duced TCR, a combination of codon optimization and cysteine 
modi!cation resulted in most prominent HA-$-TCR cell surface 
expression after gene transfer. Even strong competitor pheno-
type virus-speci!c T-cells transduced with the modi!ed HA-$-TCR 
highly expressed the HA-$-TCR on the cell surface, resulting in 
HA-$-speci!c reactivity against target cells expressing endog-
enously processed HA-$.
On bases of these results we created the clinical 
MP6$ vector encoding for an optimized and cysteine modi!ed 
HA-$-TCR; and : chain linked with a self-cleaving T"A se-
quence. Transfer of this vector into strong and weak competitor 
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virus-speci!c T-cells resulted in T-cell populations exerting robust 
HA-$-speci!c reactivity against clinically relevant target cells. 
Based on these results, a clinical study will be initiated to treat 
patients with hematological malignancies that received alloge-
neic stem cell transplantation (allo-SCT ) with virus-speci!c donor 
T-cells transduced with the MP6$ vector encoding the codon 
optimized and cysteine modi!ed HA-$-TCR.
G E N E R A L  D I S C U S S I O N
CHARACTERISTICS OF THE INTRODUCED TCR
E%cient functional avidity of the introduced TCR
TCRs introduced via gene transfer have to compete for cell sur-
face expression with not only the endogenous TCR, but also with 
mixed TCR dimers that can be formed by pairing of the endog-
enous TCR chains with the introduced TCR chains. Therefore, 
gene transferred TCRs need to exhibit high a7nity for their 
speci!c peptide-HLA complex to overcome low TCR cell surface 
expression.
The HA-" and HA-$-TCR described in this thesis are 
examples of high-a7nity TCRs, and were isolated from individu-
als with GvL and minimal GvHD. HA-" and HA-$ have been 
proven to be exclusively expressed on cells of the hematopoi-
etic system($-() and on clonogenic leukemic precursor cells($,"). 
Adoptive transfer of HA-"- or HA-$-speci!c T-cells will potentially 
result in selective elimination of patient-derived malignant and 
non-malignant hematopoietic cells whereas donor-derived 
hematopoietic cells will not be recognized. HA-$ has a more 
favorable population frequency ((%-5&8)()-5) than HA-" (6#8- &%8)
(%-6). Preferentially, for TCR gene transfer, we would like to use TCRs 
with a strong competitor phenotype('-$#). As reported previously($$), 
all HA-$-TCRs isolated and characterized up till now which are 
interesting for clinical use on bases of speci!city exhibit low TCR 
cell surface expression after gene transfer. As described in chap-
ter %, satisfying HA-$-TCR cell surface expression and functionality 
could be obtained by HA-$-TCR gene transfer into weak competi-
tor phenotype virus-speci!c T-cells. We have previously described 
that to some extent it can be predicted on bases of speci!city 
whether virus-speci!c T-cells exhibit a weak or strong competitor 
phenotype($"). In addition, we have previously demonstrated that 
expression of the introduced TCR is not a random process but 
is determined by characteristics of both the introduced and the 
endogenously expressed TCR(&). What exactly determines this TCR 
phenotype still remains unsolved. It is likely that a strong com-
petitor phenotype TCR has a high interchain a7nity, which might 
favor its TCR-CD( complex assembly over a TCR with low inter-
chain a7nity. Since in a population of virus-speci!c T-cells recog-
nizing the same viral epitope TCR repertoire diversity is limited, it 
seems plausible that the phenotype of the ‘public’ TCR dominat-
ing the viral immune response is determining the weak or strong 
competitor phenotype of the total virus-speci!c T-cell population. 
To broaden the pool of host cells suitable for HA-$-TCR transfer, 
we sought to improve HA-$-TCR cell surface expression. For this 
purpose, both codon optimization and cysteine modi!cation 
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were studied. It is remarkable that HA-$-TCR cell surface expres-
sion in strong competitor virus-speci!c T-cells bene!ted the 
most from cysteine modi!cation, whereas codon optimization 
on its own had little e-ect on HA-$-TCR cell surface expression. 
These results indicate that to be able to compete for cell surface 
expression in strong competitor phenotype virus-speci!c T-cells 
improving HA-$-TCR interchain a7nity is more e-ective than 
codon optimization of the di-erent HA-$-TCR chains. We hy-
pothesize that the improved HA-$-TCR interchain a7nity indeed 
favors HA-$-TCR-CD( assembly, and this assembly with CD( 
protects the HA-$-TCR chains from rapid degradation. Codon 
optimization has been described to improve TCR cell surface 
expression by improving mRNA stability and enhancing transla-
tion into protein($(). Although low HA-$-TCR expression appeared 
mostly due to low HA-$-TCR; chain expression, we demonstrate 
that the strongest e-ect of codon optimization was observed for 
cell surface expression of the HA-$-TCR: chain, indicating that 
not all TCR-chains might bene!t equally of codon optimization. 
The combination of codon optimization and cysteine modi!ca-
tion of the HA-$-TCR has resulted in high cell surface expression 
of this high-a7nity TCR, irrespective of which T-cells were used 
as host cells (chapter %). All TCRs that we have studied up till now 
bene!t from this combination strategy of codon optimization 
and cysteine modi!cation and demonstrate signi!cantly im-
proved TCR cell surface expression.
The improved HA-$-TCR expression described in chap-
ter % reduces the complexity of isolation strategies. First, not only 
weak competitor phenotype virus-speci!c T-cells can be used for 
HA-$-TCR gene transfer, but also strong competitor phenotype 
T-cells, and this broadens the pool of suitable host cells. Second, 
no additional puri!cation step of HA-$-TCR expressing virus-
speci!c T-cells is required, which would reduce the yield of TCR 
modi!ed cells and increase the complexity of the production 
process. In addition to improved HA-$-TCR cell surface expres-
sion, cysteine modi!cation resulted in markedly reduced expres-
sion of mixed TCR dimers, as indicated by reduced neoreactivity 
(chapter )).
HA-$-TCR transduced T-cells can be used if the pa-
tient is HLA-A*#"#$+ and HA-$+ and has been transplanted 
with a HLA-A*#"#$+ and HA-$-, or alternatively, HLA-A*#"#$ 
mismatched donor. To increase the number of patients that can 
be treated with TCR-modi!ed T-cells, characterization of more 
MiHA-speci!c TCRs is needed. Although several MiHAs have 
been identi!ed until now, few of them are described to be strictly 
expressed on hematopoietic cells. Alternatively, MiHAs presented 
in HLA class II might be safe target antigens, since HLA class II 
expression is mainly restricted to cells of the hematopoietic sys-
tem and it can therefore be argued that all HLA class II expressed 
MiHAs have a hematopoiesis-restricted expression.
Another option to increase the number of di-erent 
patients that can be treated with TCR-modi!ed T-cells, is to 
target leukemia associated antigens (LAA) like WT$ and PR(. In 
di-erent healthy donors, T-cells speci!c for WT$($)-$&) and PR( ("#-"") 
have been identi!ed after multiple stimulations with peptide-
pulsed APCs. However, most LAAs are monomorphic self anti-
gens, which are not only highly expressed on leukemic cells, but 
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can also be expressed at low level in normal healthy tissue. Most 
likely, T-cells recognizing these antigens with high a7nity have 
been deleted in the thymus to maintain self-tolerance("(,")), and 
therefore TCRs speci!c for LAAs exhibiting high a7nity for these 
antigens are lacking.
Exploring the use of high-a%nity TCRs / antigen of choice
By deleting T-cell precursors recognizing with high a7nity self-an-
tigens presented in the context of self-HLA, tolerance is induced. 
For this reason, no high a7nity T-cells directed against non mu-
tated overexpressed LAAs or tumor associated antigens (TAAs) 
which are mostly self-antigens are present in the T-cell repertoire. 
To bypass this limitation of the endogenous T-cell repertoire, high 
a7nity T-cell responses directed against LAAs presented in al-
logeneic HLA (allo-HLA) molecules can be induced. High a7nity 
T-cells directed against self-antigens presented in the context of 
allo-HLA can be present, since T-cells do not encounter foreign 
HLA molecules during thymic selection. For example, Stauss 
and collaborators engineered high a7nity HLA-A" restricted 
WT$-speci!c T-cells by stimulating HLA-A" negative PBMCs 
using B cells coated with recombinant HLA-A" monomers con-
taining single peptide epitopes("%). To separate the WT$-speci!c 
allo-HLA restricted T-cells from the non-WT$-speci!c allo-HLA 
restricted T-cells several rounds of isolation using WT$ tetramers 
were needed. In order to obtain high a7nity TAA-speci!c T-cells, 
Schendel and collaborators used an in vitro stimulation approach 
based on the same concept by stimulating HLA-A" negative 
PBMCs with DCs obtained from the same individual that were 
transfected with the HLA-A" restriction molecule and pulsed 
with several di-erent TAAs("5). Furthermore, in our lab, we have 
recently characterized an allo-MHC restricted PRAME-speci!c 
T-cell derived from an immune response in a patient transplanted 
over an HLA-A" mismatch (Amir et al, unpublished data). It is 
unclear whether engineering high-a7nity T-cells directed against 
self-antigens in non-self HLA comprises T-cells that can crossreact 
with several peptides in the non-self HLA or can even crossreact 
with di-erent non-self HLAs. Recently in our lab, we compared 
HLA-A" restricted WT$-speci!c T-cells derived from HLA-A" 
positive or negative individuals("6). In this study, WT$-speci!c 
allo-HLA restricted T-cells were separated from the non-WT$-
speci!c allo-HLA restricted T-cells by sorting the cells using WT$ 
tetramers. Although allo-HLA restricted WT$-speci!c T-cells were 
more tumor-reactive than their auto-HLA restricted counterparts, 
even after tetramer isolation the allo-HLA restricted T-cells were 
crossreactive against non-WT$ antigens. Another safety issue of 
engineering high-a7nity T-cells directed against self-antigens in 
non-self HLA might result in T-cells able to recognize healthy tis-
sue expressing low levels of the self-antigen. In the second clinical 
study using TCR modi!ed T-cells of Rosenberg and colleagues in 
which they transduced patient T-cells with a high-a7nity MART-
$-speci!c and gp$##-speci!c TCR on target autoimmune destruc-
tion of melanocytes in ear, skin and hair that required treatment 
was observed in several patients, illustrating that high-a7nity 
TCRs directed against self-antigens can indeed result in on-target 
toxicity directed against healthy tissue("').
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An alternative approach for the production of high-
a7nity TAA-speci!c T-cells involves the use of genes that encode 
monoclonal antibody chains. Generally, !rst generation CARs 
consisted of a single-chain antibody-derived antigen-binding 
motif coupled to signalling modules that are normally present 
in the TCR complex, such as the CD(-chain, whereas second- 
and third-generation CARs also contain costimulatory or anti-
apoptotic moieties. An advantage of tumour-speci!c T-cells that 
are generated in this manner is that they respond to antigen in a 
non-MHC-restricted manner, with the a7nity of an antibody. The 
a7nity of CAR-modi!ed T-cells for their target antigen is gener-
ally higher than TCR-modi!ed T-cells, which could have several 
consequences for the functionality. First, T-cells engineered 
with a CAR might unwantedly exert e-ector functions directed 
against healthy tissue expressing low levels of the target antigen. 
Second, this higher a7nity of CAR-modi!ed T-cells might result 
in unphysiologically strong activation signals. Lastly, the higher 
a7nity for their target antigen might hamper detachement to 
the target cell, and limit the ability of the CAR-modi!ed T-cells to 
serially kill target cells. 
It has been described that administration of T-cells 
modi!ed with a CAR directed against the renal cell carcinoma 
antigen carboxy anhydrase IX (CAIX) resulted in severe cholesta-
sis based on the overlooked CAIX expression by the bile duct 
epithelial cells("&). Recently, a serious adverse event was described 
by Morgan and colleagues that occurred in a patient with widely 
metastatic colon cancer who received more than $#10 T-cells 
modi!ed with a CAR targeting HER" containing costimulatory 
moieties (CD"' and )-$BB) after intensive lymphodepletion. 
Within $% minutes after cell infusion the patient experienced res-
piratory distress, coinciding with a dramatic pulmonary in!ltrate 
in association with very high cytokines followed by cardiac arrest 
and death ) days later. They speculate that the large number of 
administered cells localized to the lung immediately following 
infusion and were triggered to release cytokines by the recogni-
tion of low levels of ERBB" on lung epithelial cells((#). The concern 
was raised that second- and third-generation CARs may be 
too easily triggered by low expression of antigen resulting in a 
potent activation signal that leads to a lethal cytokine storm(($). 
However, the high amount of CAR-modi!ed T-cells infused could 
also have made it di7cult to shut down the immune response 
using steroids. Although it is still unclear whether the combina-
tion of lymphodepletion and the presence of costimulatory 
moieties in the second- and third-generation CARs used might 
have contributed to the cytokine storm, from their experiments it 
seems plausible that the lethal cytokine storm was a direct result 
from unwanted on-target reactivity directed against lung tissue 
expressing  low levels of ERBB" due to the high a7nity of the 
CAR-modi!ed T-cells. 
Alternatively, TCRs with di-erent a7nities can be 
obtained by modi!cation of TCR: or TCR; CDR$, CDR" or CDR( 
sequences(("-(6). In chapter % we describe that small adjustments 
in amino acid sequence of the TCR; chain, namely exchange 
of the $' amino acid long CDR$ region, resulted in completely 
abolished HA-$-speci!c reactivity. This suggests that minimal 
changes in TCR: or ; sequences can result in drastic changes of 
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speci!city. In addition, we previously studied whether chimeric 
HA-"-TCRs consisting of HA-"-TCR chains derived from di-er-
ent HA-"-speci!c T-cell clones isolated from a CML patient with 
an ongoing antileukemic immune response would still remain 
their HA-"-speci!city(('). Several clones exhibiting di-erent HA-"-
TCRs were characterized and on bases of HA-"-TCR usage T-cell 
clones were classi!ed in $# di-erent groups. The di-erent HA-"-
speci!c T-cell clones demonstrated restricted TCR: and ; usage 
and in addition, the HA-"-TCR: and TCR; chains of all isolated 
T-cell clones demonstrated many similarities in TCR: and TCR; 
chain sequences (('), of which the most striking similarity was 
that all HA-"-TCR: chains used the J:)" region. Therefore, we 
hypothesized that the TCR: chain was responsible for the HA-"-
speci!city of these T-cell clones, and that the TCR; chains would 
probably be interchangeable. However, it could not be predicted 
whether a speci!c chimeric HA-"-TCR consisting of a HA-"-TCR: 
of one group combined with a HA-"-TCR; of the other group 
would remain HA-"-speci!c on bases of similarities in TCR chains 
of the di-erent groups(('). Some chimeric HA-"-TCRs remained 
HA-"-speci!c, whereas others exhibited a new alloreactivity, as 
described in chapter ). From these experiments we concluded 
that it is hard to predict the dominant TCR-regions involved in 
speci!c recognition on bases of restricted TCR chain repertoire 
used by the di-erent T-cell clones and similarities in sequences of 
these TCR chains. Furthermore, it is di7cult to test for or predict 
for crossreactivity when di-erent random modi!cations in the 
CDR regions of both TCR-chains are induced.
Recently, Rufer and colleagues reported that above a 
de!ned TCR-peptide-HLA a7nity threshold, T-cell function could 
not be enhanced, indicating that there might exist a plateau of 
maximal T-cell function((&). They propose to limit a7nity improve-
ment of rationally designed TCRs to a given a7nity threshold 
which should result in optimal T-cell function while maintaining a 
limited risk of crossreactivity.
In conclusion, to broaden the applicability of TCR-
modi!ed T-cells for clinical use, characterization of more di-erent 
high a7nity TCRs recognizing either potential useful MiHAs or 
LAAs/TAAs is required. Thorough analysis of antigen expression 
restricted to malignant cells is necessary since current strategies 
to engineer high-a7nity TCRs have shown to result in reactivity 
directed against low expression levels on healthy tissue. In addi-
tion, selection of high-a7nity TCRs involved in immune respons-
es without adverse events like the HA-$- and HA-"-TCR might 
be warranted, since peptide speci!city of in vitro engineered or 
selectedTCRs can not be guaranteed.
SPECIFICITY OF THE ENDOGENOUS TCR
Rationale behind usage of virus-speci)c T-cells as recipient cells for 
TCR gene transfer
Clinical studies have demonstrated that for optimal e7cacy of 
adoptive immunotherapy persistence of the transferred T-cells 
is required()#-))). In comparison to adoptive T-cell therapy for viral 
infections after allo-SCT()%-)') persistence of adoptively transferred 
tumor-speci!c T-cells in vivo was remarkably short()),)&). To obtain 
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therapeutic cell numbers, several stimulations were required in 
upper mentioned studies and it is now recognized that long in 
vitro culture periods negatively in9uence the in vivo functional 
activity of the T-cells(%#-%"). Two conclusions were drawn based on 
studies performed on in vivo persisting tumor-speci!c T-cells. 
First, it was observed that persisting tumor-speci!c T-cells pos-
sessed longer telomeres than non-persisting T-cells(%(,%)). Second, 
persisting T-cells re-expressed CD"6 and CD"' molecules on 
their cell surface and it was suggested that persisting T-cells 
demonstrated transition from late stage e-ector into an early 
e-ector phenotype(%%). From these results it was concluded that 
less di-erentiated T-cell populations should be used for adoptive 
immunotherapy of TCR transduced T-cells.
Simultaneously, profound di-erences in survival in vivo 
of di-erent memory subsets were reported(%5-%'). Roughly, two 
distinct memory subsets are described, namely e-ector memory 
(TEM) and central memory (TCM) T-cells(%6). TEM T-cells are CD5"L 
and CCR6 negative and have strong lytic capacity and can 
release high amounts of IFN-<. TCM are CD5"L and CCR6 positive 
and are thought to exhibit stem-cell like self-renewal capacity, 
meaning that upon antigen re-exposure these T-cells are capable 
of undergoing massive proliferation and di-erentiate into e-ec-
tor T-cells. For improved persistence of TCR modi!ed T-cells, TCM 
T-cells were demonstrated to be superior over TEM T-cells
(%&). In 
this study, virus-speci!c T-cell clones derived from puri!ed TCM 
and TEM T-cells were gene marked to be able to distinguish be-
tween the two subsets and the endogenous T-cell repertoire, and 
transferred into normal macaques. Although similar in function, 
and phenotype in vitro, T-cell clones derived from TCM or TEM 
T-cells exhibited di-erent fates in vivo. Whereas TCM-derived 
clones persisted long term in the blood, TEM-derived clones 
consistently failed to persist in the blood longer than % days. In 
mouse models it was established that a TCM phenotype could 
be induced in vitro by adding a WNT pathway inhibitor, glyco-
gen synthase kinase (; to the T-cell culture, thereby generating 
T-cells with improved persistence and anti-tumor e7cacy(5#).
By using EBV- and CMV-speci!c T-cells as host cells for 
TCR gene transfer both TEM and TCM T-cells will be transduced. 
Recent studies demonstrated that distinct memory subsets are 
raised in di-erent viral infections (5$,5"). Even within one virus-spe-
ci!c memory response distinct memory subsets of virus-speci!c 
CD'+ T-cells can be found(5(). Whereas CMV-speci!c T-cells 
mostly consist of TEM T-cells, EBV-speci!c T-cells especially those 
recognizing latent antigens mostly consist of TCM T-cells. We hy-
pothesize that by using both EBV- and CMV-speci!c T-cells with 
distinct phenotypic characteristics, TCR modi!ed virus-speci!c 
T-cells can be engineered with di-erent functional characteristics 
and homing capacities and prolonged long-term persistence. It 
has been described that adoptively transferred unmodi!ed EBV-
speci!c T-cells to prevent or treat EBV positive lymphoprolifera-
tive can persist for up to & years()5). We will transfer into patients 
both EBV- and CMV-speci!c T-cells modi!ed with the HA-$-TCR. 
According to the current hypothesis that adoptively transferred 
TCM will persist superior to TEM, predominant persistence of  HA-
$-TCR modi!ed EBV-speci!c T-cells compared to CMV-speci!c 
T-cells should be observed in treated patients.
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Additional advantages of knowledge of the endogenous TCR speci-
)city of recipient cells used for TCR gene transfer
Next to their potentially bene!cial phenotype, using EBV- and 
CMV-speci!c T-cells as host cells for TCR gene transfer o-ers 
other attractive bene!ts. EBV and CMV are viruses which latently 
persist after initial infection and therefore T-cells will be repeti-
tively stimulated with antigen in vivo. Based on the hypothesis 
that T-cells speci!c for latently present viruses would be activated 
and receive co-stimulation via their endogenous TCR, EBV-
speci!c T-cells were proposed as host cells for CAR-modi!cation 
as a solution to the low proliferative capacity of !rst generation 
CAR-modi!ed T-cells(5)). Another possible advantage of the use of 
virus-speci!c T-cells is the exclusion of regulatory T-cells from the 
pool of TCR modi!ed lymphocytes that can possibly disturb the 
immune reaction. Furthermore, adoptive immunotherapy with 
EBV-speci!c T-cells in patients with post-transplant proliferative 
disease and CMV-speci!c T-cells as prophylaxis for CMV reacti-
vation(5$-5() in patients after SCT has proven to be a therapeutic 
strategy without toxicity or GvHD, and long-term persistence of 
these T-cells has been demonstrated()5). Some virus-speci!c T-cells 
can exhibit alloreactivity, directed against non-self HLA mol-
ecules(5%). However, this will only have consequences for potential 
induction of GvHD in HLA-mismatched transplantations and can 
be easily tested for by using non-transduced virus-speci!c T-cells. 
Alloreactive virus-speci!c T-cells, already capable of producing 
IFN-< after co-incubation with patient-derived DCs without trans-
fer of the HA-$-TCR, can be excluded for further use.
We hypothesize that using virus-speci!c T-cells as host 
cells for TCR gene transfer will also enable us to monitor more 
sensitively the immunological responses in patients. HA-$-TCR 
modi!ed virus-speci!c T-cells can be monitored directly ex vivo 
by staining with either virus-tetramers, HA-$-tetramers, or a com-
bination of both tetramers. Furthermore, if HA-$-TCR modi!ed 
virus-speci!c T-cells appear to be only present in low numbers in 
the patients’ circulation, an enrichment step using virus-speci!c 
tetramers can be performed to calculate precise numbers in 
vivo. In a recent report, EBV-speci!c T-cells modi!ed with a CAR 
directed to the GD" antigen expressed on neuroblastoma cells 
were compared to unselected T-cells modi!ed with the same 
CAR(55). Although CAR-modi!ed T-cells could be hardly visualized 
directly ex vivo, knowledge of the endogenous TCR facilitated 
analysis of persistence of CAR-modi!ed EBV-speci!c T-cells, 
since stimulation of the endogenous EBV-speci!c TCR resulted 
in an enrichement and subsequent detection of CAR-modi!ed 
T-cells(55).
Another potential advantage of using host cells with 
known speci!cities of the endogenous TCR has recently been 
described in a mouse model(56). It was shown that tolerization of 
one TCR could be overcome by signaling via the other TCR. In 
this model the function of the tolerized self-tumor reactive TCR of 
dual-T-cell receptor transgenic T-cells was rescued by proliferation 
induced via the virus-speci!c TCR, underlining the potency of 
TCR transfer into virus speci!c T-cells. In addition, T-cell stimula-
tion is followed by increased activation of the retroviral promo-
tor(5'-6#) resulting in improved expression of the introduced TCR as 
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also demonstrated in chapter " and (.  We hypothesize that acti-
vation of the endogenous TCR by latently present viral antigens 
can both result in increased numbers of TCR modi!ed T-cells, as 
well as in increased introduced TCR expression. 
Limiting cell surface expression of di*erent mixed TCR dimers
Previous attempts to prevent formation of mixed TCR dimers 
comprising of introduced TCR chains pairing with endogenous 
TCR chains were mainly made to improve expression of the 
introduced TCR chain. Since space on the cell membrane may 
limit the number of TCR-complexes that can be expressed, 
formation and cell surface expression of mixed TCR dimers will 
further limit expression of the introduced TCR. Preferential pair-
ing of the introduced TCR may be forced using di-erent tech-
niques. For example, murinization of the constant domains has 
been described to result in exclusive pairing of the introduced 
TCR chains(6$). Since murine domains may be potentially im-
munogenic in vivo("&,6"), two recent reports describe the minimal 
amount of murinization needed to obtain preferential pairing 
of the introduced TCR chains (6(,6)). In the TCR; chain muriniza-
tion can be limited to an exchange of !ve amino acids and in 
the TCR: it can be limited to an exchange of four amino acids. 
Also, inclusion of extra cysteine residues in the constant domains 
of the introduced TCR resulting in an additional disul!de bond 
induces preferential pairing(6%,65). As described in chapter ), forma-
tion of mixed TCR dimers comprised of introduced TCR chains 
pairing with endogenous TCR chains might not only hamper 
introduced TCR expression but might also result in potentially 
harmful neoreactivities. While no evidence of mixed TCR dimer 
induced autoimmunity was observed in earlier murine experi-
ments and !rst clinical trials using MART-$ and gp$##-TCR modi-
!ed T-cells, in a recent set of experiments an often lethal autoim-
mune pathology was observed under conditions that promote 
the expansion of adoptively transferred T-cells more strongly, and 
this pathology appeared dependent on the action of mixed TCR 
dimers(66). Whereas chapter % focused on improving introduced 
TCR expression and functionality, in addition, chapter ) dem-
onstrates that the facilitated matched pairing induced by inclu-
sion of cysteine residues in the introduced TCR chains results 
in decreased formation of mixed TCR dimers, since observed 
neoreactivities could be markedly reduced by transfer of cysteine 
modi!ed TCRs.
Alternatively, formation of mixed TCR dimers can be 
prevented by transducing <=-T-cells, since the <=-TCR chains are 
not able to pair with :;-TCR chains(6'). Human <=-T-cells redirect-
ed with :;-TCRs were fully functional in vitro and were capable 
of recognizing chronic myeloid leukemic cells. In addition, in mu-
rine studies functional activity and persistence of the cells in vivo 
was shown(6&). However, further analyses and comparative studies 
will be required to determine to what extent redirected <=-T-cells 
and :;-T-cells are di-erent with respect to homing properties 
and speci!city of the endogenous TCR and equal with respect to 
e-ector functions. Previously, the in vitro production of tumor-
speci!c T-cells by TCR gene transfer into hematopoietic stem 
cells (HSCs) was proposed as an alternative to generate T-cells 
predominantly expressing the introduced TCR('#). Transduction of 
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HSCs with TCRs results in inhibition of other TCR; chain rear-
rangements, and therefore the TCR transferred HSCs expressed 
no endogenous TCR; on their cell surface. However, it is known 
that allelic exclusion is far from complete for TCR: chains, and 
thus this approach limits but does not completely prevent the 
number of di-erent mixed TCR dimers that can be formed. In 
addition, risk of insertional mutagenesis of transduced stem cells 
may be a reason not to favor this approach.
We propose virus-speci!c T-cell populations as host cells 
for TCR gene transfer as an elegant strategy to limit the diversity 
of the TCR repertoire of the recipient T-cells. Since virus-speci!c 
T-cell populations consist of a restricted TCR repertoire('$,'"), the 
number of di-erent mixed TCR dimers formed will be limited and 
from in vivo data this appears a viable strategy to prevent neore-
activity caused by mixed TCR dimers('(). In contrast, total PBMCs 
consist of a broad TCR repertoire and vast number of di-erent 
mixed TCR dimers can be formed. In addition, the known reactiv-
ity of virus-speci!c T-cells allows detection of harmful neoreac-
tivities by introducing into these virus-speci!c T-cells as controls 
only the TCR: or TCR; chain of interest and subsequent testing 
against di-erent patient-derived cell types. By this procedure TCR 
td virus-speci!c T-cells can be selected that show no o--target 
toxicity.
In conclusion, we have demonstrated that o--target 
reactivity exerted by mixed TCR dimers possibly resulting in 
GvHD is markedly reduced due to inclusion of cysteine residues 
in the HA-$-TCR chains. Furthermore, as described in chapter %, 
the neoreactivities observed in this study were mostly allo-HLA 
restricted, posing only risks in a HLA-mismatched setting. In ad-
dition, TCR td T-cells harboring autoreactive mixed TCR dimers 
will only be able to survive when the peptide recognized is not 
expressed on the T-cells themselves, since this may lead to frat-
ricide of these T-cells. Finally, transduction of oligoclonal virus-
speci!c T-cell populations limits the number of di-erent mixed 
TCR dimers that can be formed, thereby limiting the formation of 
harmful o--target reactivities.
CLINICAL STUDY 
Treatment of hematological malignancies with T-cell depleted 
alloSCT followed by DLI signi!cantly reduces the risk and sever-
ity of GvHD, however, still this complication remains an important 
cause of morbidity and mortality. To selectively induce GvL, more 
de!ned T-cell populations with restricted anti-leukemic speci!city 
should be used.
Based on a history of extensive research on MiHA-TCR 
transfer into virus-speci!c T-cells partly described in this thesis, 
we would like to proceed with a clinical trial in which HA-$-TCR 
transduced EBV- and/or CMV-speci!c donor T-cells will be adop-
tively transferred into patients with acute leukemia. We will use 
CMV- and EBV-speci!c T-cells derived from the stem cell donor 
as host cells for TCR transfer, since these T-cells do not recognize 
antigens expressed on normal recipient cells and will therefore 
likely not induce GvHD()%,)6,)',')-'&). Furthermore, HA-$-speci!c T-cell 
clones have been screened against an EBV-LCL panel express-
ing most prevalent HLA-molecules and no crossreactivity was 
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observed. Therefore, HA-$-TCR gene transfer into virus-speci!c 
T-cells allows the rapid production of a T-cell product designed 
to result in GvL-e-ect without detrimental GvHD.
For our clinical study, two patient groups will be eligi-
ble. First, HLA-A*#"#$+ and HA-$+ patients with refractory hema-
tological malignancies who have no other treatment option left 
can be included in the study. Normally, these patients would not 
receive allo-SCT because a rapid progression can be expected 
already early after allo-SCT when DLI can not be given due to 
high risk of GvHD. Since the HA-$-TCR transduced virus-speci!c 
T-cells are designed to result in GvL without induction of GvHD, 
we hypothesize that these T-cells can be transferred as early as 5 
weeks after allo-SCT.  
Second, HLA-A*#"#$+ and HA-$+ patients with relapsed 
hematological malignancies who fail to respond to DLI or pa-
tients with early relapses of aggressive malignancies which are 
unlikely to be controlled by DLI without development of severe 
GvHD are eligible for this study. Previously, these patients had to 
be transplanted with a HLA-A*#"#$+ HA-$- or HLA-A*#"#$- do-
nor and su7cient donor material has to be available for isolation 
of virus-speci!c T-cells.
We have now designed an isolation and transduc-
tion protocol that can result in a HA-$-TCR modi!ed virus-
speci!c T-cell product in a timeframe of approximately " weeks. 
Potentially, the lymphodepleted state of patients early after allo-
SCT can induce a proliferative burst of the adoptively transferred 
HA-$-TCR transduced virus-speci!c T-cells. Since the number of 
leukemic cells should still be reduced early after allo-SCT due to 
the conditioning regimen, this will potentially result in favorable 
in vivo e-ector-to-target ratio’s, and o-ers the possibility to also 
treat rapidly growing hematological malignancies.
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Hematopoiese en het ontstaan van leukemie
Bloed bestaat uit verschillende celtypen. Rode bloedcellen of 
erythrocyten zijn verantwoordelijk voor het zuurstoftransport, 
bloed plaatjes of thrombocyten zijn betrokken bij de stolling en 
witte bloedcellen of leukocyten zijn belangrijk voor afweer tegen 
verscheidene pathogenen, zoals virussen en bacteriën. Omdat 
deze verschillende cellen een beperkte levensduur hebben, vindt 
in het lichaam een continue aanmaak plaats door hematopoi-
etische stamcellen die zich in het beenmerg bevinden. Dit proces 
wordt hematopoiese genoemd. Soms treedt er een ontsporing 
op in de hematopoiese en ontstaan er kwaadaardige (maligne) 
cellen die ongecontroleerd doorgroeien zonder zich te ontwik-
kelen. Leukemie is een vorm van kanker die gekenmerkt wordt 
door verdringing van het normale hematopoietisch systeem uit 
het beenmerg door de maligne cellen, en het accumuleren van 
grote aantallen leukemiecellen in het bloed.
Stamceltransplantatie
Er bestaan verschillende typen leukemie, die verschillend be-
handeld worden. Een aantal typen leukemie wordt behandeld 
met stamceltransplantatie. Conventionele myeloablatieve 
stamceltransplantatie bestaat uit preconditionering met chemo- 
en radiotherapie met als doel om zoveel mogelijk leukemie-
cellen te vernietigen, gevolgd door transplantatie van donor 
hematopoietische stamcellen. Behandeling met chemo- en 
radiotherapie resulteert echter ook in vernietiging van gezonde 
hemato poietische stamcellen, waardoor alle verschillende 
hemato poietische cellen niet meer gevormd kunnen worden. 
Om te voorkomen dat de patiënt overlijdt, worden gezonde 
stamcellen (graft) getransplanteerd om de normale hema-
topoiese te herstellen. Deze kunnen afkomstig zijn van de 
patiënt zelf (autoloog) of van een gezonde donor (allogeen). Na 
toedie ning van het stamceltransplantaat aan de patiënt mi greren 
de stamcellen naar het beenmerg van de patiënt en ontwikkelt 
zich een nieuw hematopoietisch systeem. 
Immuunreacties na stamceltransplantatie
Transplantatie van donorstamcellen kan resulteren in verschil-
lende immuunreacties tussen cellen van de patiënt en donor. 
Als nog aanwezige patiënt-T-cellen een sterke immuunreactie 
tegen donorstamcellen ontwikkelen en die vernietigen, is er 
sprake van afstoting, ook wel host versus graft (HvG) reactie 
genoemd. Dit is een ernstige complicatie, omdat er dan geen 
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normale hematopoiese meer plaatsvindt. Daarnaast kunnen er 
immuunreacties plaatsvinden als donor-T-cellen aanwezig in het 
donorstamceltransplantaat patiëntweefsels herkennen, ook wel 
transplantaat versus ontvanger ziekte of Graft versus Host Disease 
(GvHD) genoemd. Deze immuunreacties zijn meestal gericht 
tegen de huid, de longen, lever en darmen, en kunnen levens-
bedreigende vormen aannemen. Om deze ernstige complicatie 
van allogene stamceltransplantatie (allo-SCT ) te voorkomen, 
kunnen donor-T-cellen selectief uit het transplantaat verwijderd 
worden. Verwijdering van donor-T-cellen uit het transplantaat 
resulteert echter in een verhoogde kans op terugkeer van de 
leukemie. Donor-T-cellen zijn blijkbaar in staat om leukemiecellen 
te vernietigen die bestraling en chemotherapie hebben overleefd. 
Wanneer donor-T-cellen selectief reageren tegen resterende he-
matopoietische cellen van de patiënt, waaronder nog aanwezige 
leukemiecellen, wordt er gesproken van Graft versus Leukemia 
(GvL) e-ect. Omdat het stamceltransplantaat van de donor het 
hemato poietisch systeem van de patiënt vervangt, leidt deze re-
activiteit niet tot problemen, maar is juist curatief. GvL is belang-
rijk gebleken om terugkeer van de leukemie tegen te gaan. 
Immunotherapie na stamceltransplantatie
De erkenning dat donor-T-cellen in staat zijn om speci!ek de 
maligne cellen van de patiënt op te ruimen, leidde tot de ontwik-
keling van nieuwe stamceltransplantatiestrategieën. Patiënten 
worden getransplanteerd met donorstamceltransplantaat waar 
selectief de donor-T-cellen uit verwijderd zijn. Na 5 maanden 
worden ongeselecteerde donorlymfocyten als immunotherapie 
gegeven. Deze donorlymfocyteninfusies (DLI) induceren bij 
veel patiënten remissie van de ziekte. Helaas resulteert deze 
therapie niet alleen in een GvL e-ect, maar ook in gevaarlijke 
GvHD re acties. Uit patiënten die wel de curatieve GvL maar geen 
schade lijke GvHD reacties ontwikkelden, zijn donor-T-cellen ge-
ïsoleerd en gekarakteriseerd. Een aantal van deze donor-T-cellen 
herkenden selectief patienthema topoietische cellen, waaronder 
ook de leukemiecellen, zonder dat ze het gezonde niet-hemato-
poietische weefsel van de patiënt herkennen. Toediening van 
T-cellen met deze reactiviteit zou kunnen resulteren in selectieve 
herkenning van de leukemie zonder de levensbedreigende 
GvHD.
T-cellen en de T-celreceptor
T-cellen zijn afweercellen die belangrijk zijn in bestrijding tegen 
pathogenen, zoals bacteriën en virussen, en tegen lichaams-
vreemde of ontspoorde cellen, zoals kankercellen. T-cellen moe-
ten in staat zijn te detecteren of een cel gezond is, geïnfecteerd is 
met een pathogeen of getransformeerd is tot kankercel. T-cellen 
detecteren dit door middel van hun T-celreceptor (TCR). De TCR 
bestaat uit een TCR:- en TCR;-keten. Door middel van zijn TCR 
kan een T-cel kleine fragmenten van eiwitten, peptides genaamd, 
herkennen wanneer zij gepresenteerd worden in HLA-moleculen. 
Op alle cellen in het lichaam komen HLA-moleculen tot expres-
sie. HLA-klasse-I-moleculen presenteren peptides afkomstig van 
eiwit dat een cel zelf maakt en HLA-klasse-II-moleculen presen-
teren voornamelijk peptides afkomstig van eiwit dat cellen op 
kunnen nemen uit hun omgeving.
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Binnen het T-celcompartiment wordt onderscheid 
gemaakt tussen T-cellen die de CD) co-receptor tot expres-
sie brengen en T-cellen die de CD' co-receptor tot expressie 
brengen. CD)+ helper T-cellen kunnen peptides herkennen in 
HLA-klasse-II-moleculen. Na herkenning van geïnfecteerde of 
getransformeerde cellen is hun voornaamste rol het produce-
ren van cytokines, die e-ectorfuncties van CD'+ cytotoxische 
T-cellen en de aanmaak van antilichamen door B-cellen bevor-
deren. CD'+ cytotoxische T-cellen kunnen peptides herkennen 
in HLA-klasse-I-moleculen. Herkenning resulteert in directe lysis 
van geïnfecteerde of getransformeerde cellen door productie 
van perforine en granzyme B. 
Speci)citeit van T-cellen; minor-antigenen
Er is een correlatie tussen het optreden van GvHD en de mate 
van HLA-verschillen tussen donor en patiënt. De voorkeur gaat 
daarom uit naar een donor die dezelfde HLA-moleculen heeft 
als de patiënt. In sommige gevallen van transplantaties met 
een HLA-identieke donor treedt er nog steeds GvHD bij de 
patiënt op. In dit geval komt de reactiviteit door donor-T-cellen 
die minor-antigenen herkennen. In het DNA bestaan er tussen 
individuen kleine verschillen, ook wel single nucleotide poly-
morphisms (SNPs) genoemd. Deze kleine verschillen in DNA 
zorgen ervoor dat op het niveau van aminozuren verandering en 
optreden, die soms kunnen resulteren in een verschillend eiwit. 
Als door deze kleine verschillen patiëntcellen andere peptides 
presenteren als donorcellen, kan er een immuunreactie ontstaan. 
Op het moment dat deze verschillende peptides in staat zijn om 
een immuunreactie bij donor-T-cellen op te wekken, worden ze 
minor-antigenen genoemd. Als minor-antigenen op verschei-
dene patientcellen door het hele lichaam tot expressie komen, 
kan dit leiden tot GvHD. Er zijn echter ook minor-antigenen 
beschreven die alleen tot expressie komen op cellen van het 
hemato poietisch systeem, zoals HA-$ en HA-". Donor-T-cellen in 
staat om HA-$ en HA-" gepresenteerd in HLA-A*#"#$ te herken-
nen, vernie tigden wel de patientbloedcellen en leukemiecellen, 
maar niet de andere gezonde patiëntcellen of donorbloedcel-
len. In verschillende patiënten resulteerde deze HA-$ en HA-" 
donor-T-celrespons in GvL zonder GvHD, en sommige van deze 
patiënten zijn nog steeds ziektevrij.
D I T  P R O E F S C H R I F T
Donor-T-celresponsen spelen een belangrijke rol 
in zowel het gewenste GvL e-ect, als de levensbedreigende 
GvHD. Om op een snelle manier donor-T-cellen te genereren 
waarvan bekend is dat ze alleen de patiëntbloedcellen en leu-
kemiecellen herkennen, maar geen ander gezond weefsel, kan 
gebruik worden gemaakt van TCR-gentherapie. Omdat de TCR 
de speci!citeit van een T-cel bepaalt, resulteert introductie 
van de HA-$-TCR of HA-"-TCR in generatie van HA-$- of HA-"-
speci!eke T-cellen. Omdat bekend is dat immunotherapie met 
ongeselecteerde donorlymfocyten GvHD kan induceren, zou 
het introdu ceren van de HA-$- of HA-"-TCR in een populatie van 
diverse verschillende donor-T-cellen nog steeds GvHD kunnen 
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veroorzaken. Daarom heeft het de voorkeur om deze minor-anti-
genspeci!eke TCR-en over te zetten in een andere goed gekarak-
teriseerde T-celpopulatie. Een aantrekkelijk alternatief om donor 
T-cellen te genereren met verwachte selectieve anti-leukemie-
reactiviteit, is HA-$-TCR of HA-"-TCR gentransfer in virusspeci-
!eke T-cellen, zoals cytomegalovirus (CMV)- of Epstein-Barr-virus 
(EBV)-speci!eke T-cellen.
Er zijn nog wel een aantal verbeterpunten. Introductie 
van een TCR in verschillende CMV- of EBV-speci!eke T-cellen 
leidt niet alleen tot expressie van de endogene en geïntrodu-
ceerde TCR op het celoppervlak, maar ook tot expressie van 
TCR-dimeren. TCR-dimeren zijn combinaties van de geïntro-
duceerde TCR-ketens gepaard met de endogene TCR:-, of 
;-ketens. Introductie van één TCR in één T-cel kan dus leiden 
tot expressie van vier verschillende TCR:;-complexen op het 
cel oppervlak, en leidt dus niet altijd tot eenzelfde TCR-opmaak 
op het celopper vlak. Er is bewezen dat er competitie plaatsvindt 
voor expressie op het celoppervlak, niet alleen tussen de geïn-
troduceerde TCR en de endogene virusspeci!eke TCR, maar ook 
tussen TCR-dimeren. 
Het onderzoek, beschreven in dit proefschrift, was erop 
ge richt uit te zoeken wat de consequenties van verschil in TCR-
opmaak waren, en of er oplossingen gevonden konden worden.
E*ect van regulatie op de expressie van de geïntroduceerde TCR
TCR-en die door middel van retrovirale gentransfer in donor-
T-cellen geïntroduceerd worden, worden gereguleerd door 
virale promotoren die de expressie van de TCR-en bepalen. Het 
voordeel hiervan is dat deze regulatie tot een hoge expressie van 
de geïntroduceerde TCR leidt. Het nadeel hiervan is dat virale 
promotoren anders wer ken dan de promotoren die de expressie 
van de eigen TCR reguleren. Normaliter resulteert herkenning 
van een speci!ek peptide-HLA-complex door een TCR tot inter-
nalizatie van de TCR-complexen. Dit resulteert in beëindiging van 
alle TCR-HLA-interacties tussen T-cel en de herkende cel. T-cellen 
zijn dan tijdelijk niet in staat om op nieuwe stimuli te reageren. Zij 
ondergaan een soort van “time-out”, ook wel refractaire periode 
genoemd, die ze in staat stelt om verschillend DNA af te schrij-
ven, zodat ze kunnen delen en allerlei verschillende cytokines 
produceren. Deze refractaire periode zou T-cellen beschermen 
tegen activatie geïnduceerde celdood (AICD).
In hoofdstuk " wordt onderzocht of speci!eke stimulatie 
van zowel de geïntroduceerde als de eigen endogene TCR in 
TCR-gemodi!ceerde T-cellen leidt tot zo’n refractaire periode. 
TCR-gemodi!ceerde T-cellen lieten na speci!eke stimulatie 
van zowel de endogene virusspeci!eke TCR als de geïntrodu-
ceerde minor-antigenspeci!eke TCR vergelijkbare internalizatie 
van TCR-complexen zien. Stimulatie via één van beide TCR-en 
resulteerde in internalizatie van beide TCR-en, maar de geïn-
troduceerde TCR werd telkens veel sneller weer tot expressie 
gebracht op het celoppervlak. Ondanks deze snelle herexpressie 
ondergingen TCR-gemodi!ceerde T-cellen toch een normale 
refractaire periode, en bleven ze ongevoelig voor stimulaties 
via één van beide TCR-en. Een mogelijke verklaring voor het 
feit dat de snelle herexpressie van de geïntroduceerde TCR niet 
leidt tot de mogelijkheid om de TCR-gemodi!ceerde T-cel weer 
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te kunnen activeren via de geïntroduceerde TCR, is de gecoör-
dineerde internalizatie van de co-receptor CD'. We concluderen 
dat, ondanks de niet fysiologische regulatie via de virale promo-
tor die tot een snelle herexpressie van de geïntroduceerde TCR 
leidt, T-cellen zich toch fysiologisch gedragen en nog niet in 
staat zijn om geactiveerd te worden via hun TCR. Het lijkt erop 
dat T-cellen verschillende manieren gebruiken om hun refrac-
taire periode na stimulatie veilig te stellen, en daardoor hoeven 
TCR-gemodi!ceerde T-cellen niet te worden geacht gevoeliger 
te zijn voor AICD door verlies van hun refractaire periode. 
Persisterende expressie van de geïntroduceerde TCR
Introductie van TCR-en in CMV- of EBV-speci!eke T-cellen is 
niet alleen aantrekkelijk omdat deze T-cellen geen GvHD veroor-
zaken, maar ook omdat deze T-cellen in staat zijn om lange tijd 
aanwezig te blijven. Op die manier zou ook de anti-leukemiere-
activiteit via de geïntroduceerde TCR voor lange tijd aanwezig 
blijven. CMV- en EBV-speci!eke T-cellen blijven waarschijnlijk zo 
lang aanwezig in het bloed, omdat ze af en toe weer hun func-
tie moeten uitoefenen om het virus onder controle te houden. 
Op die momenten worden ze via hun TCR gestimuleerd met 
speci!eke virale peptides. Als deze herhaaldelijke stimulaties via 
de endogene virusspeci!eke TCR zou resulteren in uitgroei van 
TCR-gemodi!ceerde T-cellen die voornamelijk de endogene TCR 
tot expressie brengen, maar niet meer de geïntroduceerde TCR, 
kan dit tot verlies van de anti-leukemiereactiviteit leiden. Om te 
testen of dit optreedt, hebben we van HA-"-TCR-gemodi!ceerde 
CMV-speci!eke T-cellen óf de endogene CMV-speci!eke TCR óf 
de geïntroduceerde HA-"-TCR herhaaldelijk gestimuleerd. 
In hoofdstuk ( beschrijven we hoe in eerste instantie 
deze herhaaldelijke stimulaties van óf de endogene CMV-TCR óf 
de geïntroduceerde HA-"-TCR leken te resulteren in speci!eke 
uitgroei van TCR-gemodi!ceerde T-cellen die voornamelijk 
de CMV-TCR of de HA-"-TCR, respectievelijk, tot expressie 
brachten. Deze speci!eke TCR-opmaak waarbij óf de endogene 
óf de geïntroduceerde TCR domineerde op de T-cellen, kon 
echter ongedaan gemaakt worden door éénmaal de andere TCR 
te stimuleren. In aanvulling op deze experimenten werden de 
TCR-gemodi!ceerde T-cellen gesorteerd op dominante expres-
sie van óf de endogene CMV-TCR óf de geïntroduceerde TCR. 
Direct na het sorteren waren deze T-celpopulaties wel in staat 
om via beide TCR-en peptidebeladen targetcellen te herken-
nen. Echter, de TCR-gemodi!ceerde T-cellen konden alleen via 
de TCR op basis van welke expressie ze gesorteerd waren ook 
sterke interacties aangaan met niet-peptidebeladen targetcellen 
die wel óf CMV-geïnfecteerd waren, óf HA-" positief. Ook deze 
T-celpopulaties waren in staat om na een additionele stimulatie 
hun TCR-opmaak weer te veranderen, en beide TCR-en weer 
goed tot expressie te brengen op het celoppervlak. Wanneer 
de TCR-opmaak was veranderd, waren ook de sterke interac-
ties via beide TCR-en hersteld. Uit deze experimenten con-
cluderen we dat TCR-gemodi!ceerde virus-spec!eke T-cellen 
goed te gebruiken zijn voor gentherapie, omdat de kans op 
selectieve uitgroei van virus-speci!eke T-cellen, die niet meer de 
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geïntroduceerde TCR tot expressie brengen of kunnen brengen, 
heel miniem is.
Vóórkomen en voorkómen van TCR-dimeren met mogelijk gevaar-
lijke reactiviteit
Introductie van TCR-en in T-cellen resulteert in de expressie van 
vier verschillende TCR-complexen op het oppervlak. Niet alleen 
komen de geïntroduceerde TCR en de endogene TCR tot expres-
sie, maar ook " TCR-dimeercomplexen bestaande uit de geïntro-
duceerde TCR:-, en ;-keten die gepaard zijn met de endogene 
TCR-ketens. De speci!citeit van de geïntroduceerde TCR en 
de endogene TCR is bekend, maar van de TCR-dimeren is on-
bekend of en wat voor speci!citeit ze hebben. Daarom kan niet 
uitgesloten worden dat ze potentieel een gevaarlijke speci!citeit 
hebben die mogelijk in GvHD kan resulteren.
In hoofdstuk ) hebben we onderzocht of en hoe vaak 
TCR gentransfer resulteert in vorming van TCR-dimeren met een 
gevaarlijke nieuwe speci!citeit. Om dit te onderzoeken zijn zes 
verschillende virusspeci!eke T-cellen uit diverse gezonde indivi-
duen getransduceerd met zeven goed gekarakteriseerde TCR-
en. De resultaten laten zien dat zowel introductie van complete 
TCR-en, als transductie van enkel TCR:-, of ;-ketens leidde tot 
nieuwe speci!citeiten, die niet toegewezen konden worden aan 
de endogene TCR of de geïntroduceerde TCR. Voornamelijk de 
observatie dat enkel transductie van een TCR:-, of ;-keten al 
resulteerde in nieuwe speci!citeiten, wijst erop dat deze veroor-
zaakt werden door TCR-dimeren. De nieuwe speci!citeiten 
konden gericht zijn tegen HLA-klasse-I-moleculen, maar ook 
HLA-klasse-II-moleculen, en resulteerde in zowel alloreactieve 
als autoreactieve T-cellen. Door cysteïnes aan te brengen in de 
geïntroduceerde TCR, werd een extra zwavelbrug gecreëerd. Dit 
resulteerde in selectieve paring van beide geïntroduceerde TCR 
ketens, zodat de neoreactiviteit signi!cant verminderd werd. 
We concluderen dat TCR gentransfer regelmatig resulteert in 
vorming van TCR-dimeren met potentieel gevaarlijke neore-
activiteit, omdat dit fenomeen in alle virusspec!eke T-cellijnen 
die we hebben getest optrad na introductie van verschillende 
TCR:-, of ;-ketens. We pleiten ervoor om het risico op ontstaan 
van potentieel gevaarlijke TCR-dimeren te verkleinen door 
selectieve paring te bevorderen van de geïntroduceerde TCR-
ketens, en T-celpopulaties te transduceren met een gerestricteerd 
TCR-gebruik. 
Verbeterde expressie en functionaliteit van codon geoptimaliseerde 
en cysteïne gemodi)ceerde HA-#-TCR-en 
TCR-en gericht tegen minor-antigen HA-$ zijn aantrek-
kelijk voor TCR gentransfer om patiënten met hematologische 
maligniteiten te behandelen vanwege de exclusieve expressie 
van HA-$ op bloedcellen. Voor sterke reactiviteit tegen de leu-
kemiecellen is een goede expressie van de HA-$-TCR op het 
celop per vlak van de donor T-cel van het grootste belang. Helaas 
hebben we in voorgaande studies al gezien dat de HA-$-TCR laag 
tot expressie komt op het celoppervlak na TCR gentransfer. 
In hoofdstuk % werd getracht de oorzaak van deze lage 
expressie te achterhalen, en werden verschillende strategieën 
bestudeerd om de HA-$-TCR-expressie te verbeteren na TCR 
$#(
gentransfer. In dit hoofdstuk laten we zien dat de HA-$-TCR-
expressie al laag is op de oorspronkelijke HA-$-speci!eke 
T-celklonen uit de patiënt, en dus niet alleen laag is na TCR gen-
transfer. Verder tonen we aan dat de lage HA-$-TCR-expressie na 
TCR gentransfer niet veroorzaakt wordt door ine7ciënte paring 
van de HA-$-TCR:- en ;-ketens onderling, maar dat vooral lage 
expressie van de HA-$-TCR;-keten een limiterende factor is. Van 
de verschillende strategieën die bestudeerd zijn, werd de meest 
verbeterde HA-$-TCR-expressie verkregen door het aanbrengen 
van een extra zwavelbrug in de HA-$-TCR-ketens te combineren 
met codon optimalisatie van de HA-$-TCR-ketens. Deze aanpas-
sing van de HA-$-TCR leidde zelfs tot een hoge expressie van de 
HA-$-TCR in virusspeci!eke T-cellen die daarvoor predominant 
hun endogene TCR tot expressie brachten op het celoppervlak 
na TCR gentransfer. Door de hoge HA-$-TCR-expressie konden 
TCR-gemodi!ceerde virusspeci!eke T-cellen ook target cellen 
herkennen die niet met HA-$-peptide beladen waren, maar van 
zichzelf HA-$-positief waren, en dit duidt op een sterke interactie 
tussen de T-cel en de targetcel. 
Op basis van deze resultaten is een virus geconstrueerd 
dat voor klinische toepassing bruikbaar is. In de al in klinische 
studies toegepaste virale MP6$ vector zijn de codon geoptimali-
seerde en cysteïne gemodi!ceerde HA-$-TCR;- en :-keten 
ver bonden met een T"A sequentie ingebracht. Transfer via deze 
vector van de HA-$-TCR leidde zowel in virusspeci!eke T-cellen 
met een zwak competiterend en sterk competiterend feno-
type tot sterke reactiviteit tegen verschillende HA-$-positieve 
leukemiecellen.
Op basis van uitgebreid onderzoek, mede beschre-
ven in dit proefschrift, zal een klinische studie worden gestart. 
Patiënten met hematologische maligniteiten na allo-SCT zullen 
behandeld worden met virusspeci!eke donor-T-cellen getrans-
duceerd met de MP6$ vector coderend voor de geoptimaliseerde 
HA-$-TCR.
K L I N I S C H E  S T U D I E
Immunotherapie voor patiënten na allo-SCT met donor 
T-cellen met anti-leukemiespeci!citeit zou kunnen resulteren in 
exclusief GvL zonder GvHD. Echter, het is niet altijd mogelijk om 
uit donormateriaal T-cellen met een duidelijke en exclusieve anti-
leukemiereactiviteit te induceren.
Door TCR gentransfer van minor-antigenspeci!eke 
TCR-en kan in een korte kweekperiode een T-celproduct 
gegene reerd worden met een selectieve anti-leukemiereacti-
viteit. Om te voorkomen dat de T-cellen die getransduceerd 
worden alsnog zelf in staat zijn om GvHD te veroorzaken, gaat 
de voorkeur uit naar virusspeci!eke T-cellen als ontvanger cellen. 
Door CMV- en EBV-speci!eke T-cellen te transduceren, wordt 
gebruik gemaakt van de capaciteit van deze cellen om lange tijd 
aanwezig te blijven in het lichaam, en op die manier een lang-
durige anti-leukemiereactiviteit te garanderen.
Op basis van uitgebreid onderzoek, mede beschreven 
in dit proefschrift, zal binnenkort gestart worden met een kli-
nische studie waarin patiënten die HLA-A*#"#$ en HA-$ positief 
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zijn, behandeld kunnen worden met HA-$-TCR-gemodi!ceerde 
virusspeci!eke donor-T-cellen. Een voorwaarde is wel dat de 
stamceldonor HA-$ negatief is, omdat de T-cellen anders in staat 
zijn om zichzelf en het donortransplantaat te herkennen. 
Er zullen twee groepen patiënten in aanmerking komen 
voor de behandeling met allo-SCT gevolgd door immunothera-
pie met HA-$-TCR getransduceerde virusspeci!eke T-cellen. De 
eerste patiëntengroep die in aanmerking komt voor behandeling, 
zijn HLA-A*#"#$+ en HA-$+ patiënten met refractaire leukemieën 
die normaliter niet in aanmerking komen voor allo-SCT. Omdat 
hun leukemie na bestraling en chemotherapie niet voldoende 
vernie tigd is, is de verwachting dat, indien deze patiënten wel 
getransplanteerd worden, de leukemie binnen 5 maanden weer 
in grote hoeveelheden in het bloed aanwezig is. Door de hoge 
kans op GvHD kan dan nog geen DLI gegeven worden. Omdat 
het HA-$-TCR-gemodi!ceerde virusspeci!eke T-celproduct 
ontworpen is om geen GvHD te induceren, maar wel hoge anti-
leukemische reactivi teit te bezitten, kan in deze patiënten veel 
vroeger na allo-SCT deze immunotherapie toegediend worden.
De tweede te includeren patiëntengroep bestaat uit 
HLA-A*#"#$+ en HA-$+ patiënten met een recidief hematologi-
sche maligniteit, die niet in aanmerking komen voor DLI door een 
verhoogde kans op GvHD, of omdat ze niet gereageerd hebben 
op DLI. Voorwaarde voor deze groep patiënten is dat ze getrans-
planteerd zijn met een HA-$ negatieve donor, en dat er genoeg 
donormateriaal ingevroren is om virus-speci!eke T-cellen te kun-
nen isoleren.
Indien deze nieuwe behandeling bij beide groepen leidt 
tot selectieve anti-leukemiereacties zonder GvHD in patiënten 
die geen andere behandelopties meer hebben, kan de behan-
deling ook een goed alternatief voor DLI zijn in patiënten na 
allo-SCT met een recidief. Verder kan bij bewezen e-ectiviteit de 
therapie uitgebreid worden door andere TCR-en te includeren. 
Voor deze eerste studie is gekozen voor de HA-$-TCR, omdat 
over dit minor-antigen en deze TCR veel bekend is. Op dit mo-
ment is de voorwaarde dat patiënten zowel HLA-A*#"#$ en HA-$ 
positief moeten zijn, en de donor HA-$ negatief, beperkend voor 
toepassing in alle patiënt-donor combinaties. Deze combina-
tie zal namelijk in ongeveer $%8 van de patiënten voorkomen. 
Verscheidene andere TCR-en zijn nu in ons laboratorium uit-
gebreid gekarakteriseerd, en kunnen bij slagen van deze eerste 
klinische studie mogelijk ook geïmplementeerd worden.
$#%
Promotie-onderzoek. Je kan het er maar druk mee 
hebben. Vrienden die naast hun artsenspecialisatie, waarbij ze 
onregelmatige diensten moesten draaien, ook nog een sociaal 
leven weten te onderhouden, zijn mij regelmatig tot inspiratie 
geweest. Ook familie, die naast het hebben van " eigen bedrij-
ven, het opvoeden van " kinderen en het om de week naar 
Spanje moeten om daar systemen op de rails te zetten, nog 
tijd overhielden om een nieuwe zorginstelling in Zoetermeer 
op te richten, lieten me inzien dat ‘het druk hebben’ ook kan 
betekenen dat je je vooral ‘druk maakt’. Waarmee niet gezegd 
is dat het niet !jn is om er een dikke streep onder, en een grote 
vink vóór te zetten; mijn proefschrift is af!
Natuurlijk wil ik ook graag wat mensen bij naam noe-
men. Het is niet meer dan logisch om te beginnen met het 
bedanken van Renate de Boer en Renate Hagedoorn. Samen 
met RenateH heb ik in een paar jaar tijd verscheidene vec-
toren geknutseld, met constructen in combinatie met allerlei 
markergenen, omdat dit zo extreem handig is. Nog steeds is zij 
een altijd beschikbare vraagbaak bij moleculaire proeven. Voor 
RenatedB lijkt geen enkel experiment te groot. Verder is het 
ontzettend prettig samenwerken met haar, en moppert ze nooit 
als ik een experiment weer eens op het laatste moment omgooi. 
Ik ben ontzettend blij dat zij naast mij willen staan als paranimf!
Verder heb ik het altijd prettig gevonden om binnen 
het TCR gen transfer groepje te vallen, dat ondertussen eigenlijk 
die naam ontgroeid is. Lars, Manja, Esther en Menno hebben 
het transduceren, sorteren en vervolgens kweken van enorme 
aantal len clonen tot een kunst verheven. Ik ben blij dat ik daar 
wat van mocht oppikken. Dankzij Avital, Dirk, Hetty, Monique en 
Pleun is de expertise uitge breid naar karakterisatie van diverse 
T-cel responsen, waarvan die tegen schimmels mis schien nog 
wel het nuttigst voor T-cel kweken is…De studenten Gerdien 
Volbeda en Vishant Jankipersadsing wil ik bedanken voor hun 
enthousiasme en inzet tijdens hun stage op de afdeling.
Met mijn werkplekje op de %e verdieping heb ik als 
AIO veel mazzel gehad. Inge en Marieke waren, en zijn, nooit 
te beroerd om even hun licht te laten schijnen op ingewikkelde 
experimenten, waardoor ze de eretitel ‘schaduwbegeleiders’ van 
Jorrit toebedeeld kregen. Ook de rest van mijn kamergenoten 
op achtereenvolgens de %e, 6e en 5e verdieping wil ik bedanken 
voor zowel de wetenschappe lijke als niet-wetenschappelijke 
discussies.
Gerrie en Karien van het secretariaat hebben zich alle 
moeite getroost om te zorgen dat alle formulieren zo snel mo-
gelijk bij de verantwoordelijke persoon belandden. Bedankt!
Zonder het kundige sorteren van Guido de Roo, 
Maarten van der Keur, Menno van der Hoorn, Patrick van der 
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Holst en Reinier van der Linden had dit proefschrift nog véél 
langer op zich laten wachten.
Tante Fietje wil ik bedanken voor het redigeren van mijn 
Nederlandse samenvatting.
Edith en Marian, natuurlijk vind ik het leuk als jullie me in 
Cardi- komen opzoeken!
De dinsdagavonden gaven het schrijven weer wat vaart. 
Anine, Boukje en Poldy; !jn om een periode met jullie in hetzelfde 
schuitje te hebben gezeten.
En natuurlijk zijn er de mensen die ik niet bij name hóéf 
te noemen. Jullie onophoudelijke steun en geloof in mij wordt 
nooit als vanzelfsprekend aangeno men; bedankt!
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Marleen van Loenen werd geboren op $# januari $&'# te Oss. 
In $&&' behaalde zij haar gymnasiumdiploma aan het Titus 
Brandsmalyceum te Oss en begon in datzelfde jaar met de studie 
Biomedische Wetenschappen aan de Universiteit Leiden. Tijdens 
deze studie liep zij twee wetenschappelijke stages. Onder be-
geleiding van dr. Jan Wondergem en ir. Marjan Boerma heeft 
zij bij de vakgroep Klinische oncologie in het Leids Universitair 
Medisch Centrum (LUMC) onderzoek gedaan naar het e-ect van 
ioniserende straling op het hart in een rattenmodel. Haar tweede 
stage liep ze op de afdeling Hematologie binnen het LUMC 
onder begeleiding van dr. Mirjam Heemskerk. Met behulp van de 
IFN-< capture assay werd getracht minor-antigen- of leukemie-
speci!eke T-cellen direct ex vivo te isoleren. Zij behaalde haar 
doctoraalexamen in "##(. In datzelfde jaarbegon zij aan het in 
dit proefschrift beschreven promotieonderzoek onder leiding 
van dr. Mirjam Heemskerk en prof. dr. Fred Falkenburg op het 
laboratorium voor Experimentele Hematologie van de afdeling 
Hematologie (hoofd prof.dr. Roel Willemze). Sinds maart "##' 
is ze werkzaam als wetenschappelijk onderzoeker op dezelfde 
afdeling en betrokken bij het opzetten van een fase I/II klinische 
studie. In deze klinische studie zal de e-ectiviteit van behande-
ling met HA-$-TCR gemodi!ceerde T-cellen na allogene stam-
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